ACHTEN SIE AUF DIESE HINWEISE:

**Hypertrophie mit linksventrikulärer Wandstärke**
bei Patienten, die typischerweise über 60 JAHRE alt sind

**Intoleranz:**
gegenüber Herzensuffizienzbehandlung wie z.B.: ACE-Hemmer oder Beta Blocker

**Diskrepanz:**
zwischen niedervoltage und erhöhter linksventrikulärer Wanddicke

**Diagnose:**
Eines Karpaltunnelsyndroms oder einer Lumbalstenose

**Echokardiographie:**
Hypertrophie des linken Ventrikels

**Nervensystem:**
Dysfunktion des autonomen Nervensystems einschließlich von gastrointestinalen Beschwerden und unerklärbarem Gewichtsverlust

**www.verdachtunddiagnose.at** - hier erfahren Sie mehr über ATTR-CM.

---

1. Heart failure with preserved ejection fraction

Referenzen:

Akutes Koronarsyndrom/Acute Coronary Syndrome

Potential Arrhythmogenic Effects of Endothelin – A Receptor Blockade in ST-Elevation Acute Coronary Syndrome

C. Adlbrecht, R. Wurm, T. Pezawas, I. M. Lang
Division of Cardiology, Department of Medicine II, Medical University Vienna

Background Ventricular arrhythmias are the most common complication after acute myocardial infarction (AMI). Endothelin (ET), a mediator of microvascular dysfunction and cardiac remodeling, has been demonstrated to have arrhythmic potential. The present electrocardiographic study, designed to assess the pro- or anti-arrhythmogenic effects of ET-A receptor blockade in AMI is based on a randomized protocol.

Methods Patients with posterior-wall ST-elevation acute coronary syndrome (STE-ACS) were randomly assigned to receive intravenous BQ-123 at 400nmol/minute or placebo over 60 minutes, starting immediately prior to primary percutaneous coronary intervention (PCI) (n = 54), 24-hour Holter recordings (Del Mar Avionics, Del Mar Medical Systems, Irvine, CA) were performed at 2 (IQR 1–3) days (n = 29) and at 45 (IQR 33–62) days (n = 26) to assess standard Holter parameters. The predefined primary endpoint of the study was the presence of ventricular tachycardia and/or late potentials. Patient characteristics with or without available 24h ECG were similar (Table 1).

Results There was no significant difference in predefined combined primary endpoint after 45 days (0 [10%] in the BQ-123 vs 1 [10%] in the placebo group; p = 0.435).

At 2 days, an increase in the total number of supraventricular extrasystoles (SVES) in patients randomized to BQ-123 (45 (IQR 17–165) beats vs 11 (IQR 5–73) beats in placebo treated patients; p = 0.023) occurred. There was no significant difference regarding ventricular arrhythmias (extrasystoles [VES] and non-sustained ventricular arrhythmias [NSVT]) and heart rate variability (HRV) values.

Furthermore at 45 days, an increase in the total number of SVES (105 [IQR 33–226] beats in BQ-123 vs 11 [IQR 3–98] beats in placebo; p = 0.033) and thus an increase in mean SVES per hour (4.7 [IQR 1.7–10.3]/h vs 0.5 [IQR 0.1–3.5]/h; p = 0.011) was observed. As at baseline, the total number of VES and NSVT and HRV values were not significantly different between the 2 treatment groups. No patients treated with BQ-123 and one patient treated with placebo developed late potentials (p = 0.244). Beta-blocker medication was not associated with SVES in regression analysis (standardized beta 0.084; p = 0.690).

Conclusion Overall, short-term administration of BQ-123 after AMI was safe. However, SVES increased.

Proteomic Profiling of Acute Coronary Thrombosis Reveals a Local Decrease of Pigment Epithelial Derived Factor PEDF

K. Distelmaier, C. Adlbrecht, J. Jakowitsch, O. Wagner, Ch. Gerner, I. M. Lang, M. Kubicek
Division of Cardiology, Department of Medicine II, Medical University Vienna

Aims Thrombotic occlusion of an epicardial coronary artery upon atherosclerotic plaque rupture is considered the ultimate and key step in acute myocardial infarction (AMI). The pathophysiological mechanisms of coronary thrombus formation in AMI are still not fully deciphered.

Methods and Results We have analyzed soluble and particulate thrombus material aspirated from the ruptured plaque site of non-diabetic patients with ST-elevation myocardial infarction using proteomic techniques. Label-free quantitation of MS/MS data revealed an accumulation of platelet and polymorphonuclear cell specific proteins but also the presence of proteins specifically expressed in activated monocytes, T-cells, endothelial cells and dendritic cells. When culprit site derived plasma was compared to systemic plasma we observed a prominent differential regulation of complement cascade components and a decrease of anti-thrombotic pigment epithelial derived factor (PEDF). ELISA showed PEDF, which is known to have a protective role in atherothrombosis to be relatively decreased at the culprit site with a level of expression that is inversely correlated with local matrix metalloproteinase 9 (MMP-9) activities. In vitro, culprit site plasma displayed enhanced proteolytic activity towards PEDF.
**Conclusion**

Given the importance of PEDF in atherosclerosis and thrombosis it is tempting to speculate that local administration of PEDF may become a novel strategy for the treatment of coronary thrombosis.

**Clopidogrel Pre-Treatment is Associated with Reduced In-hospital Mortality in Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction**

J. Dörler, M. Edlinger, H. Alber, K. Huber*, O. Pachinger, F. Weidinger

Department of Internal Medicine III, Cardiology, Medical University Innsbruck; *5th Med. Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna

**Aims**

Pre-treatment with clopidogrel results in a reduction of ischémic events in elective coronary interventions. Data on upstream clopidogrel in the setting of primary percutaneous coronary intervention (PCI) is limited. The aim of this study was to investigate whether clopidogrel loading before arrival at the PCI centre may result in an improved outcome of primary PCI for ST-elevation myocardial infarction (STEMI).

**Methods and Results**

In a multicentre registry of acute PCI 5955 patients undergoing primary PCI in Austria between January 2005 and December 2009 were prospectively enrolled. Patients were stratified into 2 groups, a clopidogrel pre-treatment group (n = 1655 patients) receiving clopidogrel before arrival at the PCI centre and a peri-interventional clopidogrel group (n = 4320 patients) receiving clopidogrel at a later stage. Multiple logistic regression analysis including major confounding factors and stratified for the participating centres was performed to investigate the independent effect of pre-treatment with clopidogrel on in-hospital mortality.

On univariate analysis, clopidogrel pre-treatment was associated with a reduced in-hospital mortality (3.4% vs 6.1%, p < 0.01) after primary PCI. After adjustment for major confounders in multivariate analysis, clopidogrel pre-treatment remained a strong and independent predictor of in-hospital mortality (OR 0.59, 95%-CI: 0.38–0.91; p = 0.02; Table 2).

**Conclusion**

Clopidogrel pre-treatment before arrival at the PCI centre is associated with reduced in-hospital mortality compared with peri-interventional treatment in a real world setting of primary PCI. These results strongly support the recommendation of clopidogrel treatment “as soon as possible” in the setting of primary PCI.

**Table 2: J. Dörler et al.**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Odds ratio</th>
<th>95%-CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clopidogrel pre-treatment (yes vs no)</td>
<td>0.59</td>
<td>0.38–0.91</td>
<td>0.02</td>
</tr>
<tr>
<td>Cardiogenic shock (yes vs no)</td>
<td>2.03</td>
<td>1.43–2.89</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Resuscitation (yes vs no)</td>
<td>2.02</td>
<td>1.33–3.07</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Previous myocardial infarction (yes vs no)</td>
<td>1.57</td>
<td>1.02–2.42</td>
<td>0.04</td>
</tr>
<tr>
<td>Year (2005–2007 vs 2008–2009)</td>
<td>1.10</td>
<td>0.78–1.56</td>
<td>0.59</td>
</tr>
<tr>
<td>Gender (male vs female)</td>
<td>1.06</td>
<td>0.74–1.52</td>
<td>0.77</td>
</tr>
<tr>
<td>Age (per year)</td>
<td>1.05</td>
<td>1.04–1.07</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>ASA/Heparin pre-treatment (yes vs no)</td>
<td>0.75</td>
<td>0.49–1.15</td>
<td>0.19</td>
</tr>
<tr>
<td>Gp IIb/IIIa-Antagonist pre-treatment (yes vs no)</td>
<td>1.09</td>
<td>0.67–1.76</td>
<td>0.34</td>
</tr>
<tr>
<td>Secondary transfer (yes vs no)</td>
<td>0.72</td>
<td>0.49–1.06</td>
<td>0.09</td>
</tr>
</tbody>
</table>

**The Prevalence and Distribution of Culprit Artery Occlusion in Non-ST-Elevation Myocardial Infarction: “Pseudo-NSTEMI”**

J. Dörler, D. Pettener, G. Grimm, H. Krappinger, O. Pachinger, F. Roithinger, G. Zanker, F. Weidinger

Department of Internal Medicine III, Cardiology, Medical University Innsbruck

**Purpose**

Non-ST-segment elevation myocardial infarction (NSTEMI) may be associated with total occlusion of the culprit artery, which is frequently not diagnosed on the standard 12-lead ECG. This may lead to missed opportunities for prompt reperfusion therapy. We sought to determine the prevalence of acute artery occlusion and location of culprit lesions involved in NSTEMI.

**Methods**

We examined 2219 consecutive patients with NSTEMI enrolled in a multicentre registry of acute percutaneous coronary intervention (PCI). The inclusion criteria were definite myocardial infarction (elevated troponin and/or CKMB with either symptoms and/or ST-segment depression) and invasive strategy within 72 hours of symptom onset. The patients were divided into 2 groups according to the initial TIMI flow (TIMI 0I, “occluded”; vs TIMI II/III, “patent”). Baseline characteristics, treatment, culprit artery distribution and in-hospital outcome were compared.

**Results**

The prevalence of total occlusion was 33.9% in the entire cohort. In patients with total occlusion, the culprit lesion was more frequently located in the arteries supplying the infero-lateral territory (circumflex, CX; right coronary artery, RCA) compared to patients with patent arteries (CX: 31.2% vs 18.8%, p < 0.01; RCA: 31.2% vs 22.6%, p < 0.01; LAD: 26.6% vs 38.2%, p < 0.01). Patients with total occlusion had significantly shorter delays to PCI (pain to PCI: 951 [460–1730] min. vs 1302 [582–2221] min., p < 0.01; door to PCI: 360 [125–1138] min. vs 180 [791–1483] min., p < 0.01). In-hospital mortality, however, was similar in both groups (TIMI I vs TIMI II/III 2.7 vs 1.8; p = n. s.).

**Conclusion**

Totally occluded culprit lesions occur in one third of patients with NSTEMI in a real world setting and are more frequently located in CX and RCA, but may also be seen in LAD territories. Early risk stratification needs to be enhanced to improve identification of “Pseudo-NSTEMIs” that would benefit from urgent reperfusion as in STEMI.

**Cardiogenic Shock Complicating Myocardial Infarction – Patients at Risk and Differences to Patients with STE-Elevation Myocardial Infarction?**

G. Fürnau, I. Eitel, S. de Waha, St. Desch, G. Schuler, H. Thiele

Department of Internal Medicine/Cardiology, University of Leipzig-Heart Center, Leipzig, Germany

**Background**

Development of cardiogenic shock (CS) in acute myocardial infarction (AMI) is a severe and life-threatening compli-
cation and CS remains the leading cause of mortality in AMI. Currently, the risk factors for development of CS are poorly determined.

**Methods** We analyzed a cohort of 224 patients presenting with CS in AMI and compared them to 557 patients with acute AMI without CS in history and baseline characteristics.

**Results** Patients in CS were significantly older (67.0 ± 12.4 vs 63.9 ± 12.3 years; p = 0.002), but there was no difference in weight, height and body mass index (83.0 ± 15.6 vs 81.4 ± 14.7 kg; p = 0.17; 172.0 ± 10.6 vs 171.1 ± 9.0 cm; p = 0.24; 27.8 ± 4.5 vs 27.7 ± 4.3; p = 0.96, respectively). Neither smoking, nor the presence of hypertension, hyperlipidemia, diabetes or anterior wall infarctions showed higher risk for CS, but patients with CS had higher rates of prior AMI, percutaneous coronary intervention and coronary artery bypass grafts, had higher degrees of multi vessel disease and showed less rates of sinus rhythm at presentation (Table 3).

**Conclusion** The most relevant risk factors for development of CS are age, history of previous AMI, evidence of prior coronary revascularization and multivessel disease compared to AMI patients without CS.

**The Influence of CYBA (P22-PHOX) Polymorphisms in Young Myocardial Infarction Survivors (≤40 Years of Age)**

G. Goliash, H. Blessberger, J. Wofny, K. Huber*, G. Maurer, Ch. Mannhalter, R. Sunder-Plaßmann, F. Wiestbauer
Division of Cardiology, Department of Medicine II, Medical University Vienna; *3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna

**Background** Acute myocardial infarction at a young age is associated with high morbidity and long-term mortality. The NADPH oxidase system as a main source of reactive oxygen species in vascular cells has been implicated in development and progression of coronary artery disease. In our study, we investigated the effect of polymorphisms in the p22-PHOX (CYBA) gene on coronary artery disease in young patients (≤40 years).

**Methods and Results** We prospectively recruited 302 subjects into our multi-center case control study, including 102 young myocardial infarction patients (≤40 years) from 2 high volume cardiac catheterization hospitals and frequency-matched them on age, gender, and center to 200 hospital controls in an approximate 2:1 ratio per case patient. The homozygote c.-930A > G promoter polymorphism was significantly more prevalent in the controls than in the infarction patients. In the adjusted logistic regression analysis, we detected a protective effect of the c.-930A > G promoter polymorphism against premature myocardial infarction. Using a log-additive/pseudo-allele model, we detected an unadjusted OR of 0.63 (95%-CI: 0.45–0.9; p-value: 0.011). In the adjusted model the association was more pronounced with an odds ratio of 0.5 (95%-CI: 0.3–0.81; p-value: 0.005). The C242T polymorphism and the 640A > G polymorphism did not differ significantly between the study groups. Furthermore we could not detect a significant effect for these polymorphisms in the logistic regression analysis.

**Discussion** The present study suggests a protective association between the c.-930A > G promoter polymorphism in the p22-PHOX (CYBA) gene and the development of myocardial infarction in young individuals (≤40 years).

**Impact of Baseline BNP Level on Early and Late Clinical Outcomes After STEMI: 2-Year Results of the HORIZONS-AMI Study**

R. Jarai, K. Huber, R. Mehran, G. Dangas, G. Stone
3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna

**Background** B-type natriuretic peptides (BNP) are well-established predictors of outcome in ST-elevation myocardial infarction (STEMI). However, limited data are available on the association of initial BNP concentrations with frequent co-morbidities (left ventricular function, anemia, renal dysfunction) observed in patients with acute STEMI. Furthermore, the bleeding risk of patients with high admission BNP levels has also not been investigated yet.

**Methods** A total of 839 STEMI patients enrolled in the HORIZONS-AMI trial had baseline BNP levels measured in the emergency room as part of the study protocol. We compared the 2-year clinical outcomes between the low (n = 421, BNP ≤ 0.71 mg/dl) and high (n = 418, BNP > 0.71 mg/dl) BNP groups according to the median cut-off-value.

**Results** Patients with higher initial BNP levels had significantly longer time from symptom onset to first balloon inflation (225 min vs 194 min) and significantly longer door-to-balloon times (100 min vs 89 min). Surprisingly, LVEF was not significantly different among patients with low or high concentrations of BNP (50% vs 51%; p = 0.758) but the incidence of anemia (8% vs 12%; p = 0.026) and reduced renal function (eGFR < 60 ml/min/1.73 m²: 11% vs 25%; p < 0.001) was significantly higher among patients with higher admission BNP. No differences was observed in procedure related variables, ACT value, GP IIb/IIIa or stent use or in antiplatelet compliance. In multivariate survival analysis high concentrations of BNP were strong predictors of major bleeding, as well as early and late mortality and stroke but not of ischemic endpoints (TVR, re-infarction or stent thrombosis). Furthermore, higher concentrations of BNP were also predictive of worsening renal function after index PCI.

**Conclusions** In the present study we could show that high admission concentrations of BNP are associated with anemia and reduced renal function at admission to the hospital with STEMI but are not related to left ventricular function. According to the present results, patients with high admission concentrations of BNP are at significantly higher risk of worsening renal function after primary PCI. The significant association of high BNP levels with bleeding- risk should be evaluated by future studies.

**Vasospastic Angina in a Patient Presenting with Recurrent STEMI**

C. Kautzsch, G. Grimm
Department of Emergency Medicine, National Hospital Klagenfurt

**Introduction** Coronary artery vasospasm, or smooth muscle constriction of the coronary artery, is an important cause of chest pain syndromes that can lead to myocardial infarction, ventricular arrhythmias, and sudden death. If minimal or no angiographic evidence of coronary artery disease is found in a patient who has recently had angina at rest with transient ST-segment elevation, vasospastic angina is the more likely diagnosis. Once the diagnosis of coronary artery vasospasm is made, calcium channel blockers and long-acting nitrates may be used for long-term prophylaxis and treatment.

**Case Report** We report on a 50 year old male patient presenting to the emergency department with acute coronary syndrome a total of 6 times within a 4 month period. At first presentation ECG showed no significant ST-elevation in the posterior leads. Angiographic imaging showed small vessel disease without significant stenosis. Coronary angiography revealed small vessel disease without significant stenosis. Angiographic imaging of the right coronary artery showed vasospasm of the proximal RCA. The patient was treated with aspirin, clopidogrel, statins and amlodipin. One week later the patient was readmitted to our department with acute resting chest pain and significant ST-elevation in the posterior leads. Angiographic imaging showed no significant stenosis or coronary spasm. CKMB was measured 10 times above normal. With the assumption of the patient having vasospastic angina he was started on diltiazem 90 mg twice daily. One week after discharge the patient was again (3rd time) admitted with symptoms. Coronary angiography revealed small vessel disease without significant stenosis. Angiographic imaging showed vasospasm in the proximal LAD and serial spasms of the RCA. After application of intracoronary nitrate the spasms dissolved with ST-segment resolution. The patient was treated with aspirin, clopidogrel, statins and amlodipin. One week later the patient was readmitted with acute coronary syndrome without ST-segment changes and slightly elevated cardiac enzymes. Because of...
the known vasospastic angina the patient was treated with intravenous nitrates with resolution of symptoms. Diltiazem was increased to 90 mg, 3-times daily and nitrates p.o. were added (Isosorbid-5-mononitrat, 40 mg, twice daily). One month later the patient presented with STEMI (posterior leads). After intravenous nitrates were given, he was treated with diltiazem (180 mg, 3-times daily) and nitrates (40 mg, twice daily). The last episode of resting angina was documented one month later. Since then (a 12 month period) the patient is symptom-free with maximum medical therapy consisting of calcium channel blockers and long-acting nitrates.

**Discussion** In patients presenting with acute coronary syndrome and haemodynamic stability initial medical treatment should include sublingual, topical, or intravenous nitrate therapy. Until atherosclerotic coronary disease (a much more frequent cause of chest pain) is excluded, standard therapies, including antplatelet/antithrombotic, statins, and beta-blocking treatments, should be administered. Once the diagnosis of coronary artery vasospasm is made, calcium channel blockers and long-acting nitrates may be used for long-term prophylaxis. Maximum dose vasospastic medical therapy, as shown in our case, may be necessary until the patient achieves long term pain free intervals.

**Typ II Variant of Kounis Syndrome Due to Ibuprofen Use**

J. Kraus, J. Altenberger, J. Schuler, M. Pichler Immere Medizin II, Kardiologie, Landeskrankenhaus Salzburg/PMU

**Introduction** Kounis Syndrome is the coincidental occurrence of acute coronary syndromes with allergic or hypersensitivity reactions. Two types of Kounis syndrome have been described. We report a case of 2 stepped life threatening Typ II Kounis syndrome leading to acute myocardial infarction following a first time intake of ibuprofen and recurrence under acetylsalicylic acid (ASS) therapy.

**Case Report** A 53 year-old male presented because of acute shortness of breath and severe chest pain. ECG reveals ST - elevation in diaphragmatic leads. Angiography showed diffuse arteriosclerotic plaques and severe spasms in both coronary arteries. After intracoronary Nitroglycérin administration spasms resolved and symptoms improved. He received antplatelet (GPIIb/IIIa Blocker, clopidigrel, ASS) and betablocker therapy. Laboratory findings showed elevated levels of CK (479 U/L) and CK-MB (67 U/L). Allergic asthma bronchiale was known for 3 yrs and the patient was on inhalative steroid therapy. Furthermore he suffered from chronic sinusitis and nasal polyps.

Chest pain and dyspnoe occurred 1.5 hours after intake of ibuprofen (400 mg) because of headache. In the meanwhile, while recovering from STEMI, 2 episodes of severe chest pain, hypotension and ST-elevation in the inferior leads occurred. The patient was treated with Morphine, Hydrocortisone 250 mg and Diltiazem. Symptoms and ECG changes resolved within 30 minutes. Serum tryptase level and Urinary Serotonin and 5-HIES were in normal range. No hint of inflammatory vasculitis. IgE was raised to a level of 201 U/ml. We stopped ASS and Diltiazem and Clopidigrel was chosen for maintenance therapy. After 7 days the patient was discharged free of symptoms.

**Discussion** In this patient we postulate a Typ II Kounis syndrome and aspirin sensitive asthma.

NSAIDs, like Ibuprofen, inhibiting Cyclooxygenase 1 are able to cross react with ASS, and inhibit vasodilatatory prostaglandins and cause a predisposition to coronary spasms. ASS can precipitate asthmatic attacks, and provoke coronary artery spasms. Most cells located in the shoulder region of coronary arteriosclerotic plaques, play an important role in the pathophysiology of acute coronary syndrome and myocardial infarction due to allergic plaque rupture like in Kounis II syndromes.

The recurrence of ST -elevation on low dose ASS is probably an effect of the slow process of mast cell degranulation based on the massive reaction due to the Ibuprofen related allergic event.

**Conclusion** Numerous animal venoms, substances/drugs including drug eluting stents are capable to induce an allergic myocardial Infarction. Currently treatment for mast cell stabilisation is used to avoid mast cell degranulation. In this case ASS seems to play an important role to adhere the allergic reaction, on the other hand prescription of ASS is a Class I Indication for patients suffering myocardial infarction. Trials have shown ASS desensitization to be feasible. Nevertheless with regard to the massive coronary spasm in this case a provocation test with ASS was not performed for ethical reasons. We decided to maintain a clopidogrel alone regimen. An important, maybe live saving issue, is to instruct the patient to avoid Ibuprofen in the future.

**High-Sensitive Cardiac Troponin T (hs-cTnT) Assay is not Superior to a Previous cTnT Assay Generation for the Diagnosis of Acute Myocardial Infarctions in a Real-World Emergency Department**

J. Mair, T. Planer, A. Hammerer-Lercher, P. Schratzberger, A. Griesmacher, O. Pachinger
Department of Internal Medicine III, Cardiology, Medical University Innsbruck

**Introduction** High-sensitive troponin T (hs-cTnT) has been recently demonstrated to have an increased sensitivity for the early diagnosis of acute myocardial infarctions (AMI) in preselected patient populations. We compared the diagnostic performances of hs-cTnT with the 4th generation cTnT assay during a period of 2 months in a real world emergency department (ED) treating mainly adults with medical or neurological emergencies to evaluate potential benefits for routine diagnosis.

**Methods** cTnT was measured on request of the attending physicians in 2438 patients (60 ± 21 years, 52% females). It was only ordered in patients treated by internists or neurologists and measured by assays from Roche Diagnostics.

**Results** There were 451 patients with the chief complaint of chest pain and 292 with dyspnoea. These patients included 69 AMIs (delay from onset to admission 1–25 hours, median 2.5 hours). 540 patients had neurological diseases, such as stroke. The remaining patients suffered from various internal diseases. 785 patients of the whole study population had acute or chronic cardiac diseases. Using the 99th percentile cut-off the sensitivities and specificities for AMI diagnosis on admission in the whole study population were 88 and 74% (hs-TnT) and 84 and 80% (4th generation cTnT, cut-off 0.01µg/L), and using the 10% coefficient of variation cut-off (0.03µg/L) for the 4th assay generation 70% and 93%, respectively. The overall diagnostic performances for AMI diagnosis of both assay generations were comparable (area under receiver operating characteristics curves [AUC] 0.89 ± 0.03 vs 0.87 ± 0.03; p = 0.30). However, hs-cTnT was detected significantly more patients with acute or chronic cardiac diseases (AUC: 0.78 ± 0.01 vs 0.68 ± 0.01; p < 0.001).

**Conclusions** In unselected ED patients hs-cTnT assay is not superior to the previous cTnT assay for AMI diagnosis. If for both assays the 99th percentile cut-off limit is used also the early sensitivities on admission are comparable, but the 4th cTnT assay generation loses AMI specificity at 0.01 µg/L as well. However, with the endpoint detection of any acute or chronic cardiac diseases hs-cTnT is significantly superior to the previous cTnT assay due to its better assay precision at the low measuring range, which cannot be outweighed by lowering the cut-off value of the 4th cTnT assay generation to 0.01 µg/L.
Low Prevalence of the Acetylsalicylic Acid and Clopidogrel Resistance in Patients with Acute Coronary Syndromes in Patients under Pantoprazole Treatment

J. Mair, K. Brendel, H. Ott, A. Griesmacher, O. Pachinger
Department of Internal Medicine III, Cardiology, Medical University Innsbruck

Background Acetylsalicylic acid (ASA) and clopidogrel combined with prophylactic proton pump inhibitor (PPI) treatment has been standard therapy of patients with acute coronary syndromes (ACS) until the recent warning of the US Food and Drug Administration because of possible interactions of PPIs with clopidogrel metabolism. We therefore investigated the prevalence of ASA and clopidogrel low- or no responders in ACS patients with stent implantation on day 2 of coronary care unit (CCU) stay with pantoprazole treatment.

Methods We investigated 135 patients (95 males, 40 females) aged between 35 and 88 (62 ± 11) years with ST segment elevation myocardial infarction (STEMI) (n = 110) and non-STEMI ACS (n = 25). In 89 patients drug-eluting and in the remaining patients bare metal stents were implanted. All patients were loaded with 250–500 mg ASA on the first day of hospital stay and received 100 mg ASA as maintenance dose per day. Patients received 600 mg clopidogrel as a loading dose on the first day of hospital stay and 75 mg clopidogrel as maintenance dose per day. Platelet function in the morning of day 2 of CCU stay was assessed by multiple electrode platelet aggregometry (Multiplate®, Dynabyte, Munich, Germany) in hirudin anticoagulated whole blood. Based on the published literature ASA non-responders were classified as patients with > 75 U and low-responders with values between 31 and 74 U in the ADPtest®. Patients with > 47 U in the ADPtest® and > 79 U in the ASPItest® were classified as clopidogrel low- or no-responders.


Conclusions Given the low prevalence of clopidogrel (6.7%) and ASA low- or no-responders (3.7%) in our real-world ACS patients with 600 mg clopidogrel loading dose and concomitant pantoprazole treatment routine platelet function testing does not seem to be necessary in this patient group.

Aufnahmeblutdruck und Mortalität bei Patienten mit akutem Myokardinfarkt

D. Roth, H. Herkner, W. Schreiber, Ch. Havel
Universitätssklinik für Notfallmedizin, Medizinische Universität Wien


Akute Koronsyndrome bei Migranten: Risikoprofil und angiographische Befunde

2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien

Einleitung Da bei den Akut-Koronangiographien eine Häufung von jungen Patienten mit Migrationshintergrund aufgefallen ist, wurden retrospektiv demographische und klinische Daten unserer Patienten ausgewertet.


Ergebnis Es wurden 157 Patienten (25 % weiblich) mit einem mittleren Alter von 60 ± 14 (35–93) Jahren akut angiographiert. Die Koronarangiographie zeigte eine Eingefäßerkrankung bei 36 %, eine Zweigefäßerkrankung bei 25 %, eine Drei- oder Mehrgefäßerkrankung bei 35 % und keine Koronarstenosen bei 5 %. Eine Hypertonie fand sich bei 68 %, Hypercholesterinämie bei 66 %, Nikotinabusus bei 57 % und Diabetes mellitus bei 24 %. 51 Patienten (33 %) waren Migranten: 22 kamen aus dem ehemaligen Jugoslawien, 12 aus der Türkei, 7 aus dem arabischen Raum, 5 aus Nordosteuropa, 4 aus Zentraleuropa und einer aus Guinea-Bissau. Migranten waren jünger als Patienten mit österreichischer Herkunft (53 vs. 64 Jahre; p = 0,0000). Keine signifikanten Unterschiede zwischen Migranten und Österreichern gab es in der Häufigkeit von Nikotinabusus (62 vs. 54 %), Hypercholesterinämie (63 vs. 67 %), Hypertonie (67 vs. 69 %), Diabetes mellitus (24 vs. 25 %) und in der Geschlechtsverteilung (Migrantinnen 24 % vs. Österreicherrinnen 26 %). Sowohl eine korpore Eingefäßerkrankung als auch eine Zweigefäßerkrankung fand Mortalität im Vergleich zur niedrigsten Quartile (< 120 mmHg) für die 2. Quartile (120–140 mmHg) 0,49 (95 %-CI: 0,35–0,67), für die 3. Quartile (140–160 mmHg) 0,37 (0,25–0,54) und für die 4. Quartile (> 160 mmHg) 0,22 (0,13–0,38), für diastolischen Blutdruck im Vergleich zur 1. Quartile (≤ 85 mmHg) für die 2. Quartile (60–80 mmHg) 0,46 (0,31–0,68), für die 3. Quartile (80–85 mmHg) 0,35 (0,22–0,54) und für die 4. Quartile (> 85 mmHg) 0,29 (0,18–0,46); für die Pulsspannweite im Vergleich zu 1. Quartile (≤ 50 mmHg) für die 2. Quartile (50–60 mmHg) 0,62 (0,41–0,93), für die 3. Quartile (60–75 mmHg) 0,38 (0,27–0,54) und für die 4. Quartile (> 75 mmHg) 0,23 (0,15–0,34).
Die Versorgung des NSTE-ACS in der Steiermark – Eine Subgruppenanalyse des steirischen ACS-Registers

M. Suppan1, R. Riedl1, A. Berghold1, B. Pieske2, H. Brussee2, M. Grisold2, O. Luha2, N. Watzinger1
1I. Tentzeris1, S. Farhan1, R. Jarai1, E. Samaha1, A. Geppert1, G. Unger1, J. Wojta2, K. Huber3

Einleitung

Material und Methode
Die Datenerfassung erfolgt standardisiert in den 3 steirischen Herzkatheterzentren. Der Datensatz wird im Sinne eines zentral geführten und verwalteten ACS-Registers in Graz bearbeitet und aktualisiert. Die statistische Auswertung erfolgt über das Institut für Medizinische Informatik, Statistik und Dokumentation der Medizinischen Universität Graz. Es handelt sich hierbei um eine retrospektive Analyse der erhobenen Daten.

Ergebnisse

Die Entität NSTE-ACS kann in die beiden klassischen Subgruppen NSTEMI sowie IAP aufgesplittet werden. Es zeigen sich somit in der Steiermark über den Beobachtungszeitraum 49,9 % NSTE-ACS-Patienten sowie 18,1 % IAP-Patienten in Bezug auf das Gesamtkollektiv. Das Männer-Frauen-Verhältnis in der NSTE-ACS-Subgruppe beträgt ca. 60 % zu 40 %.

Diskussion
Die Erfassung und konsequente Auswertung sämtlicher steirischer ACS-Patienten bildet die Grundlage jeglicher Evidenz in der steirischen Akutversorgung des ACS. Die gewonnenen Ergebnisse werden im Sinne eines Qualitätsmanagements mit anderen nationalen sowie internationalen ACS-Registern verglichen. Die Subgruppenanalyse des NSTE-ACS zeigt hinsichtlich der demographischen Verteilung (Geschlechterverteilung, Entitätenverteilung innerhalb des NSTE-ACS etc.) Parallelen zu Datensätzen anderer Register. Seit Einführung des steirischen ACS-Registers im Jahr 2006 besteht die Möglichkeit, das Patientenkollektiv hinsichtlich Unterschiede in der Akutversorgung, geographischer Besonderheiten etc. zu bewerten.

Prognostic Value of Presentation with STE-ACS vs NSTE-ACS in Patients with Acute Occlusion of the Left Circumflex Artery

I. Tantzer1, S. Farhan1, R. Jarai1, E. Samaha1, A. Geppert1, G. Unger1, J. Wojta2, K. Huber3
13rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna; 2Division of Cardiology, Department of Medicine II, Medical University Vienna

Purpose
Acute coronary syndromes (ACS) due to acute occlusion of the left circumflex artery (LCX) may present as ST-elevation myocardial infarction (STEMI) or non ST-elevation myocardial infarction (NSTEMI) in the 12-lead ECG depending on the dominance of the LCX. Aim of this study was to evaluate the prognostic value of ST-segment changes in electrocardiogram in patients with ACS and occluded LCX.

Methods
In total, 1,490 consecutive patients, who underwent elective or acute PCI, were included in a prospective registry from January 2003 until December 2006. Forty nine patients had an angiographically proven acute occlusion of the LCX. Patients were divided retrospectively into 2 groups, those with STEMI and those with NSTEMI at presentation. Time from presentation to 1st diagnostic angiogram, all-cause mortality and the combined endpoint all-cause death and target vessel revascularisation were evaluated during a mean follow-up period of 24.56 ± 12.5 months (range 6–52 months).

Results
Twenty four of the 49 patients with an occluded LCX at the first diagnostic angiogram (49%) patients a NSTEMI and 25 (51%) patients presented with STEMI. Clinical and angiographic characteristics such as age, gender, arterial hypertension, diabetes mellitus, hyperlipidaemia, previous myocardial infarction, renal dysfunction, heart failure, drug eluting stent implantation, stent length and stent diameter, respectively, were not significantly different between the 2 groups. Time form presentation to angiogram was 842.6 ± 985.5 minutes for NSTEMI and 104.4 ± 59.5 minutes for STEMI patients (p = 0.001). Four (16.7%) and 3 (12%) patients of the STEMI and 3 (12%) patients of the STEMI group died during the follow-up (HR 1.2; 95%-CI: 0.2–5.7; p = 0.7). Seven (29.2%) patients of the NSTEMI group and 3 (12%) patients of the STEMI group reached the combined endpoint of all-cause death and target vessel revascularisation (HR 2.4; 95%-CI: 0.6–9.3; p = 0.2).

Conclusion
In this small series in 1,490 consecutive unselected “real world” patients who underwent PCI and stent implantation 49 (3.3%) had an occluded LCX, of which about half presented with STEMI or NSTEMI, respectively. For both clinics clinical long-term outcome was statistically comparable but showed a trend to higher all-cause mortality in patients presenting with NSTEMI, in which diagnostic and therapeutic angiograms were performed delayed. Patients with ACS and occluded LCX without ST-segment elevation might have a benefit of early revascularisation and should therefore be diagnosed earlier e.g. by use of 17-lead ECGs as reported elsewhere and/or by immediate diagnostic angiography when symptoms and risk constellation suspect occlusion of an epicardial coronary artery.

IFMC-to-ECG-Time from Intrahospital First Medical Contact to ECG – How to Improve Delays in an Emergency Department – A Randomised Clustered Interventional Trial

R. van Tuddler, D. Roth, C. Weiser, B. Heidinger, H. Herkner, W. Schmieder, C. Havel
Department of Emergency Medicine, Medical University Vienna

Background
The European Society of Cardiology–Guidelines for Acute Coronary Syndrome (ACS) emphasize that the assessment (including the electrocardiogram (ECG)) of patients with suspected
Aim of the Study  The aim of this study was to investigate the effect of a dedicated ECG technician (ET) on intrahospital First Medical Contact to ECG time (iFMC-to-ECG).

Materials and Methods  All patients with the chief complaint of “chest pain” presenting to the out-patient-clinic (OPC) at the ED of the Medical University Vienna were included. The study was conducted from August, 23rd to September, 20th 2010. The intervention was the availability of a dedicated ET. In the control group no ET was available. The availability of the ET was randomized to three equally distributed shifts per day (morning, day, night). The ET rotas were concealed for clinical staff. Information about availability of ETs was marked with an alert sign at triage point and registration counter.

Primary outcome was previously defined as iFMC-to-ECG in ET rotas vs non dedicated resident nurses. iFMC-to-ECG delays are presented as median and interpercentile ranges 25–75%. To compare delay times we used a Mann-Whitney-U-test.

Results  During the study period, in total 908 patients received an ECG recording for different reasons. 353 (38.8%) out of these patients had chest pain as chief complaint. 635 (69%) of all patients received their ECG within 10 minutes versus 59 patients (72.1%) of patients with “chest pain” presenting to the OPC. 353 (38.8%) out of these patients had chest pain as chief complaint.

Conclusion  Implementing an ECG technician in the ED is feasible and reduces patient delay times.

Impact of Elevated Glucose Levels in Patient Hospitlalized with Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS) on Long-Term Mortality

B. Vogel, S. Farhan, S. Mahne, I. Kozanli, R. Jarai, K. Huber 2nd. Med. Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna

Background and Aim  Due to the fact that there is only few data on long-term mortality in patients with hyperglycemia hospitalized with acute coronary syndrome, this study aimed to show the impact of elevated admission glucose on 4-year mortality in patients with NSTE-ACS.
Basic Science

Secretion of Cytokines and Chemokines by Peripheral Blood Mononuclear Cells is Triggered by Coagulation Products

Methods

This data is derived from a registry with 813 consecutive patients admitted to the cardiology department with the diagnosis of non NSTEMI between Jan 2001 and Dec 2004. Hyperglycemia is defined as a glucose level of > 140 mg/dL on hospital arrival. In 110 patients the glucose level at admission was missing, another 211 patients had evident diabetes and were excluded from the analyses. A follow-up concerning all-cause mortality up to four years was obtained.

Results

Patient with hyperglycemia were older (75.5 years SD ± 12.2 vs 68.2 years SD ± 14.8; p < 0.001) and less frequently received coronary revascularization during first hospital stay (22.8% vs 36.9%; p = 0.007) than patients with normal admission glucose levels. In-hospital mortality, as well as four-year mortality was higher in patients with hyperglycemia (10.7% vs 5.3%; p = 0.034; HR 2.15 95%-CI: 1.0–4.4 and 36.9% vs 27.3%, p < 0.001; HR 2.51 1.66–3.81, respectively) than in those without elevated admission glucose levels (Figure 3). In a Cox proportional hazard model the admission glucose level was an independent predictor for 4-year mortality (Table 5).

Conclusion

An elevated glucose level in patients hospitalized with acute coronary syndrome without ST-segment elevation is associated with worse long-term outcome.

Prozessorientierte Umsetzung von Leitlinien für den ST-Hebungsmyokardinfarkt im Krankenhaus Schwarzach

H. Wallner, M. Schmidt, L. Lafenthal, G. Goebel, J. Westreicher, L. Keiler, S. Kamitschnig, R. Lenzhofer

Innere Medizin, Kardiologie, Krankenhaus Schwarzach

Einleitung


Material und Methode


Diskussion


II – 3


Christian Doppler Laboratory for the Diagnosis and Regeneration of Cardiac and Thoracic Diseases, Medical University Vienna

Background

Chemokines are multifunctional mediators that are involved in development and homeostatic, stem-cell survival, wound healing and immune responses, as well as triggering chemotaxis and angiogenesis. Their production and release is partly controlled by cytokines such as Interleukin 1 beta (IL-1β), Interleukin 6 (IL-6) or Tumor necrosis factor alpha (TNF-α). Diagnostic analysis of cytokines and chemokines in serum or plasma has become an important issue in several disease conditions. Studies confirmed the involvement of these mediators systemic immune activation/sepsis, wound healing, autoimmune-diseases, atherosclerosis and myocardial infarction. However, cytokines and chemokines are usually not considered to be very stable after blood collection, which might therefore alter test results. Thus, the aim of the pilot study was to obtain better knowledge about stability of these mediators in blood samples for interpretation of test results.

Materials and Methods

Venous blood was taken from healthy probands (n = 7) using different blood tubes (serum, heparin, citrate and EDTA plasma). Blood tubes were either centrifuged initially within 20 minutes after venipuncture and kept frozen at -80° until further testing or were stored at 4°C, at room temperature (RT) or at 37° for up to 24 hours. Samples were evaluated for IL-1β, IL-6, TNF-α and for selected chemokines such as Interleukin-8, Epithelial neutrophil-activating protein 78 (ENA-78) and Granulocyte chemotactic peptide-2 (GCP-2) using commercially available Enzyme-linked immunosorbent assay (ELISA) kits.
Results Interestingly all examined mediators rise when samples were stored above room temperature for more than 4 hours in serum tubes. The rise of serum cytokine and chemokine levels culminated in a 79-fold increase for IL-6 ($p < 0.0081$) (Figure 5), a 22-fold increase for ENA-78 ($p < 0.0006$) and a 17-fold increase for GCP-2 ($p < 0.0026$) compared to basic values. Serum levels of IL-1$\beta$ and TNF-$\alpha$ were not detectable at baseline but rose up to 1157 pg/ml (IL-1$\beta$; $p < 0.03$) and 488 pg/ml (TNF-$\alpha$; $p < 0.03$).

Conclusions These data indicate that most cytokine and chemokine levels remain stable when analyzed within a short interval after venipuncture. When tubes were exposed to temperatures higher than 24°C (RT), levels of measured factors increased dramatically. EDTA plasma seems to be the most suitable for stability reasons and should be used for analysis of these mediators. We hypothesize that initiation of the blood clotting cascade in serum tubes, strongly mediated by the elevated levels of fibrin, concurrent with higher temperatures induce a pro-inflammatory microenvironment which triggers release of cytokines and chemokines from cellular compartments.

Regulation of Specific Glycolytic Pathways by Beta-Blockers in Normoxia and Hypoxia

A. Bühner, E. Holzwart, D. von Lewinski, H. Mächler, R. Gasser
Department of Internal Medicine, Medical University Graz

Introduction Pyruvate dehydrogenase kinase inhibits pyruvate dehydrogenase, which constitutes an important step in glucose metabolism. Cardiac metabolism of glucose is very tightly regulated to maintain the variable energy demand that is required by cardiac tissue. Energy metabolism of the cardiac myocyte can be regulated within seconds up to a few minutes or chronically regulated within the time frame of hours to days. Glucose metabolism is activated in early myocardial ischemia – a sensitive response to increased need of high-energy-phosphate in the healthy heart during extreme physical activity. However, in coronary heart disease, this activation becomes deleterious. In myocardial ischemia, inhibition or decreased gene expression of pyruvate dehydrogenase kinase is necessary in order to shift myocardial metabolism towards the fetal phenotype, thus metabolising more glucose than fat in order to preserve myocardial integrity.

Methods Myocardial tissue probes derive from the right auricle of patients undergoing cardiac surgery. A small part of the right auricle is removed when the heart is put on extra-corporal circulation. This sample is then placed in cooled Tyrode solution and hypoxia is brought about by switching 100% oxygen to 100% nitrogen (hypoxia) in one of the two chambers. By doing so, we are able to compare ischemic and non-ischemic tissue of the same patient. Snap frozen samples are stored at −70°C until RNA isolation. Quality of isolated RNA is analyzed by Agilent’s Bioanalyzer 2100 system. Ar-
Die HL-1-Zell-Linie (atriale Mauskardiomyozyten) wurde für 24h mit Sunitinib (0,1–1 µM) inkubiert. Affymetrix-Microarrays wurden verwendet, um mehr als 600 microRNAs zu analysieren. RT-PCR wurden zur Bestätigung der Microarrays durchgeführt.

**Ergebnisse**
Bei 0,1 µM (entspricht dem normalen therapeutischen Level) hatte Sunitinib keinen akuten Effekt auf die entwickelte Kraft. Vorbehandlung mit 1 µM bzw. 10 µM Sunitinib (30 min) reduzierte die entwickelte Kraft auf 76,9 ± 2,8 % bzw. 54,5 ± 6,3 % verglichen mit einer Reduktion auf 96,1 ± 2,6 % in Kontrolltrabekeln (p < 0,05 bzw. p < 0,001) (Abbildung 6). Die diastolische Spannung und die Kontraktionskinetik blieben von Sunitinib unbeinflusst.

Im Expressionsmuster der analysierten microRNAs zeigte sich nach 24h kein Unterschied zwischen unbehandelten und mit Sunitinib inkubierte Kardiomyozyten.

**Diskussion**
Die Ergebnisse zeigen, dass Sunitinib neben der be- kannten langfristigen negativen Auswirkung auf die Herzfunktion auch einen dosisabhängigen akut negativ-inotropen Effekt auf humane Myokard zeigt. Dieser zeigt sich insbesondere bei höheren Dosen, was klinisch bei eingeschränkter Clearance (z. B. eingeschränkte Leberfunktion) der Patienten berücksichtigt werden sollte. Eine Veränderung des Expressionsmusters von micro-RNAs wurde nicht beobachtet.

**Impact of Reperfusion Times on Myocardial Infarct Size and Hemodynamic Function in Rat Hearts**

**Introduction**
Mortality for emergency bypass surgery after Acute Coronary Syndrome still accounts for up to 46.7%. Aim of this study is to establish an acute Ischemia/Reperfusion-model in the rat to evaluate Ischamia/Reperfusion (IR) damage depending on a change in reperfusion time, and to improve intraoperative myocardial protection.

**Methods**
Following temporary LAD ligature (60’), male Sprague Dawley rats were randomly assigned to 60’ (group 1: n = 11) or 120’ (group 2; n = 12) in vivo reperfusion. Subsequently, hearts in each group were randomly assigned to TTC and Evans Blue staining to measure infarct size (IS) and area at risk (AAR). IS and AAR were expressed as percentage of the left ventricle. The remaining hearts were used for evaluation of hemodynamic parameters in an erythrocyte perfused isolated working heart during 45’ baseline measurements, 60’ of Custodiol-protected ice cold ischemia and 45’ of postischemic reperfusion.

**Results**
In both groups, global ex vivo ischemia significantly reduced postischemic external heart work (group 1: 70 ± 20%; group 2: 82 ± 13%; p < 0,01) and cardiac output (group 1: 74 ± 17%; group 2: 83 ± 11%; p < 0,01) compared to preischemic baseline. Coronary flow (CF) was significantly reduced only after 2h of reperfusion (group 1: 102 ± 16%, n. s.; group 2: 85 ± 16%; p < 0,05). Between the groups there was a significant difference in the recovery of CF with better recovery after 1h reperfusion (p < 0,05). Similar IS and AAR were measured in both groups (group 1: IS = 39,1%; AAR = 56,7%; group 2: IS = 35,9%; AAR = 67,91, n. s.). However, viable myocardium in the ischemic area (AAR-IS) was significantly larger in group 2 (group 1: 17,5%; group 2: 32,0%; p < 0,05).

**Discussion**
We were able to establish a standardized, reproducible in vivo IR-model in the rat. In this model, protective effects of different cardioplogic solutions can be evaluated. Additionally, the decrease of CF after 2h of reperfusion suggests that damage of vital myocardium is further enhanced after a longer reperfusion time. This might be due to endothelial dysfunction induced by metabolites of I/R Injury. Thus, improvement of endothelial protection might be an interesting therapeutic target to gain better outcome in these high-risk patients.
Experimental Acute Type B Aortic Dissection – Different Sites of Primary Entry Tears Cause Different Ways of Propagation

T. Dziodzo1, A. Jurasek1, D. Zimpfer1, V. Scheikl1, M. Stoiber1, M. Grimm2, H. Schima2, M. Czerny2
1Universitätsklinik für Chirurgie, Klinische Abteilung für Herz-Thorax-Chirurgie, Medizinische Universität Wien; 2Universitätsklinik für Herzchirurgie, Innsbruck

Objectives Many dissections seem to also have a retrograde component. The aim of the study was to evaluate different sites of primary entry tears and the propagation of the dissecting membrane, ante- and retrograde, in an experimental model of acute type B aortic dissection.

Methods The entire thoracic aortic aorta including the supraaortic branches was harvested from 26 adult pigs. An intimal tear of 15 mm was created via contralateral incisions sites 20 mm downstream the origin of the left subclavian artery. In 13 cases the dissection was created at the concavity and in 3 cases at the convexity. The aortic annulus was then sewn into a silicon ring of a driving chamber. The distal aorta was connected to a tubing with adjustable resistance elements. The circulation was driven by the pneumatically driven Vienna heart to mimic aortic flow and pressure.

Results Mean circulation time was 64 ± 45 min. A mean pressure of 152 ± 43 mmHg and a mean flow of 4.5 ± 1.0 L/min were reached. The median antegrade propagation length of the dissecting membrane was 65 mm. The median retrograde propagation length in primary entry tears at the convexity was 20 mm and was stopped by the left subclavian atery. In aortas with the primary entry tear at the concavity, median retrograde propagation length was 21 mm extending up to the ascending aorta in 16%.

Conclusions In this experimental model of acute type B aortic dissection, we confirmed that many type B dissections do also have a retrograde component. At the convexity, this component is stopped by the left subclavian artery as an anatomic barrier. At the concavity, the propagation of the dissecting membrane may extend up to the ascending aorta and may therefore cause retrograde type A dissection. These findings may substantiate clinical need for treatment of type B dissections with a primary entry tear at the concavity.

MPO (Myeloperoxidase) Expression is Up-regulated in Simulated Myocardial Ischemia in the Presence of Beta-Blockers

R. Gasser, A. Bühner, D. von Lewinski

Experimental evidence suggests a crucial role of immune reaction in the pathophysiology of atherosclerosis and acute myocardial infarction. For example, a few regulatory T-cells control a wide spectrum of the inflammatory cascade. In ischemia, a pro-inflammatory imbalance with damaging effects in terms of left ventricular performance and patient outcome is the result of this uncontrolled immune response [Am Heart J 2008; 156: 1065–73]. Ischemic injury leads to leukocyte-derived markers such as myeloperoxidase (MPO) correlates with outcome in ischemic heart disease.

In our present work using microarray technique, we have found that, in T-cell mediated immunity generally, a noteworthy down-regulation is brought about by beta-blockers. From our investigations we suspect that most important, unique pleiotropic effects of nebivolol may be centered around favourable effects upon T-cell mediated immunity generally, a noteworthy down-regulation of MPO expression. From our investigations we believe that during experimental ischemia, there is an up-regulation of MPO-expression. There is a differential regulation between different beta-blockers during myocardial ischemia, which warrant further investigation. We believe that there are complex pleiotropic effects of beta-blockers on immunity. Such pleiotropic effects have received more attention recently. For example, in the JUPITER trial, in apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events by unfolding pleiotropic anti-inflammatory actions [JUPITER Study, N Engl J Med, 2008]. Our preliminary results show that beta-blockers inhibit the expression of T-cell immunity related genes during experimental hypoxia and we find that during experimental ischemia, there is an up-regulation of MPO-expression. There is a differential regulation between different beta-blockers during myocardial ischemia, which warrant further investigation. In the light of JUPITER and other recent publications on modulating inflammation by pleiotropic effects of cardiovascular drugs, the specific property of immune modulation by beta-blockers in myocardial ischemia may warrant further attention. However, a further detailed exploration on both expression and molecular level is certainly needed.

New Insight into the Regulation of PAK4 (p21[CDKN1A]-Activated Kinase 4) in Human Atrial Tissue during Myocardial Ischemia from In Vitro Measurements in Human Atrial Tissue

R. Gasser, E. Holzwart, H. Mächler, A. Bühner, D. von Lewinski

Department of Internal Medicine, Medical University Graz

Introduction Serine/threonine-protein kinase PAK 4 is an enzyme that, in humans, is encoded by the PAK4 gene. Members of the PAK family of serine/threonine kinases serve as targets for the small GTP-binding proteins Cdc42 and Rac and have been implicated in a wide range of biological activities. Some exciting developments help elaborate the regulation of PAK activity and identify downstream signalling targets. These include the discovery of the Cool/ Pix and Cat proteins, which modulate PAK signalling, and down-stream kinases that modulate the organization of the actin cytoskeleton or gene expression. Considering these recent findings, we investigate their regulation during experimental myocardial ischemia.

Methods Myocardial tissue probes derive from the right auricle of patients undergoing cardiac surgery. A small part of the right auricle is removed when the heart is put on extra-corporeal circulation. This sample is then be placed in cooled Tyrode solution and hypoxia is brought about by switching 100% oxygen to 100% nitrogen (hypoxia) in one of the two chambers. By doing so, we are able to compare ischemic and non-ischemic tissue of the same patient. Snap frozen samples are stored at −70°C until RNA isolation. Quality of isolated RNA is analyzed by Agilent’s Bioanalyzer 2100 system. Arrays are scanned with the AB1700 Chemiluminescence Array Reader and images, data are processed by PANTHER software.

Results After 30 minutes of myocardial hypoxia we find that there is no significant regulation of PDK-expression during myocardial ischemia. There is just a trend towards a decrease in PAK4-Gene expression. There is, however, a significant difference between the expression of PAK4 during myocardial ischemia in the presence of nebivolol (0.75 ± 0.04) and control ischemia experiments (1.2 ± 0.06; ± SEM; p < 0.05): PAK4-expression is decreased during normoxia (trend) and ischemia (significant) in the presence of nebivolol (Figure 7).

In this figure, the results from real-time PCR measurements of PAK4 experiments are illustrated (O₂ko = well oxygenated, no ischemia, no drug; N₂ko = experimental ischemia, no drug; O₂at = well oxygenated, ischemia, atenolol present; N₂at = experimental ischemia, atenolol present; O₂neb = well oxygenated, nebivolol present; N₂neb = experimental ischemia, nebivolol present).
Introduction

Methylation of arginine residues in proteins and subsequent proteolysis results in the liberation of free methylarginines, including asymmetric dimethylarginine (ADMA; R-Me2), subsequent proteolysis results in the liberation of free methylarginines, and ADMA is recognised as a plasma marker of increased cardiovascular risk but it is unclear whether it ever accumulates to sufficient levels to affect NO pathways. However, it has been shown by chemical biology and gene deletion techniques that that loss of DDAH function elevates plasma and tissue ADMA levels. On the other hand it is possible that a feed back mechanism exists which regulates DDAH expression upon the availability of NO. In this context, it has to be mentioned that nebivolol as a feedback control. This is of interest since oxia could be a measure for the increased availability of NO brought about by nebivolol as a feedback control. This is of interest since several steps in the pathways of interaction have remained unclear as yet. It is certainly promising to investigate further into this interrelation of NO, DDAH and nebivolol.

Conclusion

In the present study we find that the myocardial expression of DDAH is reduced in the presence of nebivolol in both normoxia as well as hypoxia. The measured decrease of DDAH seen under nebivolol but not with atenolol both during normoxia and hypoxia could be a measure for the increased availability of NO brought about by nebivolol as a feed back control. This is of interest since several steps in the pathways of interaction have remained unclear as yet. It is certainly promising to investigate further into this interrelation of NO, DDAH and nebivolol.

Increased Matrix-Metalloproteinase-2 Expression of Infarcted Myocardium Attenuates Homing of Mesenchymal Stem Cells

M. Gyöngyösi, S. Wolbank, S. Chawart, K. M. Ali, R. Hofer-Warthärt, R. de Martel, K. Huber, G. Maurer
1Division of Cardiology, Department of Medicine II, Medical University Vienna; 2Ludwig Boltzmann Institute for Clinical and Experimental Traumatology/AUVA Research Center Austrian Cluster for Tissue Regeneration; 3Department of Biomolecular Medicine and Pharmacology, Institute of Vascular Biology and Tissue Regeneration, Medical University Vienna; 49 Med. Dept. of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna

Background

Matrix-metalloproteinase 2 (MMP2) has been shown to cleave the stromal derived factor 1, interrupting the SDF-1/CXCR4 axis of stem cell homing in the ischemic injured myocardium. We have previously shown the immediate decrease of the myocardial blood flow after intracoronary mesenchymal stem cell (MSC) delivery. The present study investigated the myocardial expression of MMP2 and CXCR4 after intracoronary or intramyocardially injected MSC in porcine closed-chest reperfused acute myocardial infarction (AMI).

Methods

Farm pigs were subjected to 90-min occlusion of the mid left anterior descending coronary artery followed by reperfusion. Allogenous porcine MSC were transiently transfected with Ad-GFP and Ad-Luc (GFP-Luc-MSC), and were injected either intracoronarily using stop-flow technique, or percutaneous intramyocardially 1-week post-AMI. Myocardial blood flow (MBF) was measured by combination of pressure wire and special designed infusion catheter under maximal hyperemia caused by adenosine. Myocardial expression of MMP2 (index of ischemic/oxidative stress) and CXCR4 receptor (index of homing signal) were measured from the infarcted tissue and border zone of infarction 1-day post GFP-Luc-MSC delivery. The global left ventricular ejection fraction (EF) was measured 1-month post cell therapy by using magnetic resonance imaging (MRI). MicroCT of the infarcted hearts were performed using cast preparation method to visualize the microvascularization 1 month after MSC delivery.

Results

The baseline parameter, such as number of delivered cells, heart rate, blood pressure and weight were similar in the two groups. MBF decreased immediately after intracoronary delivery, while no significant change in tissue perfusion could be detected using the percutaneous intramyocardial delivery mode. Intracoronary delivery of GFP-Luc-MSC increased in the expression of MMP2 (75 ± 34 kD isoform) in the infarcted myocardium 300 ± 135 vs 166 ± 49 intensity x mm²; p < 0.029), and at the border zone (338 ± 81 vs 185 ± 38 intensity x mm²; p < 0.001), with parallel decrease in expression of CXCR4 (0.058 ± 0.05 vs 0.71 ± 0.05 ng/tissue/ml; p = 0.008), as compared with intramyocardial cell transfer. Fluorescence immunochemistry indicated higher level of myocardial expression of different homing (tenascin, cadherin and integrin) and angiogenic factors (FGF-2 and VEGF) in the infarcted area and at the border zone, in the intramyocardial group. Increase in EF was significantly higher in the intramyocardial group, as compared to the animals in the intracoronary delivery group (0.8 ± 0.4 vs 5.3 ± 5.2%; p = 0.046). A significant, negative correlation was found between the decrease in MBF and increased MMP2 myocardial expression (r = 0.943) and reduced myocardial CXCR-4 expression (r = 0.631), indicating a
Inhibition of IL-1β-converterase and Caspase-1 Reduces Intimal Apoptosis Paralleled with Inhibition of Inflammation and Neointimal Hyperplasia After Balloon Injury and Stenting of the Porcine Coronary Arteries

Department für Kardiologie und Angiologie, Uniklinik Münster, Deutschland; Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin, Medizinische Universität Wien

Introduction
Intracoronary administration of the IL-1β-converterase and caspase-1 inhibitor acetyl-tyrosinyl-tyrazinyl-aspartylchloromethyl-ketone (Ac-YVAD-cmk) significantly decreases the coronary arterial tissue concentration of the proinflammatory cytokine IL-1β, the rate of apoptosis in the intima in coronary artery stenting in pigs. The aim of the present study was to evaluate the association between intimal inflammation and intimal apoptosis in relation to neointimal development after intracoronary administration of Ac-YVAD-cmk before coronary intervention (stenting or percutaneous coronary balloon dilatation [PTCA]).

Methods
Eight pigs received intracoronary infusion of 25 and 25 mg Ac-YVAD-cmk (solved in 2% DMSO and PBS solution, 1mg/min) selectively into the left anterior descending (LAD) or the left circumflex coronary arteries (LCx) before implantation of bare metal stent (BMS) (group BMS-Inhibitor) or balloon dilation with oversizing (1.3:1 balloon:artery ratio) injury (group PTCA-Inhibitor). The LAD and LCx were randomly selected for stenting or PTCA. The next 8 animals served as controls with implantation of either BMS (group BMS) or solely PTCA randomly chosen of LAD or LCx. After 4 weeks, the amount of neointimal hyperplasia (neointimal area, expressed as mm²), and degree of intimal inflammation and intimal apoptosis in relation to neointimal development after intracoronary administration of Ac-YVAD-cmk before coronary intervention (stenting or percutaneous coronary balloon dilatation [PTCA]).

Results
Injury score was similar in PTCA groups and also in stent groups, with significantly higher injury score in the intima after coronary artery stenting in pigs. The aim of the present study was to evaluate the association between intimal inflammation and intimal apoptosis in relation to neointimal development after intracoronary administration of Ac-YVAD-cmk before coronary intervention (stenting or percutaneous coronary balloon dilatation [PTCA]).

Discussion
Short exposure of coronary arteries to IL-1β-converterase and apoptosis inhibitor results in a significant decrease in intimal apoptosis paralleled with a significant inhibition of neointimal inflammation and neointimal hyperplasia, suggesting a direct role of apoptosis-induced releases of different mediators (such as IL-1β) which promote neointimal development after coronary interventions.

ÖKG-Annual Conference 2011 – Abstracts

F. Hohendanner, N. MacQuaide, G. Antoons, B. Pieske, K. Sipido, F. Heinzel
Universitätsklinik für Innere Medizin, Medizinische Universität Graz

Die zytosolische Kalziumentfernung geschieht in Kardiomzyoten vor allem durch die sarkoplasmatische Ca-ATPase (SERCA) und den sarkolemmalen Na/Ca-Austauscher (NCX), in geringerem Maße auch durch die plasmalemmale Kalzium-ATPase und Mitochondrien. Wir quantifizieren erstmals räumliche und zeitliche Inhomogenitäten in der zytosolischen Kalziumentfernung in ventrikulären Kardiomzyoten. Die Herzmuskelzellen wurden aus dem linken Ventrikel von Mäusen und Schweinen isoliert und anschließend elektrisch stimulierte (1Hz). Die zytosolischen Kalziumtransienten wurden konfokal ge- messen (Fluo-4 AM, 1.5 μs/Scan Linie). Forskolin (Forsk, 10 μM) wurde zur Stimulation, Cyclopiazonic acid (CPA, 1 μM) zur Hem- mung der SERCA verwendet. SEA400 (0.3 μM) kam zur Inaktivie- rung des NCX zum Einsatz. Zur Hemmung der Zellkonzentration wur- den Bloßstati (10 μM) oder 2,3-Butandione-Monoxim (10 μM) verwendet. Die Zeit bis zur halbmaximalen Kalziumfreisetzung (TF50), die Ca-Amplitude (Fpeak/F0) und die Zeitkonstante des Kalziumabfalls (tau) wurde für lokale Ca-Transienten (μm Intervalle entlang der Scan-line, lokal) und den Gesamt-Transienten der Zelle (global) berechnet. Der Variabilitätskoeffizient des lokalen Taus innerhalb einer Zelle (CV = Standardabweichung/Mittelwert) wurde zur Messung der örtlichen Inhomogenität der Kalziumentfernung aus dem Zytosol verwendet. Weiters wurden Zellregio- nen mit schneller (fastCaR, lokal tau < global tau) bzw. langsamer (slowCaR, lokal tau > global tau) Kalziumentfernung klassifiziert. Die Kinetic der Kalziumwiederaufnahme innerhalb von Herz- muskelzellen der Maus war nicht homogen. Die maximale Differenz der lokalen taus entlang der Scanlinie bei 1 Hz Stimulation betrug 237 ± 29 ms (Mittelwert ± S.E.M., n = 10 Zellen), entsprechend einem CVtau innerhalb einer Zelle von 14 ± 7%. Die Ausdehnung abgrenzbarer inhomogener Regionen betrug 4.6 ± 0.5 μm (fastCaR) und 5.1 ± 1.4 μm (slowCaR). In Kardiomzyoten des Schweines war- ren die Inhomogenitäten in der Kalziumentfernung wesentlich aus- geprägter (CVtau = 25 ± 5%; p < 0.01 vs. Maus; n = 10/Spiezies). Die räumliche Variation in der Kalziumwiederaufnahme war nicht durch Unterschiede in der Kinetic der Ca-Freisetzung oder die Höhe der lokalen Ca-Transienten zu erklären. Forskolin führte zu einer signifikanten Beschleunigung des globalen Taus (85 ± 8 vs. 116 ± 22 ms bei Ausgangsbedingungen, „Baseline“ BSL). Forsk be- schleunigte die Ca-Wiederaufnahme in slowCaR stärker (tau auf 72 ± 4% der BSL) als in fastCaR (tau 78 ± 5% der BSL; p < 0.05, n = 7). SERCA-Inhibierung durch CPA führte ebenfalls zu einer stärkeren Anderung der lokalen taus in slowCaR als in fastCaR (164 ± 5% vs. 134 ± 6% von BSL; p < 0.05, n = 7) und damit zu einem signifikanten Anstieg der Inhomogenität der Kalzium- entfernung (CVtau 19 ± 5% vs. 15 ± 7% bei BSL; p < 0.001). Hem- mung des sarkolemmalen NCX durch SEA400 führte zu einer Stei- gerung des globalen taus ohne signifikanten Unterschied zwischen fastCaR und slowCaR (108 ± 1% vs. 112 ± 1% von BSL). Zusammenfassend ist in Kardiomzyoten die Kalziumentfernung aus dem Zytosol nicht homogen. Im Großer Schwein finden sich ausreichendige Inhomogenitäten als bei Mäusen. Intrazelluläre Regionen mit langsamer zytosolischer Kalziumentfernung lassen sich eher durch Modulation der SERCA-Aktivität beeinflussen. Unsere Ergebnisse sprechen dafür, dass In verschiedenen Regionen der Zel- le die SERCA-Aktivität in unterschiedlichem Ausmaß zur zytosoli- schen Ca-Entfernung beiträgt.
Direct Epicardial Shock Wave Therapy for Myocardial Regeneration in Ischemic Heart Disease

**Introduction**

Recently shock waves are well known to induce tissue regenerative effects. Transhoral cardiac shock wave therapy (SWT) could be shown to augment myocardial vascularization in a porcine model of myocardial infarction. SWT even improves myocardial perfusion and causes relief of angina symptoms in humans with severe coronary artery disease. Nevertheless the underlying mechanism remains largely unknown.

**Materials and Methods**

Adult Sprague-Dawley rats were subdivided in 3 groups: sham-operated (sham), infarcted myocardium with epicardial SWT (SWT group) and infarcted myocardium without epicardial SWT (control). Four weeks following myocardial infarction (MI), SWT (100 impulses at 0.15 mJ/m²) was applied directly to the infarcted region in the SWT-group, control animals were left untreated. Cardiac function was evaluated using echocardiography. Angiogenesis was evaluated by analysis of several RNA and protein expressions.

**Results**

Fourteen weeks after epicardial SWT, left ventricular function significantly improved in the SWT-group as compared to 4 weeks after MI and as compared to the controls. Quantitative histology revealed more vital cells and more endothelial cells in the SWT group. SDF-1 and its receptor CXCR-4 were both upregulated in the treatment group as shown by immunohistochemistry. In peripheral blood higher numbers of circulating endothelial progenitor cells could be detected in the treatment group.

**Discussion**

Direct epicardial shock wave therapy induces neo-vascularisation in an experimental model of ischemic heart failure in rats. High numbers of circulating endothelial progenitor cells can be found in the peripheral blood. At the same time SDF-1 and its receptor CXCR-4 were upregulated in the myocardium. These findings indicate that one of the main mechanisms of SWT may be recruitment of vessel forming cells.

**Conclusions**

These data indicate that ATG, a therapeutic agent successfully applied in clinical transplant immunology, salvaged ischaemic myocardium, increased the homing of macrophages and EPC and improved cardiac function after experimental AMI in rats.

Intravenous and Intramyocardial Injection of Irradiated Apoptotic Peripheral Blood Mononuclear Cells (PBMC) Preserves Ventricular Function after Myocardial Infarction

**Background**

Congestive heart failure developing after acute myocardial infarction (AMI) is a major cause of morbidity and mortality. Clinical trials of cell based therapy after AMI evidenced only a moderate benefit. Of clinical relevance are reports that demonstrated that infusion of apoptotic cells lead to an initiation of immunosuppressive mechanisms. Based on these reports, we hypothesized that injection of apoptotic cells into ischaemic myocardium reduces inflammatory reactions after AMI.

**Material and Methods**

Cell suspensions of apoptotic cells were injected intravenously (IV) or intramyocardially (IM) in an experimental rat model of AMI. Sham operated animals and rats injected with control medium or viable cells served as controls. Tissue specimens were obtained 72 hours after induction of AMI to analyze the cellular infiltrate within the ischaemic myocardium. Cardiac function was analyzed by echocardiography and infarction size was determined by planimetry after 6 weeks.

**Results**

Rats that were injected with irradiated apoptotic PBMC showed enhanced homing of macrophages and endothelial progenitor cells (EPC) within 72 hours as compared to controls. Planimetric analysis showed a significant reduction of infarct size and improvement of post AMI remodelling with less signs of dilation (infarct dimension 5% in IV injected animals, 9% in IM injected rats, 25% in controls, p < 0.001, respectively) (Figure 8). Rats that were injected with viable non-irradiated PBMC or fresh culture medium showed a significant reduction of infarct dimension and an improvement of post AMI remodeling after six weeks (infarct dimension 26% vs. 12%, p < 0.01). Furthermore, echocardiography revealed an improved functional recovery in treated animals as evidenced by a reduced loss of ejection fraction (EF, 43% in controls vs. 52% in treated animals, p < 0.01, n = 13 per group).

**Conclusions**

Rats that were injected with ATG evidenced higher numbers of CD68+ macrophages and c-kit+ endothelial progenitor cells (EPC) in the ischaemic myocardium 72 hours after AMI as compared to controls. Animals injected with ATG evidenced less myocardial necrosis, showed a significant reduction of infarct dimension and an improvement of post AMI remodeling after six weeks (infarct dimension 26% vs. 12%, p < 0.01). Furthermore, echocardiography revealed an improved functional recovery in treated animals as evidenced by a reduced loss of ejection fraction (EF, 43% in controls vs. 52% in treated animals, p < 0.01, n = 13 per group).

**Anti-Thymocyte Globulin (ATG) Reduces Damage Caused by Ischaemia and Preserves Cardiac Function after Experimental Myocardial Infarction**

**Introduction**

Acute myocardial infarction (AMI) followed by cardiac remodeling is a major cause of congestive heart failure and death. Over the last decades research has focused on finding therapies to reduce inflammatory reactions after an ischaemic event. Of relevance are reports showing that infusion of apoptotic leucocytes or anti-lymphocyte serum after AMI can reduce myocardial necrosis and preserves cardiac function. In order to corroborate this therapeutic mechanism, the utilisation of immunosuppressive agents with a comparable mechanism such as anti-thymocyte globulin (ATG) was evaluated in this study.

**Materials and Methods**

For in vivo experiments, AMI was induced in rats by ligation of the left anterior descending artery. Initially after the onset of ischaemia, rabbit ATG (10 mg/rat) was injected intravenously. Untreated and sham operated animals served as controls. Histological evaluations were performed 3 days after AMI in order to analyze angiogenic cell populations in the infarcted myocardium. Cardiac function was analyzed by echocardiography six weeks after induction of MI. Determination of infarction size was conducted by planimetry.

**Results**

Rats that were injected with ATG evidenced less myocardial infarction size as compared to controls. Animals injected with ATG evidenced less myocardial necrosis, showed a significant reduction of infarct dimension and an improvement of post AMI remodeling after six weeks (infarct dimension 26% vs. 12%, p < 0.01). Furthermore, echocardiography revealed an improved functional recovery in treated animals as evidenced by a reduced loss of ejection fraction (EF, 43% in controls vs. 52% in treated animals, p < 0.01, n = 13 per group).

**Conclusions**

These data indicate that ATG, a therapeutic agent successfully applied in clinical transplant immunology, salvaged ischaemic myocardium, increased the homing of macrophages and EPC and improved cardiac function after experimental AMI in rats.

**Figure 8:** M. Lichtenauer et al.
showed signs of dilation which were accompanied by a considerable loss of ventricular function. Echocardiography revealed that ventricular function was almost preserved in the treatment groups with EF values of 55% and 55% vs. 42% in untreated controls compared to 61% in sham operated rats (n = 13 per group, p < 0.01).

Conclusions Based on these data we conclude that apoptotic cells induce the expression of pro-angiogenic factors necessary for attraction of regenerative cells to sites of ischaemia. Intravenous and intramyocardial injection of apoptotic cell suspensions results in attenuation of myocardial remodelling after experimental AMI, preserves left ventricular function and increases homing of regenerative cells.

Secretome of Apoptotic Peripheral Blood Cells (APOSEC) Confers Cytoprotection to Cardiomyocytes and Inhibits Tissue Remodeling after Acute Myocardial Infarction

Christian Doppler Laboratory for the Diagnosis and Regeneration of Cardiac and Thoracic Diseases, Medical University Vienna

Background Heart failure following acute myocardial infarction (AMI) is a major cause of morbidity and mortality. Our previous observation that injection of apoptotic peripheral blood mononuclear cells (PBMC) was able to restore long-term cardiac function in a rat acute ischaemia model prompted us to study the effect of soluble factors derived from apoptotic PBMC on ventricular remodelling after AMI.

Materials and Methods Cell culture supernatants derived from irradiated apoptotic peripheral blood mononuclear cells (APOSEC) were collected and injected as a single dose intravenously after myocardial infarction in an experimental AMI rat model and in a porcine left anterior descending coronary artery, followed by reperfusion in a rat acute ischaemia model. The porcine reperfused AMI model APOSEC led to higher values of ejection fraction (57.0% vs 40.5%; p < 0.001) and a reduced extent of infarction size (12.6% vs 6.9%; p < 0.02) as determined by MRI. Administration of APOSEC in the rat AMI model caused increased presence of CD68+ macrophages and c-kit+ endothelial progenitor cells (EPC) in the infarcted myocardium within 72 hours. Exposure of primary human cardiac myocytes with APOSEC in vitro triggered the activation of pro-survival signalling-cascades (Akt, p38 MAPK, Erk1/2, CREB, c-Jun) and increased anti-apoptotic gene products (Bcl-2, BAG1).

Conclusions Intravenous infusion of culture supernatant of apoptotic PBMC attenuated myocardial remodelling in both models of experimental AMI. This effect seems to be due to the activation of pro-survival signalling cascades in the affected cardiomyocytes and to a higher presence of regenerative cells (EPC and macrophages) within the ischaemic tissue. Thus APOSEC would appear to represent a “biological” which prevents experimental myocardial infarction by causing peri-infarct conditioning and stimulation of regenerative effects in the hypoxic myocardium.

Evaluation of the Association between Common Variants at the GCK, GCKR, MTNR1B, and G6PC2 Loci with Angiographically Characterized Coronary Atherosclerosis

VIVIT-Institute, Feldkirch

Single nucleotide polymorphisms in the genes encoding glucokinase (GCK), glucokinase regulatory gene (GCKR), melatonin receptor 1B (MTNR1B), and islet-specific glucose 6 phosphatase catalytic subunit-related protein (G6PC2) have been associated with altered glucose metabolism. Potential links between these polymorphisms and coronary artery disease (CAD) are unclear and are addressed in the present study.

We genotyped variants GCK rs1799884, GCKR rs780094, MTNR1B rs10830963, and G6PC2 rs560887 in a large cohort of 1663 consecutive Caucasian patients undergoing coronary angiography for the evaluation of established or suspected stable CAD. Significant CAD was diagnosed in the presence of coronary stenoses ≥ 50%.

Conorony angiography revealed significant CAD in 57.8% of our patients. No significant associations of variants GCK rs1799884, MTNR1B rs10830963, and G6PC2 rs560887 with angiographically determined CAD were observed. However, variant GCKR rs780094 was significantly associated with a reduced risk of coronary atherosclerosis both univariately (allelic OR 0.84 [0.73–0.96]; p = 0.013) and after adjustment for potential confounders including fasting glucose (adjusted, allelic OR 0.84 [0.74–0.97]; p = 0.015).

We conclude that variant GCKR rs780094 is significantly associated with angiographically determined CAD. Because this association is independent from fasting glucose, the polymorphism appears to be linked to CAD via non-glucose mechanisms.

Intracardiac Delivery of Mesenchymal Stem Cells Promotes Recruitment of Haematopoietic Progenitors at the Site of Ischemic Injury in Experimental Myocardial Infarction

I. Pava, A. Poovathinkal, A. Posa, S. Chawat, S. Wolbank, G. Maurer, M. Gyöngyösi
Division of Cardiology, Department of Medicine II, Medical University Vienna; Ludwig Boltzmann Institute for Clinical and Experimental Traumatology/AUVA Research Center Austrian Cluster for Tissue Regeneration, Vienna

Background Bone marrow-derived mesenchymal stem cells (MSCs) are candidates for cell-based cardiac repair based on their immune tolerance and paracrine effects, secreting various cytokines and growth factors, resulting angiogenesis and improved microvascular function. In our present experiment we have investigated the chemotactic signal of MSC for hematopoietic stem and progenitor cell (HPC) recruitment.

Methods Closed chest reperfused acute myocardial infarction (AMI) was induced by 90-min occlusion of the middle portion of the left anterior descending coronary artery, followed by reperfusion in domestic pigs (n = 11). The allogeneic MSCs (CD34+, CD45-, CD44+, CD90+) were transfected transiently with Ad-Luc plasmid vector. Two weeks post-AMI, the animals were randomized, and received either 11.6 ± 2.1 × 10⁶ transfected Luc-MSCs in 12 sites intramyocardially using the NOGA three-dimensional technology (n = 5, group Luc-MSC), or served as controls (n = 6, group C). One
day after MSC delivery, the hearts were explanted, and in vitro bioluminescence imaging were performed to visualize the injections sites loaded with Luc-MSCs. The bioluminescent positive myocardi- um and control groups regarding the weight, gender, location of coronary artery occlusion. The haemodynamic parameters, such as heart rate and blood pressure were also similar in the groups pre- and post-proce- ssure and at the 1-day follow-up. In vitro bioluminescent images displayed 8 ± 3 sites of MSC delivery. Myocardial expression of CXCR4 was significantly elevated at the injections site of infarction (0.71 ± 0.05 vs 0.59 ± 0.03 ng/mL tissue homogenate; p = 0.008) and in the plasma (5.11 ± 1.87 vs 2.62 ± 1.17 ng/mL; p = 0.006) 1 day post Luc-MSC delivery, as compared with controls. Significantly higher number of CD34+ HPC (150 ± 79 vs 110 ± 35 cells/uL tissue; p = 0.001), CD31+ HPC (700 ± 675 vs 480 ± 255 cells/uL tissue; p = 0.007) were found at the border zone of infarction in pigs with Luc-MSC injections. Trend to higher density of CD34+ cells were found in Luc-MSC group, as compared to controls (p = 0.057). There was no differences between the groups regarding the absolute num- ber of CD34+, CD31+ and CD34+CD31+ HPCs in the myocardial in- farcted (scar) area.

Conclusion Intracardially injected MSC contribute to recruitment and homing of the autologous hematopoietic stem and progenitor cells, probably due to their paracrine effect, expressing chemotactic signals for cardiac accumulation of HSC.

Selective Mobilization of Different Endothelial Pro- genitors in Experimental Closed-Chest Reperfused Myocardial Infarction

A. Poovathikal, I. Favo, A. Posa, G. Maurer, M. Gyöngyösi
Division of Cardiology, Department of Medicine II, Medical University Vienna

Background Increase in circulating various stem and progenitor cells in the peripheral blood (PB) in response to myocardial ischemia (STEMI) or chronic myocardial ischemia revealed an elevated number of circulating stem and progenitor cells in patients with STEMI.

We have previously reported the increased mobilization and homing of CD31+CD90+CD45+ endothelial mature progenitor cells from bone marrow (BM) after ischemic preconditioning. However, no data exist on the mobilization of different early endothelial progenitors (CD34+) and progenitor cell subtypes (EPS, such as CD34+CD31+ and CD31+) in experimental closed-chest reperfused AMI (most similar to human STEMI with primary percutaneous coronary inter-

Methods Under general anesthesia, closed chest reperfused STEMI was induced in 22 domestic pigs by 90-min occlusion of the mid left anterior descending coronary artery (LAD), followed by balloon deflation inducing reperfusion. The pigs were then allowed to recover. Peripheral blood samples were collected pre-STEMI, af- ter 1h reperfusion and at the day 4 post-STEMI. The total number of circulating leukocytes were measured, and the percentage proportion of the mononuclear cells were calculated by qualitative differen- tial blood analysis. The absolute number of circulating CD34+, CD34+CD31+ and CD31+ cells were determined by fluorescence ac- tivated cell sorting (FACS).

Results The number of PB leukocytes increased from pre-STEMI to day 4 follow-up. Similarly, the absolute number of PB mono- nuclear cells increased too. FACS analysis revealed elevated number of mobilized CD34+ cells immediately post reperfusion (from 347 ± 192 to 346 ± 202/uL), with further increase at day 4 (575 ± 335/uL; p < 0.05). However, no change could be observed in circulating number of CD34+CD31+ (from 251 ± 214 to 160 ± 153 and 188 ± 217/uL from pre- to post-STEMI and at 4 day) or CD31+ cells (from 181 ± 94 to 233 ± 208 and 194 ± 142/uL, from pre- to post-STEMI and at 4 day) during the 4-day follow-up.

Conclusions Differential subtypes of early BM origin stem and progenitor cells are mobilized as a response to the stimulating factor of myocardial ischemia/reperfusion within 4 days of STEMI. The time-dependency of the early endothelial progenitor cells mobiliza-

Gallensäuren-induzierte Arrhythmien am menschli- chen Vorhofmyokard: Einfluss der Konjugation und mögliche Wirkungsmechanismen

Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz


Methoden Isolierte humane atriale Herz Muskulatur: modifizierte bikarbonathaltige Tyrode-Lösung, 11,2 mM Glukose, 2,5 mM Ca2+; 37°C, pH 7,4; Elektrische Stimulation mit 1 Hz und 0,5 Hz. Es wurde das Auftreten von Arrhythmien (AEC) nach Verabreichung von den beim Menschen dominierenden primären Gallensäuren (Taurin- und Glyzin-konjugierte Cholsäure und Chenodeoxychol- säure) und der therapeutisch genutzten Ursodeoxycholsäure in stei- genden Konzentrationen (10 µM–1 mM, n = 49) analysiert. Des Weiteren wurde der L-Typ Ca2+-Kanals mit Diltiazem gehemmt und mit BayK8644 aktiviert (1 µM, n = 8, 10). Außerdem bestimmte man die absoluten Refraktärzeiten durch Ankoppellungsversuche mit ste- tig abnehmendem Stimulationsintervall nach Inkubation mit Tauro- cholsäure (n = 16).

Ergebnisse Es konnten keine Arrhythmien bei Konzentrationen < 30 µM und 1 Hz Stimulation beobachtet werden. Steigende Gal- lensäure-Konzentrationen führten zu Arrhythmien, insbesondere bei 0,5 Hz Stimulation (11 ± 2,85 AECs/min vs. keine AECs bei der Kontrolle; p < 0,01). Betreffend den verschiedenen Konjugationen konnte kein statistisch signifikanter Unterschied bezüglich der ar- rhythmogenen Potenz der Gallensäuren gezeigt werden. Nach einer Auswaschphase der Gallensäure konnte die Rückbildung der Ar- rhythmien gezeigt werden.

Die Blockade des L-Typ Ca2+-Kanals mit Diltiazem führte zu einer Erhöhung der Arrhythmie-Inzidenz während die Aktivierung mit BayK8644 Arrhythmien vollständig unterdrücken konnte.

Die absoluten Refraktärzeiten in Anwesenheit von 0,3 mM und 1 mM Taurocholsäure nahmen auf 165 ± 9 ms und 174 ± 12 ms im Vergleich zur Kontrolle 157 ± 11 ms zu (p < 0,05 und p < 0,01).

Mild Hypothermia Does Not Further Excite Sympathetic Activation after Cardiac Arrest in Pigs

M. Schwarzl1, P. Steendijk2, S. Huber1, H. Mächler1, M. Truschnig-Wilders1, B. Pieske1, H. Post1

1Department of Cardiology, Medical University Graz; 2University Medical Center, Leiden, Netherlands

Background Mild hypothermia (MH, 32–34 °C) is induced after cardiac arrest to attenuate hypoxic brain injury. Experimental data also indicate a positive inotropic effect of MH. However, increased noradrenalin levels and shivering in awake and anaesthetized patients might reflect sympathetic activation, which would be an adverse side effect of MH after cardiac arrest. We aimed to study, whether or not MH further excites sympathetic activation after resuscitation.

Methods In 16 anaesthetized pigs (64 ± 2 kg), ventricular fibrillation (VF, 5 min) was induced electrically. After resuscitation including a single bolus of adrenaline (1 mg), pigs were assigned to either normothermia (38 °C, n = 8, NT) or MH (33 °C, n = 8, intravascular cooling device). At control conditions and at 10 min, 1 h, 2 h, 4 h, and 6 h after return of spontaneous circulation (ROSC), the heart rate variability (HRV) of a 15-min-ECG-sample was analyzed, and blood samples were drawn. The high-frequent-fraction (HF, 0.07–0.5 Hz) of HRV represented parasympathetic tone, the ratio between low-frequent-fraction (LF, 0.01–0.07 Hz) and HF represented sympathetic tone. Adrenaline, noradrenaline and dopamine levels were measured via commercial RIA-kits.

Results HF decreased in both groups at 10 min after ROSC (MH: 41 ± 6 vs 68 ± 5; p < 0.05; NT: 29 ± 4 vs 64 ± 7; p < 0.05). At 2 h after ROSC, HF was already higher in MH than in NT (76 ± 3 vs 37 ± 5; p < 0.05), and LF/HF was already lower in MH than in NT (0.21 ± 0.05 vs 1.75 ± 0.43; p < 0.05). At 6 h after ROSC, HF and LF/HF were back to control values in both groups. Catecholamine levels were not different between both groups at any time point (Figure 10).

Conclusion Both HRV and catecholamine levels returned to control values in both groups again, indicating that the induction of MH does not add further sympathetic stress to resuscitated hearts. Thus, beneficial effects of MH on cardiac function do not rely on an increased sympathetic tone.

The Induction of Mild Hypothermia Improves Oxygen Supply-Demand Balance in a Model of Acute Ischemic Heart Failure in Pigs

M. Schwarzl1, P. Steendijk2, S. Huber1, H. Mächler1, M. Truschnig-Wilders1, B. Pieske1, H. Post1

1Department of Cardiology, Medical University Graz; 2University Medical Center, Leiden, Netherlands

Background The induction of mild hypothermia (MH, 32–34 °C) is guideline therapy after cardiac arrest. In normal and resuscitated porcine hearts, MH exerts a positive inotropic effect and reduces whole body oxygen demand.

Hypothesis The induction of MH is a beneficial intervention in acute ischemic heart failure.

Figure 10: M. Schwarzl et al.

Figure 11: M. Schwarzl et al.
Methods In a closed chest preparation, 15 anesthetized pigs (70 ± 1 kg) were acutely instrumented with a Swan-Ganz catheter, a left ventricular (LV) pressure-volume catheter, a right atrial pacing probe, an intrasacral balloon catheter and an intravascular cooling device. 45 µm polystyrole microspheres were infused repeatedly into the left circumflex coronary artery (coronary microembolisation, CME) until cardiac power output decreased by > 40 %. Pigs were then assigned to either normothermia (NT, 38 °C, n = 8) or MH (33 °C, n = 7). Data are reported at 6 h after CME (CME 6) vs. control.

Results The target temperature of 33.0 °C was reached at 193 ± 13 min after CME. Heart rate (bpm) increased during NT (99 ± 6* vs. 86 ± 4), but decreased during MH (65 ± 4* vs. 86 ± 4). Cardiac output was reduced to a similar degree in both groups, but mean aortic pressure (AOP) was less decreased in MH due to increased systemic vascular resistance (mmHg/l/min, MH: 20 ± 1* vs. 16 ± 1, NT: 14 ± 1 vs. 17 ± 1) (Figure 11). Also, LV dP/dtmax was less decreased vs. control in MH (–31 ± 4 %) than in NT (–45 ± 2 *%). Central venous oxygen saturation (%) was markedly higher in MH than in NT due to reduced whole body oxygen consumption during MH (mL/min, MH: 193 ± 8* vs 332 ± 18, NT: 274 ± 4* vs 311 ± 10).

Conclusion The induction of MH in acute ischemic heart failure markedly improves systemic oxygen supply-demand balance by reducing systemic oxygen demand and further exerts a slight positive inotropic effect. These data warrant clinical studies of MH as a rescue intervention in acute heart failure and cardiogenic shock.

Interleukin-33 Induces Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 in Human Endothelial Cells In Vitro

S. Stejkovic, C. Kaun, G. Maurer, K. Huber, J. Wojta, S. Demьянєts
Division of Cardiology, Department of Medicine II, Medical University Vienna

Background The plasminogen system comprises an inactive proenzyme, plasminogen, which can be converted to the active enzyme, plasmin, which degrades fibrin to fibrin degradation products. Two physiological plasminogen activators (PA) have been identified: tissue-type PA (t-PA) and urokinase-type PA (u-PA). t-PA is primarily involved in fibrinolysis, while u-PA plays a pivotal role in proteolysis of extracellular matrix, tissue remodeling and angiogenesis, as well as in atherosclerosis progression, plaque instability and restenosis. Inhibition of the plasminogen system occurs at the level of the PAs, by specific plasminogen activator inhibitors (PAs).

It is thought that IL-33, a recently described member of IL-1 cytokine family, plays a role in the pathogenesis of atherosclerosis and was shown to induce vascular permeability and the production of inflammatory cytokines in endothelial cells and to stimulate angiogenesis. IL-33 is a ligand for its specific ST2 receptor, and its signaling is negatively regulated by a soluble form of ST2 that lacks the transmembrane domain and presumably acts as a decoy receptor. Here we aimed to study a possible regulation of u-PA and PAI-1 by IL-33 in human endothelial cells (EC) in vitro.

Methods Human umbilical vein EC (HUVEC) and human coronary artery EC (HCAEC) were treated with recombinant human IL-33 alone or with soluble ST2 fusion-protein (sST2-Fc). Specific mRNA levels for u-PA and PAI-1 were determined by RT-PCR and u-PA and PAI-1 antigen was measured by specific ELISAs.

Results u-PA mRNA was up-regulated up to 5-fold in HUVEC and up to 2.4-fold in HCAEC when these cells were treated with 100ng/ml IL-33 for 9 hours whereas PAI-1 mRNA increased up to 2.5-fold and up to 2-fold, respectively. u-PA antigen increased up to 30-fold, and PAI-1 antigen increased up to 2-fold after 48 hours of incubation with 100 ng/ml IL-33 in HUVEC. The increase in u-PA and PAI-1 antigen was concentration-dependent when the cells were incubated with IL-33 at concentrations ranging from 1 to 100mg/ml. sST2 Fc abrogated the IL-33-induced increase in u-PA and PAI-1 antigen, which suggests that these effects of IL-33 are ST2 receptor mediated.

Conclusion Via induction of u-PA and PAI-1 in endothelial cells, IL-33 could contribute to the modulation of endothelial cell-mediated extravascular proteolysis in processes such as neovascularization and vascular remodeling. By modulating these processes IL-33 could affect plaque angiogenesis thereby impacting on the stability of these vascular lesions in atherosclerosis.

Injection of Apoptotic Peripheral Blood Mononuclear Blood Cells (PBMC) Increases Elastin Expression in Cardiac Scar Tissue after Myocardial Infarction

G. Werba, M. Mildner, A. Baumgartner, M. Hasun, M. Gyöngyösi, B. K. Podesser, H. J. Ankersmit, M. Lichtenauer
Christian Doppler Laboratory for the Diagnosis and Regeneration of Cardiac and Thoracic Diseases, Medical University Vienna

Background Within the last decades early reperfusion therapy significantly reduced mortality following acute myocardial infarction (AMI) and also improved survival and prognosis of patients. However, the development of chronic ischaemic heart disease and congestive heart failure represents one of the most frequent causes of hospitalization in developed countries. We have previously shown that injection of apoptotic cells improves left ventricular function after acute experimental myocardial infarction in rats. In this study we sought to investigate changes in the composition of the fibrotic scar tissue after AMI.

Materials and Methods Cell suspensions of apoptotic cells were injected intravenously or intramyocardially after experimental AMI induced by coronary artery ligation in rats. Sham operated animals and rats injected with control medium or viable cells served as controls. Immunohistological analysis was performed to analyze the cellular infiltrate in the ischaemic myocardium. Six weeks after induction of AMI the scar tissue was examined for the ratio of collagenous and elastic fibres. Cardiac function was quantified by echocardiography. Moreover, the expression of transcripts for elastin and collagen was analyzed using RT-PCR.

Results Hearts of treated animals evidenced enhanced homing of macrophages and cells staining positive for IGF-1 and FGF-2 as compared to controls. Six weeks after AMI animals treated with intravenously or intramyocardial administration of irradiated apoptotic PBMC presented a remarkable accumulation of elastic fibers, culminating in the border zone between viable myocardium and scar tissue (Figure 12). A planimetric analysis revealed that the fibrotic scar in apoptotic cell (TV and IM) injected rats was composed by 5.5% ± 1.1 and 8.9% ± 2.2 of elastic fibres compared to 0.2% ± 0.1 in controls treated with control medium or viable cells.
and 2.9% ± 0.2 in viable injected animals (p < 0.001 vs control, n = 10–12 per group).

Conclusion Injection of apoptotic cell suspensions resulted in attenuation of myocardial remodelling after experimental AMI, preserved left ventricular function and altered the composition of cardiac scar tissue. The higher expression of elastic fibres could provide passive energy to cardiac scar tissue which results in prevention of ventricular remodelling.

Bildgebung/Imaging

Vitalitätsdiagnostik in hochgradig wandverdünnnten Myokardabschnitten mittels kardialer Magnetresonanztomographie

M. Avanzini, B. Freudenthaler, A. Bastovansky, F. Weidinger, P. Wesberg
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien


Material und Methode Bei 5 Patienten mit ischämischer Kardiomyopathie und einer EF < 40 %, wo bereits im Echo eine verdünnte Narbe beschrieben war, wurde eine CMR durchgeführt. Alle Patienten waren männlich und hatten eine Infarktanamnese (4 Vorder- und 1 Vorder- und Hinterwand). Mit Steady-State-Free-Precession-(SSFP-) Techniken wurden dynamische Aufnahmen der Herzaktion vorgenommen und die linksventrikuläre Masse (LVM) und Auswurffraktion (EF) sowie das linksventrikuläre enddiastolische Volumen (LVEDV) bestimmt. Zehn Minuten nach Verabreichung von 0,1 mmol Gadolinium/kg KG wurden das LGE mittels GE-IR sowie PSIR untersucht.

Ergebnisse Das mittlere LVEDV war deutlich erhöht (279,4 ± 36,7 ml; 223–316 ml), die LVM im Verhältnis dazu nur gering erhöht (194,6 ± 30,6 g; 160–235 g). Die EF betrug im Mittel 25,7 ± 11,0 %; 12–40 %). Bei 4 Patienten fand sich im wandverdünten akinetischen Bereich eine transmurale Narbe/Fibrose sowohl im GE-IF als auch in der PSIR; beim verbleibenden Patienten zeigte sich erhaltene Myokardvitalität in den wandverdünten akinetischen Arealen in beiden Verfahren.

Diskussion Der Nachweis einer extremen Wandverdünnung Myokardabschnitten mit Wandbewegungsstörungen kann nicht a priori als fehlende Vitalität gewertet werden, sondern erfordert eine weitere Abklärung.

Value of 2D-Strain Dobutamine Stress Echocardiography Compared with 18FDG-PET for Evaluation of Viability and Scar in Patients with Low Flow – Low Gradient Aortic Stenosis. A Sub-Study of the TOPAS Study

P. E. Bartko1, S. Graf1, A. Khorsand1, R. Rosenhek1, J. Bergler-Klein1, M. Schütz2, JG. Dumesnil3, IG. Burwash3, R. S. Beanlands3, M.-A. Clavel4, H. Baumgartner5, P. Pibarot4, G. Mundigler1
1Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna; 2Department of Nuclear Medicine, Medical University of Vienna; 3Heart Institute, University of Ottawa, Canada; 4Laval University, Quebec, Canada; 5Department of Cardiology & Angiology, University Hospital, Muenster, Germany

Purpose In patients with low flow-low gradient aortic stenosis (LFAS) dobutamine stress echocardiography allows discrimination between true and pseudo severe aortic stenosis as well as the assessment of functional myocardial reserve, which is a strong predictor for post-operative outcome. Reduced left ventricular contractility needs further evaluation of the amount of residual viability (as revealed by 18FDG-PET) to estimate the potential of functional improvement. We investigated the value of peak systolic longitudinal 2-D strain (PLS) for discrimination between different viability states in comparison to 18FDG-PET.

Methods We consecutively enrolled 22 patients with LFAS, which was defined by aortic valve area (AVA) ≤ 1.2cm² (indexed AVA ≤ 0.6cm²/m²), LVEF ≤ 40% and mean pressure gradient ≤ 40 mmHg. All patients underwent N-13 ammonia (perfusion scan)
and 18FDG-PET (metabolism scan) and were thus classified as follows: Normal (N-13 ammonia uptake > 70%), perfusion/metabolism mismatch (N-13 ammonia uptake ≤ 70% and 18FDG uptake < 70%) and scarred segments (N-13 ammonia uptake ≤ 70% and 18FDG uptake < 50%). Subsequently we arranged segments into groups: viable (normal and mismatch) versus reduced viability (match and scar) and normal versus scar. PLS analysis was performed offline in the apical 4,3, and 2 chamber views by a blinded observer for each step: echocardiography at rest, 10mcg/kg/h (LDD) and peak dose (PDD) dobutamine. We used bull’s eye analysis with an 18 segment model to compare 18FDG-PET with speckle tracking echocardiography.

**Results**

16 male and 6 female patients, age 70 ± 12 years (mean ± SD) were examined. LVEF was 29 ± 11%, AVA-index 0,4 ± 0,1cm²/m². Segmental classification by 18FDG-PET. We found 324 viable segments and 18 segments with reduced viability. Sub-analysis showed 262 normal segments and 22 scarred segments. PLS values for different viability states are shown in Table 6. ROC curves with corresponding areas under the curves for differentiation of viable from segments with reduced viability as well as normal from scar tissue are shown in Figure 13. PLS cut-off values and sensitivity/specificity are shown in Table 7.

**Conclusions**

In patients with LFAS PLS is significantly impaired in segments with reduced viability compared to viable segments and even more impaired in scar compared to normal tissue. Dobutamine administration improves differentiation of viable from segments with reduced viability by PLS with best performance at LDD levels. PLS in the setting of DSE in patients with LFAS may provide a new tool to discriminate different states of viability, especially to differentiate scar from normal myocardial tissue.

### Table 7: P. E. Bartko et al.

<table>
<thead>
<tr>
<th>PLS cut-off values for differentiation between viable/reduced viability and normal/scar</th>
<th>Rest</th>
<th>LDD</th>
<th>PDD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cut-off viable/reduced viability</td>
<td>-6.8</td>
<td>-7</td>
<td>-6.8</td>
</tr>
<tr>
<td>Sensitivity/specificity</td>
<td>56%</td>
<td>62%</td>
<td>62%</td>
</tr>
<tr>
<td>Cut-off scar/normal</td>
<td>-5.6</td>
<td>-6</td>
<td>-6</td>
</tr>
<tr>
<td>Sensitivity/specificity</td>
<td>65%</td>
<td>70%</td>
<td>68%</td>
</tr>
</tbody>
</table>

---

Nicht-invasive Darstellung der elektroanatomischen Aktivierung des Herzens (NICE) in einem CRT-Patienten mit einer quadrupolaren Linkssventrikellektrode


**Hintergrund**


**Methoden**


**Resultate**

Während RV-Stimulation zeigte sich eine geringgradige Verlängerung der QRS-Dauer im Vergleich zum intrinsischen Sinusrhythmus (190 vs. 183 ms) während LV als auch BiV-Stimulation (beide: Stimulationsphase distal 1/proximal 4: 3,5V/0,5 ms) in einer Verkürzung der QRS-Dauer (122 und 142 ms) resultierte. Es zeigte sich eine große Variabilität hinsichtlich der QRS-Dauer während unterschiedlicher Stimulationssphase bei gleicher Stimulationslektrode (Tabelle 8). Die endo-/epikardiale elektroanatomische Aktivierung des Ventriksels während RV, LV und BiV-Stimulation ist in Abbildung 14 dargestellt.

**Zusammenfassung**

NICE ermöglicht die nicht-invasive Visualisierung der unterschiedlichen ventrikulären Aktivierungssequenzen während unterschiedlicher Stimulationsmodi. NICE ermöglicht somit eine individuelle elektroanatomisch-gestützte Optimierung der CRT-Programmierung. In Kombination mit den MRI-Daten sollte in Zukunft bereits präoperativ die optimale Platzierung der linksventrikulären Elektrode (abhängig von evtl. Narbenarealen und der CS Anatomie) planbar sein.

---

**Table 8: T. Berger et al. Einfluss der unterschiedlichen Stimulationsvektoren auf die QRS-Dauer während LV- und BiV-Stimulation (3,5 V/0,5 ms)**

<table>
<thead>
<tr>
<th>Vektor</th>
<th>LV only</th>
<th>BiV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distal1–Mid2</td>
<td>135</td>
<td>133</td>
</tr>
<tr>
<td>Distal1–Proximal4</td>
<td>127</td>
<td>142</td>
</tr>
<tr>
<td>Distal1–RV coil</td>
<td>122</td>
<td>139</td>
</tr>
<tr>
<td>Mid2–Proximal4</td>
<td>141</td>
<td>122</td>
</tr>
<tr>
<td>Mid2–RV coil</td>
<td>153</td>
<td>137</td>
</tr>
<tr>
<td>Mid3–Mid2</td>
<td>170</td>
<td>120</td>
</tr>
<tr>
<td>Mid3–Proximal4</td>
<td>175</td>
<td>136</td>
</tr>
<tr>
<td>Mid3–RV coil</td>
<td>180</td>
<td>128</td>
</tr>
<tr>
<td>Proximal4–Mid2</td>
<td>178</td>
<td>121</td>
</tr>
<tr>
<td>Proximal4–RV coil</td>
<td>197</td>
<td>124</td>
</tr>
</tbody>
</table>

---

**Abbildung 14: T. Berger et al. (A) Lage der Elektroden in der Durchleuchtung (RAO); NICE-Darstellung der elektroanatomischen Aktivierungssequenz während RV-Stimulation (B), während BiV-Stimulation mit distal1/proximal4 (C) und mid2/prox4 (D) Strompfad-Programmierung (Isochrome in Millisekunden).**

---

ÖKG-Annual Conference 2011 – Abstracts
Hintergrund
Durch zunehmende technische Verbesserungen hat sich die CT-Koronarangiographie (CT-KA) mittels hochauflösender Spiral-Computertomographie (CT) als zuverlässige Methode zum Ausschluss einer koronaren Herzkrankheit (KHK) etabliert. Spiral-CT-Untersuchungen werden jedoch auch zunehmend zur Erfassung anatomischer Informationen, die für eine integrative Bildgebung bei der Ablation von Vorhofflimmern (VHF) verwendet werden, durchgeführt. Da VHF in gewissem Ausmaß mit einer zugrunde liegenden KHK assoziiert ist, erscheint eine simultane CT-KA bei Patienten (P) mit Herz-CCT vor geplanter VHF-Ablation sinnvoll.

Wir untersuchten Machbarkeit, Qualität und Aussagekraft der simultanen CT-KA bei kardialer CTAufnahme von P mit VHF und fehlender KHK-Anamnese.

Methodik
Patienten mit paroxysmalem VHF und niedriger bis mittlerer Prätestwahrscheinlichkeit für KHK, bei denen zur Evaluierung hinsichtlich einer VHF-Ablation eine Herz-CCT-Untersuchung geplant war, wurden in das Register aufgenommen. Nicht eingeschlossen wurden P mit bekannter KHK, nach Koronarirrektionen oder aortokoronarer Bypassoperation.


Die Auswertung erfolgte unmittelbar nach Ende der Untersuchung. Es wurde der Ausschluss einer KHK oder Nachweis einer nicht signifikant stenosierenden Sklerose (NSS) beziehungsweise von signifikanten Koronarstenosen (>70%, SST) evaluiert. Die Qualifizierung der CT-KA als unauffällig (ASA = 0 und normales Angiogramm), nicht NSS und SST erfolgte ebenso wie die Beurteilung der Bildqualität in gut, mittel und schlecht im Konsens zweier Untersucher.

Ergebnisse
Es wurden 244 P (172 männlich) mit einem mittleren Alter von 62 ± 7 Jahren untersucht. Die mittlere Scan-Zeit betrug 13,9 ± 0,7 Sekunden. Der statistische Medianwert des ASÄ lag bei 9,5 (Interquartilsabstand 0–187,5).

Bei 243 P erlaubte die Bildqualität eine Untersuchung aller Gefässe (gut bei 182, mittel bei 61 P), bei 1 P machten hochgradig reduzierte systolische Funktion und diffusen Wandbewegungsstörungen bis zur Zeichenfehlender Vitalität der basalen Diaphragmalwand entsprechend dem LE des MRT.

Die Koronarangiographie zeigte eine hochgradige Hauptstammtstenose, mehrfache komplexe Stenosen der LAD, eine verschlossene A. circumflexa und eine proximal verschlossene rechte Koronararterie. Es wurde ein Vitalitätsnachweis mittels MR durchgeführt, wobei sich eine Wandverdickung auf ca. 5 mm im Bereich der akinetischen mittleren und apikalen Vorderwand zeigte; in diesen Abschnitten fand sich überraschenderweise kein Nachweis eines transmuralen „late enhancements“ (LE) nach KM-Gabe. Es bestand jedoch ein u. a. in den beschriebenen Abschnitten umschriebenes Fibroseareal in der Normaldickenbasalen Diaphragmalwand. Auch eine Thallium-Ruhe-Mykardzintigraphie erbrachte einen Vitalitätsnachweis in der Vorderwand. Eine Bypassoperation wurde geplant, allerdings verstarb der Patient nach einem neuerlichen Myokardinfarkt in kardiogenem Schock. Die Obduktion zeigte in der verdünnten Vorderwand und ebenfalls lediglich den rezenten, lektalen Myokardinfarkt ohne ausgedehnte, alte Narbe, die diesem zeigte sich in der basalen Diaphragmalwand entsprechend dem LE des MRT.

Diskussion

Myocardium at Risk in ST-Elevation Myocardial Infarction: Comparison of T2-Weighted Edema Imaging with the Endocardial Surface Area Assessed by Magnetic Resonance and Validation Against Angiographic Scoring

Klinik für Innere Medizin/Kardiologie, Herzcenter, Universität Leipzig, Deutschland

Objective
The objective of this study was to assess the area at risk (AAR) in ST-elevation myocardial infarction (STEMI) with 2 different magnetic resonance imaging (MRI) methods and to compare them to the validated angiographic APPROACH-score in a large consecutive patient cohort.

Background
Edema imaging with T2-weighted MRI and the endocardial surface area (ESA) assessed by late gadolinium enhancement (LGE) have been introduced as relatively new methods for AAR assessment in STEMI. However, data on the utility and validation of these techniques are limited.

Methods
One-hundred-ninety-seven patients undergoing primary percutaneous coronary intervention in acute STEMI were included. AAR (assessed with T2-weighted edema imaging and the ESA method), infarct size and myocardial salvage (AAR minus infarct size) were determined by MRI 2–4 days after primary angioplasty. Angiographic AAR scoring was performed by use of the APPROACH score. All measurements were done offline by blinded observers.

Results
The AAR assessed by T2-weighted imaging showed good correlation with the angiographic AAR (r = 0.87; p < 0.001), where-
Welche Rolle hat das koronare Multislice-CT vor Rekanalisationen chronischer Koronarverschlußse?

C. Granitz, M. Granitz, J. Kraus, K. Hergan, M. Pichler, J. Schuler
Paracelsus Private Medizinuniversität Salzburg


Daraus ergibt sich die Fragestellung, ob mithilfe der kMSCT Aussagen über die Gefäßperipherie und Kollateralisierungswege getroffen werden können. Um diese Frage zu beantworten, konnte bei 21/31 Patienten (67,7 %) exakt berechnet werden und deutlich und artefaktfrei dargestellt (70,9 %). Die Verschlusslänge des CTO-Gefäßes wurde durch die kMSCT bei 22/31 Patienten eindeutig beschrieben. Die koronare Multislice-CT (kMSCT) bietet hierfür interessante Ansatzpunkte.

Tabelle 9: C. Granitz et al.

<table>
<thead>
<tr>
<th>Männern/Frauen</th>
<th>27/4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mittleres Alter</td>
<td>60,61 ± 9,13</td>
</tr>
<tr>
<td>anamnest. Myokardinfarkt</td>
<td>9 (29 %)</td>
</tr>
<tr>
<td>anamnest. PCI</td>
<td>17 (54,8 %)</td>
</tr>
<tr>
<td>anamnest. CAGB</td>
<td>4 (12,9 %)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>6 (19,3 %)</td>
</tr>
<tr>
<td>Art. Hypertonus</td>
<td>24 (74 %)</td>
</tr>
<tr>
<td>Hyperlipidämie</td>
<td>30 (96,7 %)</td>
</tr>
<tr>
<td>Rauchen</td>
<td>15 (48,4 %)</td>
</tr>
<tr>
<td>Niereninsuffizienz (GFR &lt; 30 ml/min)</td>
<td>1 (3,2 %)</td>
</tr>
<tr>
<td>betroffenes CTO-Gefäß (LM, LAD, RCX, RCA)</td>
<td>1/86/16</td>
</tr>
<tr>
<td>1/2/3-Gefäß-Erkrankung</td>
<td>7/13/1</td>
</tr>
<tr>
<td>Führendes Symptom CCS 1/2/3/4 NYHA ≥ 2</td>
<td>3/12/1/2 3</td>
</tr>
<tr>
<td>Vitalitätsnachweis: Sintigramm/MRI/keiner/andere</td>
<td>19/5/7</td>
</tr>
</tbody>
</table>

Um kumulative Strahlendosis zu sparen, wurde bei 17/31 ein strahlensparender Algorithmus verwendet („tep and shoot“). Der mittlere Kontrastmittelverbrauch bei der kMSCT betrug 88 ml. Diskussion Wenn die kMSCT technisch gelingt, kann die Charakteristik des Koronarverschlusses mit ausreichender Qualität dargestellt werden. Dies ermöglicht eine bessere Planung der Therapiestrategie im Herzkatheterlabor. Ein besonderes Augenmerk sollte zukünftig auf die Darstellung des Kollateralkreislaufs gelegt werden, da sich aus diesen Informationen wichtige Implikationen bezüglich eines retrograden Zugangsweges ergeben.

Ascending Aortic Distensibility Coefficients Rather than Local Aortic Pulse Wave Velocities Discriminate Healthy Volunteers From Patients with Coronary Artery Disease

Department of Internal Medicine III, Medical University Innsbruck

Background Cardiac Magnetic Resonance (CMR) is a unique method to determine regional and local aortic elastic parameters. So far no study has compared the use of local distensibility coefficients (DC, 10 – 3 × mmHg) and local ascending aortic pulse wave velocities (PWV, m/s), determined by CMR in patients with coronary artery disease. This study investigates the use of local (ascending) aortic DC ascending in healthy volunteers and patients with CAD and compares the results to regional and local pulse wave velocities. This is of clinical importance since we showed previously the limitations of local PWV determination in a diseased population.

Methods We performed velocity encoded, phase contrast CMR (retrospectively ECG-gated, temporal resolution: 20 ms) in 18 healthy volunteers as well as in 26 patients with coronary artery disease (CAD) (n = 42, mean age 46.6 ± 20.3 years, 11 female). Measurements were performed at the levels of the ascending and descending thoracic, as well as the abdominal aorta. Flow-volume curves and cross-sectional area changes were determined during early systole. Regional PWVT was determined by the established transit-time method and served as a reference standard. DC ascending was determined as the product of the relative area change during systole and the pulse pressure (mmHg). Local PWVQA was determined as the ratio of the flow (Q) and area (A) variations.

Results Healthy volunteers differed significantly from CAD patients in regional PWVT (4.93 ± 0.59 vs 9.16 ± 3.57 [m/s]; p < 0.001) and DC ascending (23.07 ± 8.47 vs 6.80 ± 4.34 [10 – 3 × mmHg]; p < 0.001). Local ascending aortic PWVQA, however, failed to detect differences between healthy volunteers and CAD patients (3.48 ± 1.79 vs 2.46 ± 3.49 [10 – 3 × mmHg]; p = 0.267). Furthermore DC ascending correlated inversely with age (r = -0.739; p = 0.001) and PWVTT (r = -0.538; p < 0.005). Local PWVQA did not correlate with age (p = 0.374) or regional PWVT (p = n. s.).

Conclusion This pilot-study indicates that local aortic DC ascending is a robust method for the assessment of CAD patients. Local PWVQA, however, failed to detect differences in local aortic stiffness between the 2 studygroups. For the assessment of local ascending aortic elasticity in CAD patients with CMR, DC ascending should be preferred to local PWVQA.

Early Microvascular Obstruction After Acute Myocardial Infarction Predicts Clinical Long-Term Outcome: Data From a 5 Year Follow-Up

G. Klug, S. Schenk, A. Mayr, M. Nocker, T. Trieb, M. Schacke, O. Pachinger, B. Metzler
Department of Internal Medicine III, Medical University Innsbruck

Aims Early and late microvascular obstruction (MVO) assessed by cardiac magnetic resonance imaging (CMR) are prognostic markers for combined clinical endpoints after acute myocardial infarction (AMI). However, there is a lack of studies with long-term follow-up periods (> 24 months).
Background The use of late-enhancement (LE) CMR imaging offers a high specificity for the detection of myocardial injury in myocarditis. Nevertheless, it was shown to be insensitive for the detection of symptomatic myocarditis with limited or nonfocal irreversible injury. We aimed to identify focal as well as diffuse, visually not detectable regions of necrotic myocytes by a pixel-based volumetry (PBV) assessment of LE sequences and compared it with CMR acquired functional parameters.

Methods Cardiac MRI was performed in 51 patients, 23 female, aged 40 ± 17 years within the first week after onset of symptoms of acute myocarditis. PBV of LE areas were calculated using an individual signal intensity cut-off value of the myocardium in each patient. Parameters of global left ventricular function were determined from short-axis cine cardiac magnetic resonance sequences.

Results LE was detected in 40 patients (79%) and comprised at mean 5.6 ± 7.8% (0.5–36.3%) of overall myocardial pixel. Extent of LE did not correlate with left ventricular ejection fraction (LV-EF) (p = 0.4) nor with end-diastolic-volume (EDV) (p = 0.3). However, LV-EF of patients with a focal extent of LE (15/40 patients, 37.5%) was significantly lower (p < 0.03) than global LV function of patients with diffuse LE (25/40 patients; 62.5%) detected by PBV.

Conclusion Left ventricular ejection fraction was significantly higher in patients with diffuse myocarditis than in patients with focal myocarditis. Our approach of using a pixel-based volumetry of CMR late enhancement images based on individual signal intensity cut-off values offers an accurate quantitative assessment of disseminated myocarditis.

Size Matters! Impact of Gender, Age, Height, Weight and Overweight on Heart Dimensions

S. Pfaffenberg, E. Lolic, P. Bartko, E. Pernicka, T. Binder, G. Maurer, J. Mascherbauer
Division of Cardiology, Department of Internal Medicine II, Medical University Vienna

Background Many diseases cause changes of the size of the heart. The judgment whether a heart is normally sized or enlarged is important, particularly when heart dimensions determine patient management as for example in patients with valvular heart disease. However, the impact of overweight on heart dimensions and potential gender differences are unclear.

Methods We prospectively included 516 outpatients (women: n = 316, age 15–91 years, height 143–183 cm, weight 32–128 kg; men: n = 200; age 16–82 years, height 156–200 cm, weight 54–240 kg) without known cardiac disease and with unremarkable clinical status who underwent a standard echocardiographic evaluation. Multiple linear regressions on the impact of height, weight, age, gender, body mass index (BMI), and body surface area (BSA) on heart dimensions were performed.

Results Women had significantly smaller hearts: left ventricular end-diastolic diameter (EED) 41.4 ± 3.4 vs 46.0 ± 3.8 mm; p = 0.0007; right ventricular EDD 28.0 ± 3.3 vs 32.2 ± 3.5 mm; p < 0.0001; left atrial area 14.2 ± 3.2 vs 16.3 ± 3.7 cm²; p < 0.0001; right atrial area 12.5 ± 2.9 vs 15.6 ± 3.9 cm²; p < 0.0001. By multivariable analysis left ventricular dimensions were independently influenced by gender, height, BMI, and age (all p < 0.0001) while only gender and BSA had an independent impact on right ventricular size (all p < 0.0001). Both left and right atrium size, were independently influenced by BSA, gender, and age (all p < 0.0001).

Conclusions Women have smaller hearts than men, independent from height and weight. Furthermore, age, height, weight, and consequently BMI and BSA determine heart dimensions. These results are important as patient management in many cases depends on dis-
crepations of heart dimensions from “normal values”. Normal values and cut-offs should therefore account for gender, age, and body size.

**Refinement of Echocardiographic Criteria for Left Ventricular Non-Compaction**

C. Stöllberger, B. Gerecke, J. Finsterer, R. Engberding
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien

**Background and Aim**
Left ventricular noncompaction (LVNC) is a cardiac abnormality of unknown etiology whose echocardiographic criteria are still controversial. Cooperation between echocardiographic laboratories may contribute to uniformly accepted criteria.

**Methods and Results**
Echocardiograms from patients proposed for inclusion into a registry were jointly reviewed. Three experts with 17–26 years experience with LVNC agreed on a common definition of LVNC: 1.) > 3 prominent trabecular formations along the left ventricular endocardial border visible in end-diastole; 2.) trabeculations move synchronously with and have the same echogenicity as the myocardium; 3.) trabeculations form the noncompacted part of a 2-layered myocardial structure, best visible at end-systole; 4.) perfusion of the intertrabecular spaces from theventricular cavity is prarinent at end-diastole; 5.) Color-Doppler echocardiography or contrast echocardiography, and 5.) absence of other cardiac anomalies. During 3 sessions 115 cases (37 % females, age 18–87, mean 57 years) were reviewed. Eleven patients (18 % females, age 47–77, mean 60 years) were excluded because of < 4 trabeculations (n = 5), lack of a 2-layered myocardial structure (n = 1) and poor image quality (n = 5). The observers agreed on inclusion or exclusion in all cases. Consensus was achieved that measurements of the thickness of the myocardial layers, and calculation of the non-compacted:compacted ratio is investigator-dependent, and standards for measurements were impossible to achieve.

**Conclusions**
When diagnosing LVNC, end-systolic as well as end-diastolic images have to be considered. > 3 trabeculations as well as a 2-layered myocardium are required for diagnosing LVNC. Since our criteria are not anatomically controlled, there is an urgent need to compare echocardiographic images with pathoatomic findings for assessing sensitivity and specificity.

**Anwendung der Stressechokardiographie in Österreich**

Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin II, Medizinische Universität Wien

**Einleitung**
Unter den nicht-invasiven diagnostischen Untersuchungsmethoden in der Kardiologie ist die Stressechokardiographie (SE) ein kostengünstiges, sensitives Verfahren ohne Strahlenbelastung. Ziel unserer Studie war, die Anwendung der SE in Österreich zu erfassen.

**Material und Methode**
Die Datenerhebung erfolgte mittels strukturiertem Fragebogen in Österreichs Spitälern mit internen bzw. spezifisch kardiologischen Abteilungen. Erhoben wurden die Häufigkeit der Anwendung, die Indikation, die Anzahl der Untersucher pro Abteilung, die Art der verwendeten Geräte und angegebene Techniken, die Zeitaufwand für die Untersuchung sowie auftretende Komplikationen.

**Ergebnisse**

**Diskussion**
Da 74 % aller internistischen Abteilungen Österreichs die SE nicht oder maximal 10× pro Jahr nutzen und in nur 4 Abteilungen die in Qualitätsrichtlinien empfohlene Untersuchungszahl (100 Untersuchungen/Jahr) erreicht wird, ergeben sich mehrere Fragen: Warum wird die SE in Österreich so selten angewendet? Können die Qualitätstrends in den Referenzlaboren in Österreich von den Untersuchern beeinflusst werden?

**Projekt „CQI Echo“ – Systematisches Qualitätsmanagement im Echolabor**

Abteilung für Kardiologie und Intensivmedizin, Landeskrankenhaus Graz-West

**Einleitung**
In einem 2009 publizierten Positionspapier der European Association of Echocardiography (EAE) wird ein systematisches Qualitätsmanagement in den Referenzlaboren für Echokardiographie empfohlen. Die Durchführung und Qualitätserstellung der Untersuchungen sind von entscheidender Bedeutung für die Anzeige von Veränderungen im Herzen und das daraus resultierende diagnostische Raster. Um sicherzustellen, dass die besten möglichen Ergebnisse erzielt werden, ist es erforderlich, eine systematische Qualitätserstellung durchzuführen.

**Methoden und Material**
Die Qualitätssicherungsmaßnahmen umfassen die Erstellung und Durchführung von Standardoperationen, die regelmäßige Überprüfung der Ergebnisse, die Dokumentation der Untersuchungsergebnisse, die Erstellung von Berichten und die Feedback-Mechanismen. Die Qualitätssicherungsmaßnahmen sind von entscheidender Bedeutung für die Anzeige von Veränderungen im Herzen und das daraus resultierende diagnostische Raster. Um sicherzustellen, dass die besten möglichen Ergebnisse erzielt werden, ist es erforderlich, eine systematische Qualitätserstellung durchzuführen.

**Ergebnisse**

**Danksagung**
Die Autoren danken allen Beteiligten für ihre Unterstützung und ihre konstruktive Rückmeldung. Die Autoren danken allen Beteiligten für ihre Unterstützung und ihre konstruktive Rückmeldung.

**Literatur**

und Befunderstellung sind bereits seit mehreren Jahren etabliert. Die Untersuchung ist ein Teil des Projektes „CQI Echo“ (Continuous Quality Improvement of Echocardiography).


**Schlussfolgerung** Eine systematische Evaluatorierung der echokardiographischen Untersuchungen nach definierten Qualitätskriterien ist neben der Kenntnis der wichtigsten Kennzahlen eine entscheidende Maßnahme zur Qualitätssicherung im Echolabor. Standardisierte Abläufe der echokardiographischen Untersuchung sowie Befunderstellung, welche sich an aktuellen internationalen Empfehlungen orientieren sollten, sind dabei die Grundvoraussetzungen.

**Abb. 16** W. Weihs et al.
Conclusions The mid-term results of robotically assisted totally endoscopic aortic repair are very satisfactory and well comparable with conventional and mini-thoracotomy approaches. Complex defects including removal of malpositioned occluders can be repaired using endoscopic methods.

Mechanisms of Symptomatic Spinal Cord Ischemia after TEVAR—Insights from the European Registry of Endovascular Aortic Repair Complications (EuREC)

M. Czerny on behalf of the EuREC-2-Investigators
Herz-Gefäßchirurgie, Inselspital Bern, Schweiz

Methods and Results We analyzed 523 consecutive patients undergoing surgical repair for acute and chronic thoracic aortic pathology using HCA. Duration of surgery and duration of HCA as well as logistic EuroSCORE levels, reflecting the extent and severity of the underlying disease, are independent risk factors for adverse outcome. As such, advanced age alone should no longer be considered as a contraindication for surgery in these patients.

The Influence of Gender on Mortality in Patients After Thoracic Endovascular Aortic Repair

M. Czerny, G. Sadeck, M. Funovics, A. Juraszek, T. D佐dizio, M. Grimm, M. Ehrlich
Herz-Gefäßchirurgie, Inselspital Bern, Schweiz

Aims The aim of this study was to determine if gender affects mortality in patients after thoracic endovascular aortic repair (TEVAR).

Methods We retrospectively analyzed 286 consecutive patients undergoing TEVAR at our institution during a 12-year period (female 29%, median age 69a). Chronic health conditions, risk factors as well as early and long-term outcome were assessed. Follow-up data were available in all patients.

Results For female gender, 1-year survival and 5-year survival was significantly lower for male gender. No significant gender influence was observed (OR 0.96; 95%-CI: 0.59–1.56). Furthermore, no significant gender influence could be observed according to the individual indication atherosclerotic aneurysms (OR 0.78; 95%-CI: 0.41–1.47), acute type B dissections (OR 0.78; 95%-CI: 0.21–2.83), penetrating ulcers/intramural hematoma (OR 1.48; 95%-CI: 0.53–4.19) as well as traumatic aortic lesions (OR 1.48; 95%-CI: 0.53–4.19). Age (OR 3.6; 95%-CI: 1.24–10.45) as well as COPD (OR 3.09; 95%-CI: 0.98–9.73) were independent predictors of mortality in females.

Conclusions Gender does not affect mortality in patients after TEVAR irrespective of the underlying indication, atherosclerotic aneurysms, acute type B dissections, penetrating ulcers/intramural hematoma as well as traumatic aortic lesions. Classical risk factors such as age and the presence of COPD at the time of TEVAR remain the most important risk factors in females.

Minimally Invasive Mitral Valve Surgery—Technique and Perioperative Results in 341 Patients

J. Dumfarth, H. Hangler, J. Kilo, E. Puttmann, S. Sansroth, M. Grimm, M. Mueller
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck

Objective Minimally invasive intracardiac surgery through a lateral minithoracotomy was introduced in the mid 1990s with a then prohibitive complication and mortality rate. Diffusion of the technique is still limited although results are now excellent in specialized centers. The results of Austria’s first minimally invasive mitral valve surgery program are analyzed.

Methods From 03/2001 to 01/2011 341 patients underwent minimally invasive mitral valve surgery at our institution. Additional tricuspid annuloplasty (TVP) was indicated for severe tricuspid regurgitation or tricuspid annular dilatation > 40 mm. Left atrial ablation (RF-Maze) was performed using unipolar radiofrequency for chronic AF.
Results Perioperative mortality was 0.6% (2 patients). After implementation of the minimally invasive valve program TVP or Maze procedure in addition to MVP or MVR was added after 54 successful isolated MV procedures. 295 patients had mitral valve repair, in 46 elective prosthetic mitral valve replacement was performed. 4 patients (1.2%) had intraoperative conversion to valve replacement for failed repair, 9 patients (2.6%) needed conversion to median sternotomy for intraoperative complications. All pathologies amenable to valve repair were addressed by the minimally invasive technique, annuloplasty ring sizes ranged from 24–40 mm (mean 32.7 mm). Repair techniques included predominantly leaflet resection, sliding leaflet plasty, PTFE chordae insertion, papillary muscle splitting, papillary muscle transposition, chordal transfer, pericardial patch plasty, prosthetic ring annuloplasty and prosthetic valve replacement.

Conclusions Minimally invasive mitral valve surgery can be performed safely with excellent results if the classic repair techniques are employed. If required, additional procedures like TVP, RF-Maze and others can be performed by the same approach. The minimally invasive access is the procedure of choice in our institution for most mitral valve procedures excluding valves with severe annular calcification.

Wahrnehmungsstörungen und kognitive Residuen nach kardiochirurgischen Eingriffen

SKA-Rehabilitationszentrum St. Radegund


Ergebnisse 42,9 % der Patienten berichteten retrospektiv im AHV von Wahrnehmungsstörungen mit verschiedener Intensität (akustische, optische Halluzinationen, Zönästhesien, Mikro-, Makropsien, Metamorphopsien, Veränderungen der Wahrnehmungsschärfe). Es bestand kein signifikanter Zusammenhang zwischen der Interventionsart und der Wahrnehmungsstörungen. 7,1 % der Patienten hatten ein Delir mit der Notwendigkeit zur psychopharmakologischen Behandlung. Patienten nach einem AKE (20,44 ± 2,29) zeigten geringere postoperative MMSE-Werte als CABG-Patienten (28,57 ± 1,01, t[21] = 3,05, p < 0,01), während präoperativ keiner Unterschied bestand. Es zeigten sich keine signifikanten Veränderungen im MMSE-Punktwert in den weiteren Testreihen. Wahrnehmungsstörungen waren mit einer geringeren Operationsdauer assoziiert (t[19] = 4,47, p < 0,01). EKZ und AKZ zeigten keine signifikanten Effekte hinsichtlich der Wahrnehmungssymptomatik.


Hybrid Treatment of Aortic Stenosis and Coronary Artery Disease by Transcatheter Aortic Valve Replacement and Percutaneous Coronary Intervention

A. Heinz, L. Müller, T. Bartel, S. Müller, G. Friedrich, O. Pachinger, M. Grimm, N. Bonaros
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck

Background The presence of coronary artery disease (CAD) is a significant risk factor for increased mortality in patients undergoing aortic valve replacement for severe aortic stenosis (AS). Transcatheter aortic valve replacement shows promising results. The aim of the study was to analyze the short and mid-term outcome of hybrid treatment of patients with AS and CAD by percutaneous coronary intervention (PCI) and transcatheter aortic valve implantation (TAVI).

Methods From February 2008 till December 2010, 11 patients with severe AS and CAD were treated with TAVI and PCI: the male:female ratio was 8:3. The median age was 82 years (range 79–88) and median logistic EURO Score 29.64% (range 8.1–74.5%). The follow up period was 262 days (range 43–564 days).

Results All 10 patients received successfully a biological aortic valve implantation. Twelve bare metal coronary stents were implanted (2 patients received 2 stents). Median interval between PCI and TAVI was 29 days (range 2–210 days). We observed no perioperative mortality (30-days). Three patients died during follow up (between 43–84 days post-operative). No coronary or valvular re-intervention was required.

Conclusion Combined treatment of concomitant CAD and AS by transcatheter procedures for high risk patients provides satisfactory peri-operative and 1-year results.

Intraoperative and Intermediate-Term Results of an Interdisciplinary Transcatheter Aortic Valve Implantation (TAVI) Program

V – 6
A. Heinz, N. Bonaros, T. Bartel, S. Müller, G. Friedrich, O. Pachinger, M. Grimm, L. Müller
Department of Internal Medicine III, Cardiology, Medical University Innsbruck

Background The aim of the study was to evaluate results of first 3 years of our institutional TAVI program in high risk patients, who were excluded from conventional surgical therapy due to an increased operative risk.

Methods From February 2008 till December 2010, 52 cases with severe aortic stenosis were included in our TAVI-program by a cardiac-surgical-cardiological team. The access-rate was transapical in 26 patients, in 18 transfemoral and in 3 transaxillary. The median follow up period was 304 days (range 1–1058 days).

Results 48 patients had successful TAVI, 2 needed to be converted from initial TAVI to conventional replacement, 2 had balloon valvuloplasty only and 11 patients needed PCI before TAVI. The perioperative mortality (30-days) was 5.88% (3 patients) and during follow up 13.73% (7 patients). No patient suffered myocardial infarction, 2 had peri-operative stroke and 2 during follow up. In 9 patients peri-operative renal failure needing hemofiltrations was observed.

Conclusion Due to interdisciplinary cooperation of cardiac-surgery and cardiology our TAVI program implying transfemoral, transapical and transaxillary excess could be established with low complication- and mortality-rate.
Minimally Invasive Double Valve Surgery Can Safely Be Combined with Additional Procedures

J. Kilo, H. Hangler, K. Stifter, L. Mueller, M. Grimm
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck

Objective Although minimally invasive cardiac surgery is well established, diffusion of the technique is limited. Contraindications are not only conditional on the disease but also on the surgeon’s experience and attitude. To evaluate disease related contraindications we investigated our patients receiving minimally invasive double valve surgery with or without additional procedures.

Methods 331 patients undergoing minimally invasive mitral valve surgery between 2001 and 2010 were analyzed. Additional tricuspid annuloplasty (TVP) was indicated for severe tricuspid regurgitation or tricuspid annular dilatation > 40 mm. Left atrial ablation (RF-maze) was performed using unipolar radiofrequency.

Results After implementation of the minimally invasive valve program, TVP was added after 54 successful isolated MV-procedures. 70 patients (25.3%) had combined mitral and tricuspid surgery. TV surgery was always performed as ring annuloplasty. 17 double valve patients had additional RF-maze. 12 patients underwent closure of the left atrial appendage (LAA). 13 patients underwent additional PFO closure. Mortality in the double valve group was 1.4% and 0.45% in the MV only group (p = n.s.).

Conclusions Minimally invasive TVP can be added safely to MV surgery. Further procedures like RF-maze, LAA- or PFO-closure can also safely be performed. Neither mortality nor major complications related to the combined procedures were increased.

Minimally Invasive Mitral Valve Reconstruction on the Fibrillating Heart – An Attractive Surgical Strategy for High-risk Patients

J. Kilo, H. Hangler, K. Stifter, A. Heinz, M. Grimm, L. Mueller
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck

Objective Reoperative mitral valve surgery is associated with high operative risk. An aortic valve prosthesis (AVP) can severely impair visualization to the mitral valve, so that these patients are often denied surgery. Furthermore, patients with severely calcified aorta are usually considered inoperable.

Mitral valve repair without aortic crossclamping on the fibrillating heart may be an attractive surgical option for these extremely high-risk patients.

Methods We report the series of 7 patients undergoing mitral valve surgery via a right-sided minithoracotomy without aortic crossclamping on the fibrillating heart. Three patients had an AVP in situ, 3 patients underwent CABG before, 2 patients presented with porcelain aorta. Reconstruction was possible in 6 patients, 1 patient, who underwent mitral valve repair plus CABG before, received mitral valve replacement. Cannulation for cardiopulmonary bypass was performed femorally in 3 and via the axillary artery in 4 patients.

Results No fatalities were observed. One patient required rethoracotomy for bleeding. One patient suffered from ischemic embolism to the leg due to the arterial pressure line. The postoperative course was uneventful in all other cases. No patient presented with significant residual mitral insufficiency in control echocardiography.

Conclusion Mitral valve reconstruction via a right-sided minithoracotomy is an attractive surgical option in high-risk reoperative settings.

Sorin Freedom SOLO: Hämodynamisches Outcome nach operativem Aortenklappenersatz mit einer Stentless-Perikardprothese – Eine retrospektive Analyse

N. Taheri, M. Thalmann, M. Grabenwöger
Herz- und Gefäßchirurgische Abteilung, Krankenhaus Hietzing, Wien


Resultate 74 Patienten (42 Frauen, 32 Männer, mittleres Alter 74.6 ± 7.6 Jahre) erhielten eine Freedom-SOLO-Prothese in Aortenposition, jeweils 50 % isolierter bzw. kombinierter AKE. Der durchschnittliche „logistic EuroScore“ betrug 11.0 ± 7.6. Die durchschnittliche EKZ bzw. AKZ lag bei 117,4 ± 29,6 bzw. 78,3 ± 22.3 Minuten. Das FU erfolgte durchschnittlich nach 14,3 ± 8,2 Monaten. Der maximale bzw. mittlere Druckgradient betrug früh-postoperativ 19,0 ± 8,8 bzw. 10,9 ± 5,4 mmHg PO und 19,9 ± 12,2 bzw. 11,2 ± 7,8 im FU. Kein Patient verstarb während des Eingriffes. Die 30-Tages-Mortalität lag bei 6,8 %. Mit 36 % und 30 % waren Pleuraraussseh und vorübergehendes VHF die häufigsten Komplikationen. Nur 2 Patienten mussten wegen eines paravalvulären Leaks re-operiert werden.

Minimally Invasive Repair of Atrial Septal Defects – Ten Years of Experience

K. Stifter, J. Kilo, A. Heinz, H. Hangler, M. Grimm, L. Mueller
Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck

Introduction Atrial Septal Defects (ASD) apply for 5–10% of congenital heart disease. The extent of the defect rises from a persistent foramen ovale to the sinus venous defect and anomalous drainage of one or more pulmonary veins (PAPVC). We reviewed our experience on the minimally invasive surgical technique.

Methods We reviewed all patients undergoing minimally invasive ASD-closure at our institution from 2001–2010. Analysis was performed concerning ASD-pathology, patient characteristics and operative variables.

Results From 01/2001 through 12/2010, 38 patients underwent minimally invasive ASD-closure. 20 defects were closed directly, 18 by patch. Since 2007, also Sinus Venosus Defects are successfully treated minimally invasive (n = 10). Intratral bafflue correction of PAPVC and reconstruction of vena cava superior is feasible (n = 4). The mean age was 40.7 years, mean weight was 70.2 kg. Mean aortic crossclamp time was 53.7 min. There was no fatality and no severe perioperative complications. One patient experienced occlusion of femoral artery late postoperatively (2.6%).

Conclusion Minimally invasive correction of defects of the intraatrial septum has successfully been introduced into clinical routine at our institution. Operative morbidity is very low and even complex reconstructions can be performed with good results. Median sternotomy is only performed in smaller children any longer at our institution.
Kardiomyopathie/Cardiomyopathy (CMP)

Seizure-Associated Tako-Tsubo-Cardiomyopathy

2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien

Background Tako-Tsubo-cardiomyopathy (TTC) is characterized by chest pain, dyspnea, electrocardiographic changes resembling an acute coronary syndrome, and transient wall-motion abnormalities in the absence of coronary artery obstruction. TTC occurs frequently after emotional or physical stress. Seizures have been reported as triggers of TTC. It is unknown if seizure-associated TTC differs from TTC associated with other triggers. Aim of the review was to compare seizure-associated TTC with TTC-series comprising > 30 patients.

Methods and Results Own observations and literature search identified 36 seizure-associated TTC cases (6 male, mean-age 61.5 years). Seizure-type were tonic-clonic (n = 13), generalized (n = 5), status epilepticus (n = 6), grand mal (n = 2) or not reported (n = 13). Twelve patients had a history of epilepsy, in 15 patients TTC-associated seizure was the first or the information was not given (n = 9). In 17 patients TTC occurred immediately after the seizure, in 9 patients 1–72 hours postictally, and in 10 patients, the interval was not reported. In 20 patients neurologic, in 14 psychiatric disorders were reported. Seventeen patients suffered from medical comorbidities like arterial hypertension (n = 11), hypotremia (n = 2) or cancer (n = 2). Compared with 974 patients reported in TTC-series, patients with seizure-associated TTC were younger (61.5 vs 68.5 years; p < 0.0001), more frequently males (17 vs 9%; p = 0.004), had less frequently chest pain (6 vs 76%; p < 0.005), cardiogenic shock (25 vs. 8%; p = 0.003) and recycledness (14 vs 3%; p = 0.004).

Interpretation Seizure-associated TTC manifests frequently as sudden hemodynamic deterioration which could result in patient’s death in the absence of adequate help. Probably, some cases of sudden unexpected death in epileptics are attributable to TTC.

Prognostic Significance of Family History in Cardiomyopathy

P. Hörmann, J. Zschocke, O. Pachinger, G. Poelzl
Department of Internal Medicine III, Cardiology, Medical University Innsbruck

Aims Family history plays an important role in ischemic cardiomyopathy (ICM) as well as in non-ischemic cardiomyopathies (NICM). Familial screening of patients with dilated cardiomyopathy has been shown to allow for an early diagnosis of the disease in family members and thus can improve survival in these patients. However, it is unclear if a positive family history and hence a higher propensity for a genetic background of the disease has an influence on survival in unselected patients with cardiomyopathy (CM). Our aim was to compare the prognosis of ICM and NICM patients with positive and negative family history in order to assess the influence of family history on survival.

Methods and Results From 2000 to 2009 clinical and laboratory variables of 1223 consecutive outdoor patients with heart failure were evaluated. Follow-up (mean 39.4 months) and information on family history of CM and aetiology of CM were available in 1098 patients. The end point was defined as death from any cause or heart transplantation. NICM patients (n = 767) had a positive family history in 24.8%, with no significant difference in age at presentation between groups. Patients with ICM (n = 331) had a positive family history in 24.2%; those with positive family history were younger at presentation (61.7 vs 65 years; p = 0.009). There were no significant differences in NYHA classes between patients with or without family history in either group. Sex-stratified bivariate Cox regression analysis showed a significant association of positive family history with reduced transplant-free survival in NICM patients (HR 1.36 [SD 1.01–1.82; p = 0.041]) but not in ICM patients (HR 0.86 [SD 0.6–1.24; p = 0.432]).

Conclusion In this cohort of unselected patients with CM the propensity for a genetic background was comparable high in ICM and NICM. In NICM patients a positive family history was associated with worse prognosis. These results further highlight the importance of a meticulous family history in particular in NICM patients not least in view of evolving prospects in genetic testing.

Immunosuppressive Therapy in Biopsy-proven Virus-negative Inflammatory Cardiomyopathy

Department of Internal Medicine III, Cardiology, Medical University Innsbruck

Introduction The role of immunosuppression in the treatment of myocarditis is still debated. Hence it was the aim of our single center study to investigate the response to immunosuppressive therapy in patients with virus-negative inflammatory myocarditis (autoimmune virus-negative inflammatory cardiomyopathy).

Methods and Materials From 2001 to February 2011, 416 patients with suspected myocarditis were subjected to left ventricular endomyocardial biopsy and right cardiac catheterization. Inflammatory, virus-negative myocarditis was diagnosed in 69 patients, defined by immunohistochcmical analysis quantifying the number of infiltrating activated lymphocytes (> 7/mm²) and leukocytes (> 14/mm³) and with conventional histological criteria (WHO Task force/Dallas Criteria). The presence of persisting viral genome was excluded by polymerase chain reaction analysis. Patients were tested for CMV, EBV, PVB19, HHV6,8, HSV1,2 using qualitative PCR in endomyocardial biopsy and in whole blood. In addition serological antibody screening was applied for all above viruses and for antmyocardial antibodies. 57 patients were treated with azathioprine and prednisone for 6 months in addition to conventional therapy for heart failure. Up to now clinical follow-up, control endomyocardial biopsy, and right heart catheter data results after 6 month therapy are available in 31 patients. Clinical 6-month follow-up only is available in 9 patients.

Results Mean age at study entry was 47 (range 18–68, 33% female). Immunosuppression was well tolerated and resulted in an improvement of LV-ejection fraction (26.7 ± 14.0%–39.0 ± 13.6%; p < 0.0001), and NYHA class (2.4 ± 0.09–1.5 ± 0.6; p < 0.0001), and a decrease of NTProBNP (995 ng/l [IQR 249–2460]–294 ng/l [IQR 89.7–764.2]; p = 0.009). Cardiac output increased from 3.8 ± 0.9/min–4.5 ± 0.9/min (p = 0.013); PCWP decreased from 19.3 ± 9.9 mmHg–12.5 ± 4.8 mmHg (p = 0.001).

Conclusion Patients with evidence of inflammatory, virus-negative myocarditis/imflammatory cardiomyopathy clearly benefit from immunosuppressive therapy on top of conventional HF therapy.

An Unusual Manifestation of Tako-Tsubo-Cardiomyopathy

S. Schatz, R. Karnik, M. Gattermeier
Innere Medizin, Landeskrankenhaus Mostviertel Waidhofen/Ybbs

Introduction Tako-Tsubo-cardiomyopathy is characterized by typical symptoms of cardiac ischemia and transient abnormalities of left ventricular wall motion (usually “apical ballooning”) in absence of significant coronary heart disease.
We report the case of a 79-year-old man with a recent manifestation of cardiogenic syncope, presenting an unusual “inverted” pattern of Tako-Tsubo.

Methods We evaluated our patient by 12-lead ECG, Holter monitoring, echocardiography and coronary angiography. A periodical follow-up has been performed.

Results We present a 79-year-old man, recently suffering from recurrent cardiogenic syncope without any other cardiac symptoms. During the Holter monitoring a symptomatic episode of non-sustained ventricular tachycardia was detected. In coronary angiography a left bundle-branch block was found, as well as an atherosclerotic stenosis of the proximal right coronary artery, incompatible with the clinical manifestation of the patient. A spontaneous resolution of the ECG finding was observed after 8 months.

Conclusions Our findings are consistent with the occurrence of Tako-Tsubo cardiomyopathy in patients with other underlying cardiac diseases. It demonstrates that in these cases, a non-ischemic syndrome can occur, which may lead to a life-threatening clinical picture. Therefore, the differentiation between myocardial ischemia and Tako-Tsubo syndrome is crucial for the management of patients with non-ischemic cardiogenic syncope.
text. Easily available biomarkers for cardiac toxicity are desirable to detect cardiac damages and support the decision of treatment continuation. N-terminal-pro-B-type natriuretic peptide (NT-proBNP) has been shown to increase in chemotherapy-induced cardiac toxicity. The aim of this prospective analysis was to investigate the role of NT-proBNP as possible early indicator for sunitinib-induced cardiac toxicity.

**Patients and Methods**
All patients with mRCC assigned for first-line treatment with sunitinib were analyzed for history or evidence of cardiac diseases. Monitoring included assessment of clinical symptoms, electrocardiograms, echocardiograms and biochemical markers of cardiac damage NT-proBNP and cardiac Troponin T (TnT). Echocardiograms and electrocardiograms were obtained at baseline, every 3 months and at increase of biochemical markers. NT-proBNP (Roche Elecsys) and TnT were assessed at baseline and then every 4 weeks, as well as routine laboratory parameters. A significant clinical finding indicating cardiac damage was defined as a newly pathological echocardiogram, development of cardiac clinical symptoms, new changes in the ECG or increased TnT.

**Results**
Forty-five patients with a median age of 66 years (range 40–82 years) were included in this analysis, 98% of pts had undergone nephrectomy. After a median treatment period of 15 weeks (2–101), 34 (76%) patients experienced an increase of NT-proBNP when compared to their baseline values. New changes in ECG and echocardiograms were observed in 7 (21%) and 6 (18%) patients, respectively. Echocardiography detected regional wall motion disturbances (n = 4), progression of diastolic dysfunction (n = 2) and severe congestive heart failure in 1 patient. NT-proBNP levels without increase from baseline were always associated with the complete absence of clinical findings for cardiac toxicity. Higher NT-proBNP levels during treatment were significantly more often associated with the presence of a cardiac event (p = 0.001). A wide range of NT-proBNP was observed during sunitinib-treatment, with events occurring mainly in pts with NT-proBNP levels above 1000 pg/ml.

**Conclusion**
Our observations indicate that increased NT-proBNP plasma levels might serve as an easily assessable marker for cardiac toxicity. An increase of NT-proBNP during treatment may indicate overt or subclinical cardiac damage. An interdisciplinary approach between cardiologists and oncologists is essential to allow continuation of tumor-treatment under cardiac therapy for optimal outcome of these patients.

**Metabolic Benefits of Eccentric Endurance Exercise in Overweight and Obese Individuals**

C. Boehnerl, P. Rein, C. Haesy, A. Vontiba, S. Aczel, V. Kienle, T. Bodanzky, H. Drexel
VMT-Institute, Feldkirch

The interplay of muscle contraction with an external force can result in one of 3 types of muscle activity: shortening or “concentric” when muscle contraction is stronger than the external force; lengthening or “eccentric” when the external force is stronger; and isometric when both forces are equal. Eccentric endurance exercise (e.g. hiking downwards) is less strenuous than concentric exercise (e.g. hiking upwards) but its metabolic effects are largely unknown; no data exist in overweight and obese individuals.

We allocated 43 overweight and obese sedentary individuals to an exercise intervention program, consisting of hiking downwards a pre-defined route in the Austrian Alps over 2 months. For the opposite site way, a cable car was used where compliance was recorded electronically. The difference in altitude was 540 meters; the distance was covered 3–5 times a week. Fasting and postprandial metabolic profiles were obtained at baseline and after the 2 months period. Compared with baseline, eccentric exercise significantly lowered fasting glucose (98 ± 11 vs 96 ± 14 mmol/l; p = 0.042) and improved glucose tolerance (242 ± 48 vs 219 ± 60 mg dl−1 x h; p = 0.001). Furthermore, eccentric exercise significantly improved triglyceride tolerance (1841 ± 893 vs 1466 ± 656 mg x dl−1 x h; p = 0.001) and postprandial leukocyte count (69.4 ± 11.7 vs 67.0 ± 13.0 G L−1 x h; p = 0.044).

We conclude that eccentric exercise is a promising new exercise modality with favourable metabolic effects. This little strenuous exercise could become especially important, as a large proportion of patients suffer from comorbidities that confer a low tolerance for higher-intensity training protocols.

**OAK-Therapieeffizienz bei Patienten mit Vorhofflimmern**

R. Breier, N. Preis, G. Gaul, M. Winkler
2. Medizinische Abteilung, Hanusch-Krankenhaus, Wien

**Eindeutung**
The orale Antikoagulation (OAK) bei Patienten mit Vorhofflimmern ist ein viel diskutiertes Thema. Ziel der Studie war, die Therapieeinstellungszualität zu überprüfen und jene Patienten mit erhöhtem Risiko für Komplikationen aufgrund einer unzureichenden Therapieeinstellung zu eruieren.

**Methoden**


**Ergebnisse**
Das durchschnittliche Alter betrug 76,04 Jahre. Tabelle 10 zeigt die Verteilung der erhobenen INR-Werte im Beobachtungszeitraum.

Es zeigte sich eine Abnahme der INR-Werte außerhalb des therapeutischen Bereiches, umso länger die Patienten in Kontrolle waren. Als häufigste Komplikationen sind Hämatome zu nennen, die bei 26,4% (n = 33) der Patienten vorkamen. In allen 3 Beobachtungszeitraunen wurden Unterdosierungen häufiger verzeichnet als Überdosierungen.


**Diskussion**
Von insgesamt 212 Patienten hatten lediglich 4,72% (n = 10) der Patienten mehr als 50% der erhobenen INR-Werte außerhalb des therapeutischen Bereiches und haben somit unter der OAK-Therapie keinen adäquaten Schutz vor hämorrhagischen als auch ischämischen Ereignissen. Für diese Patienten stellt sich die Situation komplexer. Am Beispiel der Thrombose in einer Arteriographie des Patienten wird die Bedeutung der Therapieeinstellung deutlich.

**Tabelle 10:**

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>≤ 365d (n = 594)</th>
<th>366–769d (n = 2443)</th>
<th>≥ 770d (n = 1858)</th>
<th>Insgesamt (n = 4895)</th>
</tr>
</thead>
<tbody>
<tr>
<td>INR 2–3</td>
<td>58,92 % (n = 330)</td>
<td>68,11 % (n = 1664)</td>
<td>72,96 % (n = 1356)</td>
<td>68,85 % (n = 3370)</td>
</tr>
<tr>
<td>INR 3–4</td>
<td>11,62 % (n = 69)</td>
<td>13,79 % (n = 205)</td>
<td>11,03 % (n = 611)</td>
<td>12,48 % (n = 3370)</td>
</tr>
<tr>
<td>INR x &lt; und &gt; 4</td>
<td>29,46 % (n = 157)</td>
<td>18,09 % (n = 442)</td>
<td>15,99 % (n = 297)</td>
<td>18,67 % (n = 1119)</td>
</tr>
<tr>
<td>INR 4</td>
<td>5,39 % (n = 32)</td>
<td>3,60 % (n = 88)</td>
<td>2,91 % (n = 54)</td>
<td>3,55 % (n = 174)</td>
</tr>
<tr>
<td>INR 2</td>
<td>24,07 % (n = 143)</td>
<td>14,49 % (n = 354)</td>
<td>13,08 % (n = 243)</td>
<td>15,12 % (n = 740)</td>
</tr>
</tbody>
</table>
Frage, ob eine Therapieumstellung auf ein Ersatzpräparat einen Vor-
teil bringen würde. Hier muss aber auch erwähnt werden, dass zumeist als Ursache eine Incompliance von Therapiebeginn an vor-
lag und somit ein Therapieerfolg unter anderen Medikamenten eben-
so nicht zu erwarten wäre.

Neue Biomarker zur Früherkennung und Risikostrati-
fikation kardiovaskulärer Ereignisse – die „Graz Heart Study“ (Comet-Projekt „BioPersMed“)  

C. Colantonio, G. Steiner, E. Kraigher-Krainer, S. Pätzold, A. Schmidt, B. Pieske  

Universitätsklinik für Innere Medizin, Medizinische Universität Graz

Hintergrund 
Die Risikostratifizierung asymptomatischer Patienten mit erhöhtem kardiovaskulärem Risiko erfolgt heute auf dem Boden klassischer Risikofaktoren mithilfe von Score-Systemen (z. B. EuroSCORE). Allerdings ist die Zuverlässigkeit dieser Systeme un-
genügend. Durch neue laborchemische und biophysikalische Biomarker könnten die Früherkennung und Risikostratifizierung verbessert werden. Allerdings liegen derzeit keine Modelle vor, in denen die Kombination neuartiger Biomarker mit etablierten Risiko-
markern untersucht wurde. Im Rahmen der 2010 angefangenen „Graz Heart Study“, die über das Comet-Projekt (K-Projekt) markiert wurde, nimmt der niedergelassenen Bereich.

Methodik 
In der „Graz Heart Study“ werden seit Ende 2010 pro-
spektiv 1000 Probanden mit kardiovaskulärem Risikofaktoren, aber noch keinem atherosklerotischen Ereignis eingeschlossen und longitudinal nachbeobachtet. In Kooperation mit der Biobank der Medizi-
nischen Universität Graz werden Blut- und Urinproben, Speichel, sowie DNA für genetische Analysen aserviert. In einer detaillierten kardiovaskulären Phänotypisierung werden neben Routinepara-
metern die systolische und diastolische Ventilkraft, kardiales Remodelling sowie moderne echokardiographische Parameter (strain, strain-rate) erhoben. Die vaskuläre Funktion wird umfassend u. a. durch Endothelfunktion, Pulswellenanalyse und Analyse der Mikrozirkulation (Endopad und Endothelfunktionsprüfung) be-
stimmt. Die körperliche Leistungsfähigkeit wird mittels Spiroergo-
metrie und 6-Minuten-Gehtest erhoben. Zusätzliche Untersuchun-
gen in Subgruppen beziehen zerebrale artherosklerotische Ereignis-
egen (Schädel-MRT), Augenhintergrunduntersuchung und eine umfas-

Erste Ergebnisse 
In einer Pilotstudie zu Zeitaufwand, Unter-
suchungsablauf und Compliance wurden seit Ende 2010 19 Proban-
den eingeschlossen. Die Teilnehmer wiesen mindestens einen klas-
sischen kardiovaskulären Risikofaktor auf: Arterielle Hypertonie (100 %), Dyslipoproteinämie (93 %), Adipositas (BMI > 25kg/m²: 79 %). 26 % der Patienten hatten ein manifesten Diabetes, 32 % einen HBA1c ≥ 6 %. 58 % der asymptomatischen, subjektiv gesun-
den Probanden zeigten bei normaler linksventrikulärer Funktion ein NTproBNP > 100 pg/ml. 58 % zeigten erhöhten Hinweis auf diasto-
lische Dysfunktion mit E/E’-Wert > 10.

Schlussfolgerung 
In der „Graz Heart Study“ wird in einem groß-
populationsbasierten Ansatz an subjektiv gesunden Patienten mit erhöhtem kardiovaskulärem Risiko die Bedeutung neuer biophysika-
lischer und biochemischer Biomarker für Risikostratifizierung und Prädiktion kardiovaskulärer Komplikationen analysiert. In unserem Probedurchlauf konnten wir die Machbarkeit des diagnostischen Phänotypisierungsansatzes nachweisen. Die Compliance lag bei 100 %, alle Patienten durchliefen in weniger als 4 Stunden das Stan-
darduntersuchungsprogramm.

Es zeigte sich, dass asymptomatische, bisher als gesund klassifizier-
te Probanden mit kardiovaskulärem Risiko bereits in erheblichem Umfang erhöhte NTproBNP-Werte und ein pathologisches E/E’ als mögliches Korrelat für subklinisches kardiovaskuläres Remodelling aufwiesen. Dieser erste Befund belegt die klinische Relevanz dieses Forschungskonzepts.

P-Glycoprotein-Affecting Food in the Diet of Hospi-
talized Patients  
L. Jungbauer, C. Stöllberger, F. Weidinger  
Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien

Introduction Dahitratan, apixaban und rivaroxaban are new antithrombotic drugs (NAD) which had in clinical trials a similar effect as Vitamin-K-antagonists (VKA) for stroke prevention but a lower complication rate. NAD are claimed to have less food-interac-
tions than VKA. However, NAD-absorption is dependent on the in-
testinal P-glycoprotein- (P-gp-) system which is influenced by drugs and food components. Aim of the cross-sectional study was to screen the diet of hospitalized patients for P-gp-affecting food.

Methods From the literature P-gp-affecting food components like phenolic acids and analogs, flavonoids, tannins, stilbenes, curcuminoids, coumarins, lignans and quinines were identified. The weekly order for food supply of a 214-beds community hospital in Vienna in November 2010 was analyzed regarding the frequency of P-gp-affecting food components.

Results The following P-gp-affecting foods were identified: Coffee, black tea, peppermint tea, orange juice, apple juice, chocolate powder, red wine, oranges, lemon, tangerines, kiwi, apples, rapeseed oil, tomatoes, cabbage, red cabbage, leek, onions, root veg-
etables, bell peppers, lettuce, carrot, cauliflower, broccoli, rutabaga, romain lettuce, spinach, peas, string beans, celery root, strawberries, raspberries, raisins, chocolate cake, mustard, black pepper, and curry powder. This food compounds are frequently associated with ben-
eficial health effects.

Conclusions P-gp-affecting food is frequently ordered for hospi-
talized patients. We suggest to investigate the influence of P-gp-
affecting food on serum-levels of NAD and coagulation parameters, and to re-analyze bleeding and embolic events in NAD-investigating trials considering the patients’ diet. Since drugs like clopidogrel are also substrates of the P-gp-system, more attention should be directed to drug-drug and drug-food-interactions due to influences on the P-gp-system.

Spezielle Induktionstechniken im Kontext ärztlicher Hypnose für den kardiovaskulären Patienten  
P. Keil, H. Brussee, R. Gasser  
Universitätsklinik für Innere Medizin, Medizinische Universität Graz

Einleitung Hypnose ist eines der ältesten bekannten Heilverfah-
ren. In den vergangenen Jahrzehnten erlebte sie besonders im anglo-
erischen Raum eine Renaissance, die sich auch immer mehr auf Europa erstreckt. Durch eine Literaturrecherche wird hier eine Darstellung spezieller Induktionstechniken, insbesondere von Schnellinduktionstechniken im Kontext von Einsatz- und Anwen-
dungsmöglichkeiten in der Kardiologie dargestellt.

Methodik 1.) Literaturrecherche: Da es sich bei der klinischen Hypnose um ein ausgesprochen individuelles und dynamisches Heilverfahren handelt, finden sich in der einschlägigen Fachliteratur hauptsächlich Fallbeschreibungen, in die diverse Techniken etc. ein-
gebettet wurden. Diese veröffentlichten Fallbeispiele wurden im Rahmen der Diplomarbeit analysiert und ausgewertet.

2.) Ausbildungs- und Selbsterfahrungen: Die Wahl dieser Methode beruht auf der Tatsache, dass sich die Techniken und Methoden der klinischen Hypnose nach Erickson am effizientesten durch Selbst-
erfahrung und Übung mit ausgedehten Literatur-
recherchen erlernen lassen. Die Beschreibung von Selbsterfahrung stellt eine klassische Methode im Bereich der Hypnotherapie dar.

Ergebnisse Es gibt auch in Zeiten der „5-Minuten-Medicine“ Me-
thoden der medizinischen Hypnose und vertieften Kommunikation, die das Erreichen der Therapieziele für Patienten und Ärzte verbessern können. Es ist möglich, eine Erhöhung der Compliance bei gleichzeitiger Reduktion der Wirkstoffdosis zu erreichen. Dies ist zum einen wegen der immer größer werdenden Nachfrage seitens der Patienten nach komplementären und additiven Behandlungs-

ÖKG-Annual Conference 2011 – Abstracts

J KARDIOL 2011; 18 (5–6) 175
Methoden und zum anderen aufgrund der heute schon weit verbreiteten Anwendung derartiger Verfahren im angloamerikanischen, aber auch im europäischen Raum von Bedeutung. Ein Thema in diesem Zusammenhang war der Einsatz von Hypnose in der Kardiologie. Es zeigte sich ein Verlauf der maximalen Sauerstoffaufnahme, die sich leicht aneignen die Hypnosechniken und deren Adaptierung auf eine klinische Entsprechung, wobei vor allem auf diejenigen Techniken eingegangen wurde, die sich leicht erlernen und mit minimalen Zeitaufwand bei gleichzeitig maximalem Outcome durchführen lassen (vgl. „Schnellinduktionen“). Ein weiterer Schwerpunkt wurde auch auf die Neuarbeitung von klinisch relevanten Techniken gelegt.

Schlussfolgerung
Die Neugierde des Patienten ist darin, besonders diejenigen Werkzeuge und Methoden aufzuzeigen und zusammenzufassen, die besonders rasch und einfach im alltäglichen kardiologisch-ärztlichen Bereich Anwendung finden können.

Entwicklung der ergemotischen Leistungsfähigkeit bei Sportstudenten und -studentinnen von 1986–2009

P. Panzer, M. Wönnich, P. Hofmann, F. Fruhwald

1Abteilung für Kardiologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz; 2Rehabilitationszentrum St. Radegund; 3Institut für Sportwissenschaft, Universität Graz

Einleitung

Methoden
Alle Sportstudenten müssen sich vor Beginn des Studiums einer leistungsdiagnostischen Untersuchung unterziehen. Die Daten der vergangenen 24 Jahre wurden hinsichtlich Veränderungen über die Zeit ausgewertet. Zur Beurteilung der Leistungsfähigkeit wurden die maximal erbrachte Leistung (Pmax), die maximale erbrachte Leistung pro kg Körpergewicht (Pmax/kg) und die maximale Sauerstoffaufnahme bezogen auf das Körpergewicht (VO2max/kg) herangezogen.

Ergebnisse


Diskussion
Unsere Langzeituntersuchung zeigt, dass die Sportstudenten größer und schwerer geworden sind, wohingegen die Studentinnen auf gleichem Niveau geblieben sind. Die Leistungsfähigkeit stieg bei den Studenten leicht an, bei den Studentinnen hingegen blieb sie auf einem konstanten Niveau.

Health Related Quality of Life, Anxiety and Depression after PCI in NSTEMI Patients

VI – 8

H. Sipötz, M. Winkler, G. Gaul, O. Friedrich, S. Höfer

KLI für wissenschaftliche Forschung in der interventionellen Kardiologie, Wien

Purpose
Our study sets out to examine the correlation between changes in Health Related Quality of Life, anxiety and depression after PCI.

Methods
308 NSTEMI PCI patients (71.8% men; age: 63.3, SD: 9.3) at 6 centers in Austria completed the HADS depression/anxiety and the MacNew HRQoL questionnaire before discharge and 1, 6 and 12 months after discharge.

Results
MacNew-HRQoL Score increased significantly during the 12 months follow up period in all 3 subscales (emotional, physical, social). The MacNew-Global mean value increased from 5.1 ± 10.5–5.5 ± 1.0. Clinically relevant increase of MacNew-Glob-Global of 0.5 or more was found in 45%–54%, clinically significant decrease of 0.5 or more in 12%–14% of the patients.

Change in MacNew-HRQoL was significantly correlated to changes in HAD anxiety and depression score: Clinically relevant decrease of MacNew-HRQoL was associated with a pronounced increase in mean HAD score (anxiety: 3.1–4.9, depression: 3.2–4.7), whereas clinically relevant increase of MacNew-HRQoL was correlated to a more moderate decrease (anxiety: 1.7–2.5, depression: 1.3–1.7).

At the baseline before discharge probable caseness of anxiety disorders (HADS anxiety ≥ 11) was found in 11.6% of the patients, probable caseness of depression disorder (HADS depression ≥ 11) in 5%. During the 12 months follow up period this status maintained in 3.6–4.4% (anxiety) and 2.5–3.6% (depression) of the cases. With respect

Table 11: H. Sipötz et al.
to probable anxiety disorder improvement (7.6–8.8%) and deteriora-
tion (5.2–8.4%) balance each other leading to the result that the per-
centage of mood disorder remains relatively stable during the follow-
up period (9.6%–12%). In the case of probable depression disorder
deterioration (4.8–7.2%) exceeds improvement (1.6–2.9%) by far.
Therefore the percentage of probable depression disorder increased
significantly from 5% to 10% after 6 and 12 months, respectively.

**Discussion** Overall, change of HRQoL after PCI is closely associ-
ated with changes to both HADS anxiety and HADS depression in a
very similar fashion. Clinically relevant decrease of HRQoL is cor-
related to a pronounced deterioration of anxiety and depression
symptomatology. Conversely clinically relevant increase of HRQoL is
not as strongly linked to improvement of signs of anxiety and de-
pression.

However, anxiety and depression differ distinctly with respect to the
percentage of cases with probable mood disorder in the follow up
period. Whereas we found a doubling of cases with probable depres-
sion disorder the number of cases with probable anxiety disorder re-
 mains stable. Interestingly this is not due to a greater number of pa-
tients deteriorating to the level of probable mood disorder but to the
fact that only very few patients with probable depression disorder at
the baseline improve their status.

Our findings show that the evaluation of anxiety and depression pro-
vides important additional information for a better understanding of
HRQoL outcome in PCI-patients.

The clinically relevant change in MacNew Global score, HADS
anxiety and depression during the 12 months follow up period after
PCI shows Table 11.

### Gefäßbiologie/Vascular Biology

**Association between Inflammation and Atherosclerosis in Metabolic Syndrome Patients: The Same in all Arterial Beds?**

Internistische Abteilung, Landeskrankehaus Feldkirch

While inflammatory markers are firmly established as predictors of
clinical atherothrombotic events, data on their association with di-
rectly visualized atherosclerosis are controversial. We aimed at in-
vestigating the association of C-reactive protein and of leukocytes
with atherosclerosis in different arterial beds.

We enrolled 405 consecutive Caucasian patients with the Metabolic
Syndrome (MetS) who were referred to coronary angiography for
the evaluation of stable coronary artery disease (CAD) and who did
not have a history of peripheral arterial disease (PAD). Significant
CAD was diagnosed in patients with significant coronary artery lumi-
nar narrowing ≥ 50% (n = 232), subjects without such lesions
served as controls (n = 173). Additionally, we enrolled 200 MetS
patients who underwent routine duplex sonography for the evalua-
tion of suspected or established PAD and in whom PAD was verified
sonographically.

The inflammatory markers CRP and leukocytes did not differ sig-
nificantly between patients with stable CAD and controls (0.47 ±
0.71 vs 0.43 ± 0.48 mg/dl; p = 0.472; 6.9 ± 1.7 vs 6.9 ± 1.8 G/L;
p = 0.856, respectively). In contrast, CRP as well as leukocytes were
significantly higher in PAD patients compared to both, patients with
stable CAD (0.94 ± 1.88 vs 0.47 ± 0.71 mg/dl; p = 0.001 and 7.6 ±
2.3 vs 6.9 ± 1.7 G/L; p = 0.003, respectively) and controls (0.94 ±
1.88 vs 0.43 ± 0.48 mg/dl; p = 0.008; 7.6 ± 2.3 vs 6.9 ± 1.8 G/L;
p = 0.005, respectively).

In conclusion, CRP and leukocytes do not differ between MetS
patients with or without stable CAD but are significantly elevated in
MetS patients with PAD. This is well in line with the extremely high
cardiovascular event risk of PAD patients.

### Effect of Drug-eluting Stent and Drug-Eluting Balloon On Endothelium-Dependent and -Independent Vasomotion of the Coronary Arteries

C. Plas, G. Maurer, M. Gnyngyèsi
Division of Cardiology, Department of Medicine II, Medical University Vienna

**Background** The 1st generation drug-eluting stent (DES) implanta-
tion has been shown to result in long-term endothelial dysfunction
and vasoconstriction; both phenomena have been suggested to be in
association with delayed healing and late thrombosis. In contrast,
human coronary arteries showed a relatively preserved endothelium-
dependent coronary vasomotion after 2nd generation DES implanta-
tion or use of drug-eluting balloon (DEB). The aim of the present
study was to investigate the endothelium-dependent and indepen-
dent vascular response of coronary arteries after use of different
intracoronary devices, such as DEB, plain balloon, bare metal stents
(BMS) and DES.

**Methods** Domestic pigs underwent coronary artery balloon dil-
tion with DEB (size of 3 mm, length of 15 mm, inflation time of 2 ×
30 sec) or plain balloon (3/15 mm, 30 sec), or stent implantation with
BMS or DES (both 3.0/15 mm, 30 sec). The dilated segments of
DEB and plain balloon, and the proximal reference segments of the
stented arteries (without stent) have been prepared 5 ± 1h after per-
cutaneous coronary intervention (PCI) for in vitro measurements of
endothelium-dependent and -independent vasomotor reaction. Iso-
metric circular wall tension (contractile response) and maximal
vasodilatation of the arterial segments were determined after bolus
application of sodium-nitroprussid (endothelium-independent reac-
tion) and substance-P (endothelium-dependent vasomotion) directly
into the organ bath solution, and expressed in wall tension develop-
ment (mN).

**Results** The endothelium-dependent vasomotor response is shifted
to vasoconstriction after implantation of DES or BMS, but only par-
tially after DEB or plain balloon, indicating a severe or mild dys-
function of the endothelium, as compared to control (non-instru-
mented) arteries (23.4 ± 6.7, 24.3 ± 4.7, 17.2 ± 6.3, 10.6 ± 3.5 and 10.4 ± 3.9 mN, respectively), with significant difference between control arteries and DES or BMS (p < 0.005) and DEB (p = 0.028). Sensitivity of vascular smooth muscle to sodium-nitroprussid was impaired in DES or BMS-treated arteries, but in less extent in DEB or plain balloon-dilated segments (0.05 ± 0.02, 0.06 ± 0.05, 0.10 ±
0.1, 0.1 ± 0.05 and 0.25 ± 0.1 mN, respectively) with significant
differences between non-PCI arteries and DES (p = 0.005) and DEB (p = 0.026) or plain balloon (p = 0.047), indicating less media (muscular) damage of balloon intervention when com-
pared to stenting.

**Conclusion** Coronary arteries treated with plain balloon, DEB,
BMS and DES showed partial loss of endothelial-dependent and
independent vasodilator response, in increasing order of magnitude,
which might influence the long-term outcome of PCI, regarding re-
stenosis, vessel remodeling and thrombosis. The presented in-vitro
experiments have a potential guidance for engineering of new
intracoronary devices.

![Figure 17: M. K. Renner et al. Cross-sectional thrombus areas.](image-url)
The Role of B-lymphocytes in Thrombus Resolution

Purpose
Splenectomy is associated with complex venous thromboembolism such as recurrent deep venous thrombosis, portal vein thrombosis, and chronic thromboembolic pulmonary hypertension (CTEPH). The spleen serves not only as a red blood cell filter but also constitutes an immunological organ. The aim of our study was to decipher the population of spleen cells responsible for misguided thrombus resolution after splenectomy.

Methods
We utilized a mouse model of stagnant flow venous thrombosis to characterize thrombus resolution. Splenectomy was performed one month before vena cava ligation. In defined groups, whole spleens, spleens depleted of B-lymphocytes or B-lymphocytes alone were reinfused intraperitoneally. On days 3, 7, 14 and 28 after vena cava ligation thrombi were harvested for histology.

Results
Thrombus areas of splenectomized mice were significantly larger than those of controls at all time points (ANOVA, n = 8; p < 0.05). Reinfusion of autologous whole spleen-homogenates reconstituted a normal pattern of thrombus organisation. Reinfusion of spleen tissue depleted of B-lymphocytes could not accelerate thrombus resolution significantly. However, reinfusion of autologous splenic B-lymphocytes in previously splenectomized mice normalized thrombus resolution (Figure 17).

Discussion
Reinfusion of spleen cells can restore the normal process of venous thrombus organisation in a mouse model. Our data substantiate the case of a male with atrial fibrillation after surgery and about the overlap with low-molecular-weight heparin use in postoperative AF-patients. The spleen serves not only as a red blood cell filter but also constitutes an immunological organ. The aim of our study was to decipher the population of spleen cells responsible for misguided thrombus resolution after splenectomy.

Fatal Basilar Artery Occlusion Shortly After Initiation of dabigatran

L. Schäffl-Doweik, C. Stöllberger, M. Reiter, J. Finsterer
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien

Objective
Concerns about initiation and monitoring of dabigatran after surgery and about the overlap with low-molecular-weight heparin are strengthened by the case of a male with atrial fibrillation (AF) for 30 years.

Case Report
After an embolic stroke 27 years previously, phenprocoumon was started, but resumed after 7 years for unknown reasons. In the following years he was without any drugs. At age 78 years, he suffered from acute pain of his right leg leading to right-sided embolotomy. Antithrombotic therapy comprised enoxaparin 60 mg/bid, on the 5th postoperative day phenprocoumon 9 mg/d and on the 6th postoperative day 6 mg/d. Because the discharge-INR was only 1.18, enoxaparin was recommended until the INR was > 2.0. The patient’s son, a general practitioner, changed phenprocoumon to dabigatran 110 mg/bid on the 8th postoperative day. No blood tests were performed thereafter. Sudden pain in his left calf induced readmission on the 13th postoperative day. Blood tests showed gamma-glutamyltransferase 126 U/l, prothrombin time 33 sec, fibrinogen 359 mg/dl, antithrombin 87%, INR 2.5 and D-dimer 20 µg/ml. No surgery was indicated but dabigatran was resumed, dalteparin 5000 IE/bid and 40 µg alprostadil-infusion were started. After 8 hours he was found comatose. Computed tomography showed a pulmonary lesion suggestive of malignoma and basilar artery occlusion. Partial mechanical recanalisation was achieved but a steady perfusion could not be achieved even after application of 5 mg alteplase into the basilar artery, and the patient eventually died.

Conclusion
In postoperative AF-patients dabigatran should be avoided. Drug-interactions of dabigatran should be studied, and vitamin-K-antagonists with their easily measurable effect should be used in postoperative AF-patients.
These 2 groups. Subsequently the remaining centers were fused accordingly, as there was no difference between them concerning outcome respectively. This procedure resulted in 2 significantly different groups, each group consisting of several centers without significant differences in outcome. Bivariate comparison of patient characteristics and in hospital management between the 2 groups was followed by a multivariate Cox regression model. The endpoint for the latter was time to death.

**Results** During the follow-up period of up to 60 months 253 (61.7%) patients had died. The mean follow-up period was 23.1 months. The 2 best-practice hospitals included 186 patients and 220 patients were included by the other hospitals. Several parameters differed between best-practice and other hospitals (Table 12, Figure 18). In a multiple Cox regression model, patient age (HR 1.04, 95%-CI: 1.03–1.06; p < 0.001), male sex (HR 1.41, 95%-CI: 1.08–1.84; p = 0.012), length of index hospitalization (HR 1.01, 95%-CI: 1.01–1.02; p = 0.002) and the quality of prescribed HF specific medication at discharge from index hospitalization (HR 0.78, 95%-CI: 0.64–0.94; p = 0.009) were independently associated with time to all-cause death.

**Conclusion** Quality of HF specific medical therapy at discharge was identified as an important modifiable parameter associated with long-term survival after hospitalization for decompensated HF.

**Therapeutische Interventionen im Rahmen der akuten Herzinsuffizienz: Daten des EuroHeart Failure Survey – Pilot Phase**

**K. Bangert, P. Abend, V. Riegelh, F. Fruehwald**

Universitätsklinik für Innere Medizin, Medizinische Universität Graz

**Einleitung**


**Patienten und Methodik** Im Beobachtungszeitraum wurden an einem frei wählbaren (aber konstanten) Wochentag alle Patienten mit akuter Herzinsuffizienz gebeten, an diesem Survey teilzunehmen. Die Patienten wurden über die zentrale Notaufnahme an der gesamten Klinik für Innere Medizin verteilt, die wenigsten wurden auf der kardiologischen Station betreut. Neben Ätiologie, Risikofaktoren, Begleitkrankungen, Prognoseprädiktoren, und aktuell bestehenden klinischen Zeichen und Symptomen wurden alle diagnostischen und therapeutischen Maßnahmen während des stationären Krankenhausaufenthaltes dokumentiert. Zudem waren nach 3, 6 und 12 Monaten Follow-ups vorgesehen.

**Ergebnisse**

Insgesamt wurden 37 Patienten (17 männlich, 20 weiblich; mittleres Alter 78 ± 12 Jahre) in diese Auswertung eingeschlossen. Vor der Hospitalisierung nahmen 22 Teilnehmer (60 %) einen ACE-Hemmer (ACE-H) bzw. Angiotensin-Rezeptor-Blocker (ARB) ein (ACE-H: n = 17 [46 %]; ARB: n = 5 [14 %]). Bestätigung wurde insgesamt 24 Patienten (67 %) eine der beiden Medikationen (ACE-H: n = 19 [53 %]; ARB: n = 5 [14 %]) zur Dauertherapie empfohlen. Weiters hatten 25 Rekrutierten (68 %) bei der Aufnahme eine Therapie mit einem Betablocker (BB), welche nach dem Krankenhausaufenthalt in 23 Fällen (64 %) fortgeführt wurde. Spironolacton wurde initial von 4 Teilnehmern (11 %) und am Tag der Entlassung von 6 Patienten (17 %) zur Therapie der HI eingesetzt. 23 Patienten (62 %) hatten eine Vortherapie mit Diuretika, am Entlassungstag wurde diese Therapie bei 29 Patienten (81 %) dokumentiert. Die mittlere Dosierung von Furosemid lag bei Aufnahme bei 51 ± 37 mg und bei Entlassung bei 41 ± 35 mg. Im Verlauf der Hospitalisation nahm die Zahl der mit Digitalis therapierten Patienten von 10 (27 %) auf 16 (44 %) zu. Am Aufnahmestag wurde NT-proBNP bei 27 (73 %) Erkrankten bestimmt, der mediane Wert lag bei 3433 ± 4655 ng/l (min 824, max 35.000).

**Table 12: C. Adlbrecht et al.**

<table>
<thead>
<tr>
<th>Best-practice hospitals</th>
<th>Other hospitals</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70.3</td>
<td>73.5</td>
<td>0.009</td>
</tr>
<tr>
<td>Male (%)</td>
<td>70</td>
<td>59</td>
</tr>
<tr>
<td>History of co-morbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease (%)</td>
<td>68</td>
<td>58</td>
</tr>
<tr>
<td>Previous myocardial infarction (%)</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>70</td>
<td>68</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>37</td>
<td>43</td>
</tr>
<tr>
<td>Atrial fibrillation (%)</td>
<td>27</td>
<td>33</td>
</tr>
<tr>
<td>Stroke (%)</td>
<td>12</td>
<td>15</td>
</tr>
<tr>
<td>Chronic obstructive lung disease (%)</td>
<td>20</td>
<td>18</td>
</tr>
<tr>
<td>NYHA functional class</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NYHA II (%)</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>NYHA III (%)</td>
<td>62</td>
<td>55</td>
</tr>
<tr>
<td>NYHA IV (%)</td>
<td>36</td>
<td>44</td>
</tr>
<tr>
<td>Left ventricular ejection fraction (%)</td>
<td>30</td>
<td>29</td>
</tr>
<tr>
<td>Baseline NT-proBNP (pg/mL)</td>
<td>3433 ± 4655</td>
<td>3454 ± 5534</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>121 ± 18</td>
<td>123 ± 20</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>71 ± 11</td>
<td>72 ± 13</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>76</td>
<td>79</td>
</tr>
<tr>
<td>Serum creatinine &gt; 2mg/dL (%)</td>
<td>13</td>
<td>16</td>
</tr>
<tr>
<td>In hospital management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure specific medication at discharge</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>ACE-ARB + BB = None (%)</td>
<td>27</td>
<td>47</td>
</tr>
<tr>
<td>ACE-ARB + BB = -50% (%)</td>
<td>59</td>
<td>42</td>
</tr>
<tr>
<td>ACE-ARB + BB = ≥50% (%)</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>ACE-ARB + BB = 100% (%)</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Echocardiogram performed (%)</td>
<td>91</td>
<td>76</td>
</tr>
<tr>
<td>Index days in hospital (days)</td>
<td>15 ± 9</td>
<td>17 ± 15</td>
</tr>
</tbody>
</table>

**Figure 18: C. Adlbrecht et al.**

These 2 groups. Subsequently the remaining centers were fused accordingly, as there was no difference between them concerning outcome respectively. This procedure resulted in 2 significantly different groups, each group consisting of several centers without significant differences in outcome. Bivariate comparison of patient characteristics and in hospital management between the 2 groups was followed by a multivariate Cox regression model. The endpoint for the latter was time to death.

**Results** During the follow-up period of up to 60 months 253 (61.7%) patients had died. The mean follow-up period was 36.6 ±
Prevalence and Prognostic Significance of Elevated Serum Phosphate Levels in Chronic Heart Failure

M. Ess, K. Heitmair-Witzorrek, H. Ulmer, M. Frick, G. Poelzl
Department of Internal Medicine III, Cardiology, Medical University Innsbruck

Purpose Elevated serum phosphate (SP) levels are associated with an excess risk of cardiovascular disease in patients with and without chronic kidney disease. Also, a graded independent relationship was found between SP and the risk of death or cardiovascular events in patients with prior myocardial infarction. Recently, higher SP was associated with an increased risk of heart failure in a community-based sample. The aim of our study was to investigate the relevance of this emerging cardiovascular biomarker in patients with chronic heart failure.

Methods From 2000 to 2009 clinical and laboratory parameters of 977 ambulatory patients (NYHA class I: 23%, class II: 48%, class III/IV: 29%; mean LV-EF: 32%) of our heart failure program with SP data available were evaluated. Long-term follow-up (mean 40.4 months) was available in 939 patients. The primary endpoint was defined as death of any cause or heart transplantation. Sex stratified Cox proportional hazards models, adjusted for age, ischemic etiology, NYHA class, LV-EF, pulse pressure, heart rate, glomerular filtration rate, body mass index and diabetes, were performed to calculate hazard ratios (HR) and 95% confidence intervals for SP.

Results Prevalence of elevated SP (> 1.45 mmol/l) was 5.8% in men and 6.0% in women. SP was significantly correlated with severity of heart failure as assessed by NYHA class (p < 0.001) and LV-EF (r = -0.10; p = 0.002). Death of any cause or heart transplantation was recorded in 313 patients. Multivariate sex stratified Cox regression analysis revealed SP to be independently associated with adverse outcome (HR 2.03 [95%-CI: 1.30–3.15]; p = 0.002). Compared with the lowest SP quartile, adjusted HR for patients in the second quartile was 1.08 (95%-CI: 0.68–1.51), 1.17 (95%-CI: 0.84–1.63) in the third quartile and 2.08 (95%-CI: 1.53–2.83) in the highest quartile (p < 0.001). Corresponding 5 years cumulative survival/time to transplantation rates were 71%, 72%, 69% and 53%.

Conclusions We found an independent relation between higher levels of SP and the risk of death or heart transplantation in ambulatory patients with chronic heart failure, most of whom had SP levels within the normal range. These findings further highlight the clinical importance of serum phosphate in cardiovascular disease.

The Effect of CCM Therapy on Myocardial Efficiency and Oxidative Metabolism in Patients with Heart Failure

Division of Cardiology, Department of Medicine II, Medical University of Vienna

Introduction Cardiac contractility modulation (CCM) is a device-based therapy that involves delivery of non-excitatory electrical signals resulting in improved ventricular function and a reversal of maladaptive cardiac fetal gene programs. Our aim was to evaluate whether acute application of CCM leads to an increase in myocardial oxygen consumption in patients with chronic heart failure patients using C-11 acetate positron emission tomography (PET).

Methods and Results We prospectively enrolled 21 patients with severe heart failure. C-11 acetate PET was performed before and after activation of CCM device. In 12 patients an additional stress study was performed. At resting conditions, myocardial blood flow (MBF) did not significantly differ between activated and deactivated CCM device (CCM off: 0.81 ± 0.18 ml min⁻¹ g⁻¹; CCM on: 0.80 ± 0.15 ml min⁻¹ g⁻¹; p-value = 0.818), myocardial oxygen consumption remained unchanged (CCM off: 6.81 ± 1.69 µl O₂ min⁻¹ g⁻¹; CCM on: 7.15 ± 1.62 µl O₂ min⁻¹ g⁻¹; p-value = 0.241) and the work metabolic index (WMI) reflecting myocardial efficiency did not alter significantly (CCM off: 4.93 ± 1.14 mmHg × ml/m²; CCM on: 5.21 ± 1.36 mmHg × ml/m²; p-value = 0.344). Under dobutamine, MBF, MVO₂, and WMI did not differ between deactivated and activated CCM-device, but increased significantly when compared to resting conditions.

Discussion These results indicate that CCM does not induce increased myocardial oxygen consumption, even under stress conditions.

New Biomarkers of Kidney Injury as Predictors in Chronic Heart Failure: a Head-to-Head Assessment

S. Neuhold, M. Pischke, C. Adlbrecht, S. Shayagfar, T. Szekeres, C. Rath, R. Pacher, M. Hülsmann
Universitätsklinik für Herz-Thorax-Gefäßanästhesie und Intensivmedizin, Universitätsklinik für Innere Medizin II; Klinische Abteilung für Kardiologie, Medizinische Universität Wien

Background Worsening renal failure is an established strong and independent predictor of impaired outcome in chronic heart failure. To estimate kidney function in clinical practice today serum-creatinine or the glomerular-filtration-rate, which is also based on serum-creatinine are used. Serum-creatinine is highly affected by other biological variables and notoriously unreliable to capture an only mild impairment of kidney function. Therefore, new biomarkers of kidney injury, such as Neutrophil gelatinase-associated lipocalin (NGAL) and Cystatin C are currently evaluated across the cardiovascular continuum for their predictive properties. Cystatin C being a marker of glomerular filtration and NGAL a marker of tubular inflammation signal different pathogenetic pathways. To our best knowledge, a head-to-head assessment of these promising biomarkers has never been reported. We have studied these emerging biomarkers in a cohort of stable chronic heart failure patients without substantial renal disease and compared them to traditional markers of renal impairment and NT-proBNP.

Methods In this long-term observational study, 99 consecutive patients with chronic systolic heart failure and without renal dysfunction based on non-cardiac reasons were included. NT-proBNP and Cystatin C were measured using commercially available assays by Roche Diagnostics, NGAL was measured using the standardized clinical platform ARCHITECT® analyzer, Abbott Diagnostics. The endpoint was a combined endpoint consisting of all-cause mortality and hospitalizations for cardiac reasons. The median observation period was 35 months.

Results 82% of the patients were male, 44% had an ischemic etiology of HF the mean age was 61 ± 11 years, mean LVEF was 33 ± 10%. The median GFR was 79.8 ml/min/1.73m² (Q1–Q3 55.5–104), median NT-proBNP was 803 pg/ml (Q1–Q3 404–1942), median Cystatin C was 1.28 mg/L, (Q1–Q3 1.072–1.688) median NGAL was 5.4 ng/mL (Q1–Q3 2.8–10.2) or median NGAL/urine creatinine ratio 0.06 (Q1–Q3 0.03–0.15). 20 patients died, 39 were hospitalized for cardiac reasons within the observation period. Cystatin C concentrations did not correlate with NGAL concentrations. Cystatin C highly correlated with GFR (r = 0.621; p < 0.001) and NT-proBNP (0.454; p < 0.001) and modestly with proteinuria (0.226; p = 0.035). NGAL did not correlate with GFR, NT-proBNP or proteinuria. Using a univariate model only Cystatin C carried prognostic significance (p = 0.012, CI: 1.277–7.110, HR 3.01), unlike NGAL, proteinuria or GFR. In a multivariate model consisting of NGAL, Cystatin C, proteinuria, gender and age again only Cystatin C carried prognostic significance (p = 0.042, HR 2.912, CI: 1.040–8.155). GFR was left out of the multivariate model due to strong multicollinearity with Cystatin C.

Conclusion Cystatin C proved to be of higher predictive value than traditional markers of renal impairment and the new marker NGAL in this cohort of chronic heart failure patients with only mild renal dysfunction.
Abnormalities in Renal and Liver Function are of Additive Value in Predicting Prognosis in Chronic Heart Failure

G. Pöld, M. Ess, C. Koppelaert, M. Rudnicki, H. Ulmer, M. Frick
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin III, Medizinische Universität Innsbruck

Purpose The cardio-renal syndrome is common and serum creatinine (Crea) is an established biomarker in chronic heart failure (CHF). Recent findings also indicate a predictive role of liver function abnormalities such as gamma-glutamyltransferase (GGT) in CHF. Both renal and liver dysfunction may be attributed to venous congestion in this setting. We therefore aimed to investigate the prevalence of coexisting organ dysfunction and its effect on disease progression in CHF.

Methods From 2000 to 2009 clinical and laboratory parameters of 1221 consecutive ambulatory patients (NYHA class I: 25%, class II: 48%, class III/IV: 27%; median LV-EF: 29%) of our heart failure program were evaluated. Long-term follow-up (median 39 months) was available in 1160 patients. The endpoint was defined as death of any cause or heart transplantation.

Univariate and sex stratified Cox proportional hazards models, adjusted for age, ischemic etiology, NYHA class, LV-EF, heart rate, body mass index, DM were performed to calculate hazard ratios (HR) and 95% confidence intervals for Crea and GGT.

Results Prevalence of sex-specific serum level elevation was 47% for Crea and 44% for GGT. Both variables were significantly correlated with disease severity as assessed by NYHA class and LV-EF. The combined endpoint was recorded in 391 patients. As Crea as well as GGT were associated with adverse outcome in univariate (p < 0.0001 for both variables) and multivariate analysis (p = 0.03 and p < 0.0001, respectively).

When patients were stratified according to dichotomized serum level elevations to Crea+/GGT-, Crea-/GGT+, Crea+/GGT+ and Crea-/GGT+ prevalence was, respectively, 32%, 21%, 24%, and 23%. The estimated 5-year event rate in patients with Crea-/GGT- was 14%, as compared to 30% with Crea+/GGT+ (HR 2.24, 95%-CI: 1.63–3.08; p < 0.0001) and 24% with Crea+/GGT+ (HR 2.30, 95%-CI: 1.66–3.26; p < 0.0001). In patients with Crea elevated, an estimated elevation of GGT (Crea+/GGT+) significantly raised the estimated 5-year event rate to 37% (HR 3.14, 95%-CI: 2.3–2.46; p < 0.0001).

Conclusions Both renal and liver function abnormalities are common in ambulatory patients with chronic heart failure and associated with adverse outcome. The presence of liver dysfunction clearly increases the risk of adverse events in patients with cardio-renal syndrome. Our findings further highlight the clinical importance of second organ dysfunction in heart failure.

Guideline Adherence in the Treatment of Chronic Heart Failure. Data from the EuroHeart Failure Survey – Pilot Phase at the University Heart Failure Clinic Graz

E. Smolle, V. Riegel, C. Oberschneider, J. Haas, F. Fruhwald
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin; Universitätsklinik für Frauenheilkunde und Geburtshilfe, Medizinische Universität Graz

Introduction Heart failure is a common disease of the elderly and, as people grow older these days, it is important to apply standards in heart failure treatment. The European Society of Cardiology (ESC) has published guidelines to standardize therapy. However, treatment may differ significantly from these guidelines in many cases.

Patients and Methods To evaluate guideline adherence, we investigated 66 patients in the setting of the EuroHeart Failure Survey – Pilot Phase (EHFS), which is an observational research program started by the ESC. It includes a basic registry as well as a 3-, 6- and 12-months-followup. We compared the basic registry parameters to the 12-months-follow-up data focusing on pharmacological treatment. The NYHA-classification, rehospitalization and survival have also been examined.

Results 66 patients (15 female, 51 male; median age: 62 years, IQR: 52–70) have been included in the EHFS between October 2009 and May 2010. Primary cause of heart failure has been ischemic in 25 patients (40%), idiopathic in 34 patients (55%) while other causes have been rare (n = 3; 5%).

We were able to follow up all patients after 12 ± 2 months either by telephone or personally at routine checkups at the university heart failure clinic Graz. Functional impairment at baseline has been ischemic in class 1 in 8 patients, class 2 in 38 patients, class 3 in 13 patients and class 4 in 5 patients. After 12 months there have been 7 patients in class 1, 27 patients in class 2, 33 patients in class 3 and 3 patients in class 4. More patients deteriorated than improved over the 12 months period (n = 22; 36% vs n = 12; 20%; respectively; n. s.). 27 patients remained in the same NYHA class within the 12-months.

4 patients (6%; all male) died within the follow up period. Interestingly, those in class 3 or 4 at baseline had a similar risk to die within 12 months as those in class 1 or 2. Furthermore, those with ischemic heart failure had no greater 12-months risk to die than those with non-ischemic etiology. 16 patients (24%; 4 female, 12 male) had to be rehospitalized (1-3 times within the last six months) with heart failure being the reason for 12 rehospitalizations. Cardiac cause other than heart failure, vascular cause and renal dysfunction were documented once each and other causes have been documented twice. Those with a baseline left ventricular ejection fraction (LV-
Introduction

Right ventricular cardiomyopathies (RVC) are most often associated with worse prognosis. Standard evaluation criteria for heart transplantation (HTx) do not necessarily apply to this condition. Hemodynamic perturbation such as Fontan-like-circulation (FLC) indicates advanced right heart failure. Right heart catheterization may be helpful for the assessment of optimal timing for HTx.

Methods and Results

We report on 4 patients (2 males, 41 ± 9 years) with advanced RVC who underwent invasive hemodynamic testing for the evaluation for HTx. The extent of common clinical signs of right heart failure such as leg edema, jugular and/or hepatic vein distension, ascites, and elevation of liver function tests were strikingly heterogeneous. Also, NYHA classification (2.25 ± 0.5) and NT-proBNP (2870 ± 1851.9) did not add unequivocally to decision-making. Right heart hemodynamics revealed markedly reduced CI (2.14 ± 0.64) and FLC with equilibrated pressure tracings between the right atrium (RAM 16 ± 4 mmHg) and the pulmonary artery (PAPm 16 ± 5 mmHg). In this condition blood is propelled passively through the right heart using the left atrium as driving force. Based on these findings all patients were listed for HTx with three of them being already successfully transplanted and one still on the waiting list.

Conclusion

In patients with right ventricular cardiomyopathies evidence of Fontan-like-circulation may substantially contribute to evaluation for HTx particularly in patients not clearly fulfilling standard criteria.

ELICARD: Telemonitoring of Severe Chronic Heart Failure Patients in a Real World Setting

T. Sturmburger, V. Eder, C. Ebner
Kardiologe, Krankenhaus der Elisabethinen Linz

Background

Rates of readmission after hospitalization for heart failure remain high despite considerable advances in medical and device therapy. Telemonitoring patient management may help to detect early signs of decompensation, allowing optimization of treatment in chronic heart failure and improvement of adherence to medical therapy. Recent trials provided conflicting results in terms of the impact of home-based telemonitoring. The purpose of this study was to retrospectively review the 1-year hospitalization due to decompensation.

Methods

We observed 21 patients with chronic heart failure after an episode of acute decompensation either assigned to telemonitoring (tele group) or usual care (control group). Telemonitoring was accomplished using a mobile telemonitoring system based on mobile phones and radio frequency identification (RFID) technology. Patients were able to collect daily information about weight, blood pressure, heart rate and self-assessed health status by means of touching smart objects (measurement devices and icons) with the mobile phone. Transmitted values were reviewed every weekday by a clinician responsible for managing heart failure. Patients assigned to control group were followed by their treating clinicians according to the current standards and guidelines for treatment of patients with heart failure. We assessed the effect of telemonitoring in terms of readmission due to worsening heart failure.

Results

11 patients were assigned to tele group and 10 patients to usual care group with a median age of 73.0 yrs and 71.5 yrs, LVEF 50% vs. 50% (45% vs. 50%) (p = 0.001).

Conclusion

Home monitoring reduced hospitalization due to worsening heart failure in patients with advanced chronic heart failure compared with usual care. In contrary to recent studies our results are based on the involvement of heart failure physicians and their immediate therapeutic response dependent on the telemonitoring data.
EINLEITUNG

MATERIAL UND METHODE

ERGEBNISSE
Es fanden sich 164 Patienten mit der Entlassungsdiagnose AS. Von diesen hatten 49 Patienten (Durchschnittsalter 76 ± 9 Jahre) eine symptomatische hochgradige Stenose (definiert als Klappenöffnungsfläche < 1 cm², mittlerer Gradient ≥ 50 mmHg, maximale Flussgeschwindigkeit > 4 m/s). Vier Pat. (8 %) mit hochgradiger Aortenstenose verstarben während des stationären Aufenthalts, 5 Pat. (10 %) lehnten jegliche Therapie ab. 21 Pat. (43 %) wurden einem chirurgischen Aortenklappenersatz zugeführt. Die übrigen 19 Patienten (39 %, Durschnittsalter 84 ± 9 Jahre) wurden aufgrund eines log. Euroscore > 15 % bzw. STS-Score > 10 % und/oder anderer Kontraindikationen (reduzierter Allgemeinzustand/Pflegebedürftigkeit n = 16, fortgeschrittenes Malignom n = 2) keinem chirurgischen Aortenklappenersatz zugeführt. Vier Pat. (5 %) bekamen einen Aufenthalt von mehr als 6 Monaten, 2 Patienten (3 %) und eine Patientin (1 %) wurden in ein anderes Krankenhaus transferiert. Vier Pat. (8 %) mit hochgradiger AS wurden noch in der ersten Woche post PCI operiert.

DISKUSSION
Die vorgelegten Ergebnisse der TAVI retrospektiven Analyse sind mit den Ergebnissen der TAVI prospektiven Studie vergleichbar. In der prospektiven Studie zeigte sich, dass TAVI bei hochgradiger AS eine effektive und sichere Alternative zum chirurgischen Klappenersatz darstellt. Die retrospektive Analyse bestätigt diese Ergebnisse und unterstreicht die Bedeutung der TAVI für Patienten mit schwerer AS.

LITERATUR

MULTIPLE ELECTRODE AGGREGOMETRY AND VASODILATOR STIMULATED PHOSPHOPROTEIN-PHOSPHORYLATION ASSAY IN CLINICAL ROUTINE FOR PREDICTION OF POSTPROCEDURAL MAJOR ADVERSE CARDIOVASCULAR EVENTS

B. Frey et al.

Background Reduced antiplatelet effect of clopidogrel assessed with multiple electrode aggregometry (MEA) and vasodilator stimulated phosphoprotein-phosphorylation (VASP-P) assay has been proven to predict major adverse cardiovascular events (MACE) after coronary stenting. So far no consecutive registry has evaluated the usefullness of different adenosine diphosphate-based platelet function tests to predict outcome in unselected patients. Hence, our objective was to determine the feasibility of MEA and VASP-P for clinical routine and whether low-response to clopidogrel as determined by MEA and/or the VASP-P assays predicts MACE in a “real-life” population undergoing coronary stenting.

Methods Three-hundred consecutive patients were included in this prospective registry. Blood was sampled 6–24 hours after stenting to measure MEA and VASP-P assays.

Results The use of glycoprotein-IIb/IIIa-blockers in this unselected cohort limited MEA to 196 measurements. Concerning the VASP-P assay, 300 measurements were achieved. ROC-curves of sensitivity and specificity estimates for MACE were plotted for VASP-P assay. The area under the ROC-curve was 0.683 (p = 0.014) for the platelet reactivity index (PRI) calculated from median fluorescence intensities (FI) with an optimal cut-off at 60.2 % PRI. Patients above 60.2 % had a significantly increased risk for MACE for the platelet reactivity index (PRI) calculated from median fluorescence intensities (FI) with an optimal cut-off at 60.2 % PRI. Patients above 60.2 % had a significantly increased risk for MACE for the platelet reactivity index (PRI) calculated from median fluorescence intensities (FI) with an optimal cut-off at 60.2 % PRI. Patients above 60.2 % had a significantly increased risk for MACE for the platelet reactivity index (PRI) calculated from median fluorescence intensities (FI) with an optimal cut-off at 60.2 % PRI.

Conclusions VASP-P assay is feasible for clinical routine to measure clopidogrel effects and to predict postprocedural MACE in unselected patients. With regard to differing cut-offs, exact stan-
ExoSeal® versus AngioSeal® – Comparison of 2 Arterial Closure Devices in Terms of Bleeding Complications

Background
The ExoSeal®-system represents a new, purely extravascular closure system, which seals the artery from the outside via an absorbable Polyglycolic acid plug. Up to now one trial (ECLIPSE) reported similar results regarding major access-site-related adverse events when comparing this device with manual compression. As many other institutions we treat almost all femoral puncture sites using a closure device instead of manual compression. The AngioSeal®-device is the most frequently used system, which consists of an intravascular anchor and an extravascular absorbable collagen sponge. The aim of this study was to compare these 2 devices in terms of bleeding complications in everyday clinical life.

Material and Methods
This study was performed in patients who underwent a coronary angiography at the Medical University of Vienna between July and December 2010. We prospectively analyzed 45 patients who were treated with ExoSeal® and 90 control patients (ratio 1:2) who were treated with AngioSeal® and were matched according to age, sex, and procedure (diagnostic or interventional). The occurrence of bleeding complications was evaluated based on a standard complication feedback form completed by physicians of the cardiological wards.

Results
The 2 study groups are homogeneously distributed in terms of gender, age, intra-interventional administration of Heparin, duration of intervention and severity of CHD (Table 13).

Both groups show an equally low rate of bleeding complications (ExoSeal®: n = 1; AngioSeal®: n = 2). One bleeding complication occurred after a diagnostic angiography, the other 2 events occurred after an interventional procedure. All three events were defined as less-severe complication (hematoma), which were treated using conventional compression after assessment by echo or computer tomography.

Conclusion
Our results suggest that ExoSeal® is as safe as AngioSeal® for closure of the puncture side of the femoral artery after coronary angiography. These data should be confirmed in a larger patient population.

Table 13: C. Gangl et al.

<table>
<thead>
<tr>
<th>Gender (m/f)</th>
<th>AngioSeal® (n = 90)</th>
<th>ExoSeal® (n = 45)</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostical/Interventional</td>
<td>62 (69 %)/28 (31 %)</td>
<td>31 (69 %)/14 (31 %)</td>
<td>n. s.</td>
</tr>
<tr>
<td>Age</td>
<td>69 (IQR 61–75)</td>
<td>69 (IQR 62–77)</td>
<td>n. s.</td>
</tr>
<tr>
<td>Heparin (IE)</td>
<td>4189</td>
<td>4196</td>
<td>n. s.</td>
</tr>
<tr>
<td>Duration of intervention</td>
<td>97 Min</td>
<td>111 Min</td>
<td>n. s.</td>
</tr>
<tr>
<td>CHD-severity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–VD</td>
<td>12 (13 %)</td>
<td>9 (20 %)</td>
<td>n. s.</td>
</tr>
<tr>
<td>1–VD</td>
<td>19 (21 %)</td>
<td>10 (22 %)</td>
<td>n. s.</td>
</tr>
<tr>
<td>2–VD</td>
<td>25 (28 %)</td>
<td>15 (33 %)</td>
<td>n. s.</td>
</tr>
<tr>
<td>3–VD</td>
<td>34 (38 %)</td>
<td>11 (25 %)</td>
<td>n. s.</td>
</tr>
</tbody>
</table>

5 Years Clinical Follow-up of Patients Treated with Combined Delivery of Intracoronary and Intramyocardial Bone-marrow Mononuclear Cells

Background
The MYSTAR prospective randomized study revealed a moderate but significant increase in global left ventricular ejection fraction (EF) in patients receiving combined delivery of bone-marrow mononuclear cells (BM-MNC) either 3–6 weeks (mean 32 ± 12 days, Early group) or 3–4 months (mean 93 ± 15 days, Late group) post acute myocardial infarction (AMI), with no difference between the groups 3 months post BM-MNC therapy. We have evaluated the effect of the cardiac stem cell therapy on long-term (5 years) clinical outcome.

Methods
Between 2002 and 2006, patients with recent AMI and primary percutaneous coronary intervention, and EF between 30–45% were included in the MYSTAR study. The 5-year clinical follow-up (FUP) included the records of major adverse cardiac events (MACCE, defined as all-cause mortality, re-AMI, reintervention of the infarct-related artery (IRA) and stroke), implantation of automatic cardioverter-defibrillators (ICD) and hospitalization due to angina pectoris or acute or chronic heart failure. Kaplan-Meier survival analyses were performed to compare the clinical outcomes of the Early and Late groups. Predictors for worse long-term outcome were assessed by using Cox proportional hazard analysis.

Results
MACCE occurred in 16.7% of patients (10% in Early and 23.3% in Late groups, log-rank p = 0.197) during the 5 years FUP. All-cause death occurred only in Late group (10% vs 0%, log-rank p = 0.024) (cardiac death 6.7% vs 0%). ICD was implanted in 6.7% and 10% of patients, repeated hospitalization was necessary in 16.7% of patients in both groups (non-significant), respectively. Patients with MACCE had a significantly lower baseline unipolar voltage value of the intramyocardially injected area (6.2 ± 2.7 vs 8.3 ± 2.7 mV; p = 0.025). Mortality was associated with significantly lower baseline 99m-Tc-Sestamibi tracer uptake (44.2 ± 15.4% vs 58.4 ± 15.6%; p = 0.042), unipolar voltage (4.8 ± 1.2 vs 8.3 ± 2.7 mV; p = 0.002) and local linear shortening values (index of segmental wall motion disturbance) (7.4 ± 3.2% vs 11.1 ± 3.7%; p = 0.021) of the injected area, with no other differences regarding the baseline data. Low unipolar voltage value proved to be significant predictor for poor outcome at 5-year FUP by Cox regression analysis when adjusted for the classical predictors of MACCE.

Conclusions
Combined delivery of BM-MNC leads to a favorable event-free survival rate in patients with a low (30–45%) EF post-AMI. Late (at least 3 months post-AMI) cardiac stem cell therapy resulted in a higher incidence of death during the 5-year FUP, as compared with the cardiac stem cell therapy between 3–6 weeks post-AMI. NOGA-derived baseline parameter might help to identify patients with significantly better long-term clinical outcome after cardiac stem cell therapy.

AngioSeal® after Femoral Artery Puncture – Does Additional Compression Bandage Increase the Safety?

Background
To investigate the efficacy of compression bandage in patients after percutaneous transfemoral coronary angiography in addition to the general appliance of AngioSeal®.

Materials and Methods
We conducted a randomized controlled study which was approved by the local ethics committee. Included patients were randomly assigned to an additional compression bandage at the arterial puncture site accompanied by bedrest of four hours or just four hours lasting bedrest after direct closure by utilizing AngioSeal®.
Postinterventional Cardiac Marker Release has Limited Prognostic Relevance Compared with Standard Risk Factors and Markers in Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Interventions

JV – 8
J. Mair, M. Brauer, E. Bode, H. Alber, D. Pachinger
Universitätsklinik für Innere Medizin III, Kardiologie, Medizinische Universität Innsbruck

Introduction The aim of the study was to investigate the prognostic significance of postinterventional cardiac troponin T (cTnT) and creatine kinase (CK) release in patients with stable coronary artery disease (CAD) undergoing elective percutaneous coronary interventions (PCI).

Materials and Methods Evaluation of mortality and a combined clinical endpoint (mortality, need for coronary revascularization, myocardial infarction, hospitalization for cardiac causes, or stroke) during a 40.5 ± 8.6 month follow-up in 136 consecutive patients (73% males, age: 66.6 ± 9.9 years) receiving 1–5 stents (1 in 77.9%) for 1–3 vessel disease (1 vessel disease in 54.4%). 55.1% of patients had a reduced left ventricular ejection fraction (LVEF). Pre PCI laboratory assessment included CK, cTnT, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high sensitivity C-reactive protein (hs-CRP). Post-PCI CK and cTnT were measured after 4 hours and on the next day if indicated.

Results 13 patients died (6 cardiac death) and 68 patients reached the combined endpoint (37 cardiac events). Post PCI CK increased above the upper reference limit in 11 and cTnT (> 0.03 µg/L) in 16 patients. Univariate Kaplan-Meier survival rate analysis showed that hs-CRP and diabetes were the only significant predictors of all-cause mortality, and diabetes and a reduced LVEF of cardiac mortality. hs-CRP, diabetes, and a reduced LVEF were the only significant predictors of combined cardiac events. In an age- and gender-adjusted multivariate Cox regression analysis, hs-CRP and detectable cTnT (> 0.01 µg/L) before PCI were the only significant predictors of all-cause mortality, diabetes for cardiac mortality, and a reduced LVEF for combined cardiac events.

Discussion In comparison with traditional risk factors and markers post-PCI cardiac marker release is of low prognostic importance for predicting cardiac mortality and future cardiac events in patients with stable CAD undergoing elective PCI.

Compression of Iatrogenic Femoral Pseudoaneurysm by Instillation of Physiological Saline Solution

VIII – 6
W. Miekusch, A. Carls, M. Heke, I. Miekusch, M. Haumer
Interne Abteilung, Thermenklinikum Mödling

Background Arterial puncture for angiographic procedures carries a considerable risk of access site complications. The incidence of pseudoaneurysms has been reported in up to 8%. Recently, there are data available describing a para-aneurysmal saline injection as novel therapeutic alternative to percutaneous thrombin injection. The aim of the present study was to report the success rate of para-aneurysmal saline injection in patients with post-catheterization pseudoaneurysms at the vascular access site.

Materials and Methods The study was designed as a prospective cohort study. We enrolled consecutive patients with pseudoaneurysms after percutaneous procedures who underwent percutaneous pseudoaneurysmal saline injection to compress the arterial feeder of respective femoral pseudoaneurysms.

Results We included 51 patients (55% male) in our final analysis. In 22 patients (43%) the para-aneurysmal saline injection appeared successful the day after injection. Demographic variables were well balanced in our study population. We observed no differences in coagulation findings. Interestingly, the larger the angle (median 140° vs median 110°; p < 0.001) between the feeding femoral artery and the fistula and the longer the fistula (median 12.5 mm vs median 10.3 mm; p = 0.009) the higher was the investigated treatment suc-
cess. Moreover, the peak systolic velocity in the fistula seems also inversely but not significantly linked to the respective treatment success (median 2.5 m/s vs median 2.9 m/s; p = 0.07).

Discussion We observed that simple anatomical features of the pseudoaneurysmatic fistula significantly predict the success rate of paraaorticysmal saline injection.

Single-Center Experience with Transcatheter Aortic Valve Implantation: Cumulative Survival and 3-Year Follow-up

BAII


1Universitätsklinik für Innere Medizin, Medizinische Universität Graz;
2FH-Joanneum Graz

Background Transcatheter aortic valve implantation (TAVI) is an emerging new treatment option for elderly patients with symptomatic severe aortic stenosis (AS) and high risk for surgical aortic valve replacement. Since TAVI was introduced into clinical cardiology only a few years ago, data on long-term clinical outcome is scarce. Therefore we analyzed our patient series in this regard with a follow-up period of more than 3 years.

Patients and Methods Between May 2007 and March 2011, in our center a total of 165 patients (age: mean ± SD 81 ± 6 years, median 82 years, range 62–91 years; male = 37%) underwent TAVI with a 26 or 29 mm self-expanding CoreValve bioprosthesis (Medtronic Inc., Minneapolis, MN). Mean logistic EuroSCORE was 26 ± 15% (median 20%, range 6–73%). A transfemoral access was used in 162 patients, a left subclavian approach in 3 patients. Follow-up visits, including clinical assessment and echocardiographic evaluation, were scheduled at 30 days, 3 months, 6 months, and 12 months after the procedure, and on a yearly basis thereafter. Cumulative survival rates were calculated using Kaplan-Meier life-table analysis.

Results Acute procedural success rate was 99.4%. In 1 single patient the procedure had to be aborted due to inadequate annulus measurement. Device implantation resulted in a clear-cut clinical improvement accompanied by a significant and sustained reduction of peak and mean transaortic pressure gradients as well as a significant and sustained increase of aortic valve area. Cumulative 30-day, 1-year, 2-year, and 3-year survival rates were calculated as 93.2% (patients at risk = 162), 84.1% (patients at risk = 109), 74.3% (patients at risk = 59), and 70.4% (patients at risk = 36), respectively.

Discussion TAVI emerges as a promising new treatment option for elderly patients with symptomatic severe AS and high risk for surgical aortic valve replacement. Since TAVI was introduced into clinical cardiology only a few years ago, data on long-term clinical outcome is scarce. Therefore we analyzed our patient series in this regard with a follow-up period of more than 3 years.

Transradial Approach for Percutaneous Coronary Interventions with Thromboaspiration in Patients with STEMI

H. Pejkov, S. Kedev, S. Antov, O. Kalpak, J. Kostov, I. Spiroški, S. Kaeva

Interventional Cardiology, Uni-Clinic for Cardiology, Skopje, Mazedonien

Objective We sought to evaluate the effects of manual thromboaspiration on myocardial reperfusion performed during percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).

Background Complete reperfusion after primary PCI is compromised by the presence of intraluminal thrombus. Thus effective and safe extraction of thrombus in a timely fashion is important for successful reperfusion.

Methods In the period from 01.01.2010–31.12.2010 in 650 patients with STEMI PCI was performed. In 616 patients (94.8%) PCI was performed through transradial approach and in 34 (5.2%) we use transfemoral access. The mortality rate in examined group was 4.5%. Thirty patients (age 51 ± 12 years, males 78%) with STEMI and angiographic evidence of intraluminal thrombus underwent thromboaspiration during a 12-month period. Thromboaspiration was performed after the presence of thrombus was confirmed angiographically by the operator. Thrombectomy was performed using 6-F-Aspiration Catheter. Myocardial reperfusion using thrombolysis in Myocardial Infarction (TIMI) flow was assessed.

Results The infarct-related artery was left anterior descending (19%), right coronary artery (59%), left circumflex artery (22%). The coronary lesion was Type B in 62 % and Type C in 38% patients, with an average length of 18.2 ± 4.6 mm and reference vessel diameter of 3.2 ± 0.4 mm. The preprocedural TIMI-flow was 0 in 62%, 1 in 13%, 2 in 22% and 3 in 3% of patients. The postprocedural TIMI flow was 0 in 3 %, 1 in 6%, 2 in 25% and 3 in 66% of patients. The in-hospital mortality was 0 and the 30 day mortality was 2%.

Conclusion Manual thrombectomy is safe and effective in establishing myocardial reperfusion after STEMI.

Mesh Covered Stents and Myocardial Blush in ACS Patients: First Results of an Ongoing Trial

N. Preis, O. Friedrich, G. Gaul, J. Spitz, M. Winkler

2Medizinische Abteilung, Hanusch-Krankenhaus, Wien

Purpose Our ongoing single centre retrospective trial sets out to examine the outcome of PCI in ACS patients using a mesh covered stent device designed to provide embolic protection compared to a control group in which conventional stent devices were employed. Endpoints were myocardial blush and TIMI immediately after PCI and 6 months mortality.

Method Our trial included 71 ACS-patients (MI or unstable AP) with single vessel disease. In 34 patients the mesh covered stent was employed (median age: 65.5, 70.6% men; 67.7% STEMI, 12.9% NSTEMI, 19.4% unstable AP). The control group with conventional stent devices (DES or BMS) included 34 patients (median age: 63.0, 73.0% men; 72.7% STEMI, 9.1% NSTEMI, 18.2% unstable AP).

Myocardial reperfusion after PCI was assessed by Myocardial Blush Grade (MBG) and by using the Quantitative Blush Evaluator (QuBE) a computer program created by Vogelzang et al. (2009) which provides a quantitative measure for myocardial blush. The QuBE value reflects both the filling and emptying phase of the vessels, by summing the maximum increase in greyvalue and the maximum decrease after that. The score is a observer independent measure.

Table 14: N. Preis et al.

<table>
<thead>
<tr>
<th></th>
<th>Mesh covered stent</th>
<th>Conventional stent device DES/BMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIMI pre PCI</td>
<td>0</td>
<td>46%</td>
</tr>
<tr>
<td>1</td>
<td>5.9%</td>
<td>26.3%</td>
</tr>
<tr>
<td>2</td>
<td>28.5%</td>
<td>16.2%</td>
</tr>
<tr>
<td>3</td>
<td>17.7%</td>
<td>37.8%</td>
</tr>
<tr>
<td>TIMI post PCI</td>
<td>0</td>
<td>2.7%</td>
</tr>
<tr>
<td>1</td>
<td>8.8%</td>
<td>16.2%</td>
</tr>
<tr>
<td>2</td>
<td>91.2%</td>
<td>81.1%</td>
</tr>
<tr>
<td>MBG post PCI</td>
<td>0</td>
<td>10.8%</td>
</tr>
<tr>
<td>1</td>
<td>2.9%</td>
<td>13.5%</td>
</tr>
<tr>
<td>2</td>
<td>91.2%</td>
<td>75.7%</td>
</tr>
<tr>
<td>Modified QuBE value*</td>
<td>Median</td>
<td>4</td>
</tr>
<tr>
<td>Q1</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Q3</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Min</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Max</td>
<td>8</td>
<td>8</td>
</tr>
</tbody>
</table>

* Significant differences in quantitative assessment of myocardial blush between patients treated with mesh covered stents and the control group (p < 0.05, Mann-Whitney-U-Test)
Conclusion Improvement of TIMI flow by local abciximab administration is more effective when using the abciximab first strategy compared to using thrombus-aspiration first strategy. The abciximab first strategy seems to be more effective to achieve optimal final TIMI flow than the thrombus-aspiration first strategy.

Intracoronary Administration of Abciximab via an Intracoronary Perfusion Catheter in Patients with a Thrombotic Coronary Occlusion – a Single Center Experience

C. Roth, G. Delle Karth, I. M. Lang, G. Kreiner, C. Gangl, S. Loga, R. Berger, T. Neunteufel
Klinische Abteilung für Kardiologie, Universitätssklinik für Innere Medizin II, Medizinische Universität Wien

Aim At concentrations superior to those achieved with the standard intravenous dose for coronary procedures, abciximab has an active dethrombotic effect by displacing platelet-bound fibrinogen. This analysis investigates whether administration of abciximab by local intracoronary infusion through the ClearWay Catheter improves coronary blood flow (TIMI flow) by reducing thrombus burden.

Methods and Results This retrospective study included 43 patients who presented with an acute coronary syndrome due to an intracoronary thrombus between May 2009 and December 2010. The primary endpoint was defined as improvement in Thrombolysis In Myocardial Infarction (TIMI) flow after intracoronary administration of abciximab via the ClearWay (CW) RX perfusion catheter.

The population (mean age 58 ± 11 years) consisted of 36 patients (84%) with an ST-elevation myocardial infarction and 7 patients (16%) with a non-ST-elevation myocardial infarction. Nine patients (21%) presented with cardiogenic shock. The balloon-diameter of the perfusion catheter was 1 mm in 16 (37%), 1.5 mm in 7 (16%), 2.0 mm in 41 (34%), and 2.50 mm in 6 patients (14%), respectively.

Successful positioning of the balloon within the thrombus was not possible in 5 patients (8%). After infusion of abciximab using the perfusion catheter TIMI flow improved by one grade in 14 patients (37%), by 2 grades in 3 patients (8%), and by 3 grades in 5 patients (14%). TIMI flow remained unchanged in 13 patients (34%), and even worsened by one grade in 5 patient (15%) (chi-square-test – p < 0.0001). The procedure was complicated by an air embolization in 5 patients (12%). Air embolization occurred using a 2 mm balloon (3 patients) or a 3 mm balloon (2 patients), but not using a 1 mm or 1.5 mm balloon (qui-square-test – p < 0.07). After the use of the perfusion catheter in these patients TIMI flow improved by one degree in 2 of these patients, and was unchanged in 2 of these patients (no documentation in one patient). After additional treatment with thrombolysis (38 patients – 88%), initial balloon dilatation (33 patients – 77%), direct stenting (10 patients – 23%), and stent implantation (39 patients – 90%), the final TIMI flow was TIMI 3 in 33 patients (77%), TIMI 2 in 4 patients (9%), and TIMI 1 in 6 patients (14%).

Conclusion The intracoronary infusion of abciximab using the ClearWay (CW) RX perfusion catheter helps to improve myocardial perfusion in patients with acute coronary syndrome due to an intracoronary thrombus. The use of perfusion catheters with a balloon ≥ 2 mm can be associated with air embolism.

The Course of NT-proBNP in Patients who underwent Percutaneous Transcatheter Aortic Valve Implantation

Department of Medicine I, Division of Cardiology, Department of Cardio-Thoracic Surgery, Medical University of Vienna

Background Natriuretic peptides have been shown to predict outcome in patients with severe aortic stenosis after aortic valve replacement. The aim of this study was to evaluate the course of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients...
who underwent percutaneous transcatheter aortic valve implantation (TAVI).

**Methods** Between May 2007 and February 2011, 53 symptomatic pts with severe aortic stenosis successfully underwent TAVI (30 pts received an Edwards Sapien valve, 23 pts a CoreValve). NT-proBNP (Roche Elecsys) were assessed before and 30 days, 3, 6, and 12 months after TAVI.

**Results** Patients had an age of 83 ± 5.9 years, the logistic EuroScore was 26.3 ± 11.6%, the baseline aortic valve area 0.6 ± 0.1 cm², and the mean gradient 59.6 ± 19 mmHg. Baseline NT-proBNP was significantly correlated to the logistic EuroScore (r = 0.43; p = 0.002), and to LVF (r = 0.3; p = 0.0001), but not to age. After TAVI NT-proBNP decreased in trend from 2364 pg/ml (n = 50, IQR 1254–7253) to 1815 pg/ml (n = 32; IQR 838–3392; paired t-test p = 0.045) after 30 days, to 1536 pg/ml (n = 29; IQR 702–3393; p = 0.238) after 3 months, to 1382 pg/ml (n = 29, IQR 447–3375; p = 0.095) after 6 months, to 1290 pg/ml (n = 17, IQR 733–3101; p = 0.145) after 12 months, and to 737 pg/ml (n = 10, IQR 286–1851; p = 0.032) after 2 years. Baseline NT-proBNP in 22 pts who died after TAVI during 3 months, to 1382 pg/ml (n = 29, IQR 447–3375; p = 0.095) after 6 months, to 1290 pg/ml (n = 17, IQR 733–3101; p = 0.145) after 12 months, and to 737 pg/ml (n = 10, IQR 286–1851; p = 0.032) after 2 years. Baseline NT-proBNP in 22 pts who died after TAVI during FUP (mean 193 days) was in trend higher (2945 pg/ml, IQR 1641–8618) compared to 31 survivors (1777 pg/ml, IQR 785–3674; p = 0.105).

**Conclusion** After TAVI, NT-proBNP levels tended to decrease. If baseline NT-proBNP seems to be a predictor for outcome after TAVI should be confirmed in larger patient populations.

**Phenotyping versus Genotyping for Prediction of Adverse Events in Clopidogrel Non-Responders**

J. Siller-Matula, G. Deille Karth, I. M. Lang, T. Neunteufl, M. Kozinski, J. Kubica, T. Grybowski, B. Jilma
Universitätsklinik für Klinische Pharmakologie; Universitätsklinik für Innere Medizin III, Medizinische Universität Innsbruck

**Background and Aim** Although prognostic values of different tests for assessment of clopidogrel responsiveness have been shown in independent studies, no direct comparison between the assays has been made so far. Therefore, we investigated which laboratory approach has the best predictive value for adverse events in patients taking clopidogrel.

**Methods** In this prospective cohort study polymorphisms of CYP2C19*2 and CYP2C19*17 genes, vasodilator-stimulated phosphoprotein phosphorylation (VASP) assay, Multiple Electrode Aggregometry (MEA; adenosine disphosphate + prostaglandine E1: ADP+PGE1), Cone and Platelet Analyzer (CPA: ADP) and Platelet Function Analyzer (PFA100: collagen+ADP) were performed in 416 patients with coronary artery disease undergoing percutaneous coronary intervention. The rates of events (definite and probable stent thromboses and major bleedings) were recorded during a 12-month follow-up.

**Results** Receiver operator characteristic analysis showed that platelet aggregation by MEA predicted stent thrombosis better (c-index = 0.90; p < 0.001; sensitivity = 90%; specificity = 83%) than the VASP assay (c-index = 0.62; p > 0.05; sensitivity = 70%; specificity = 38%), CPA (c-index = 0.62; p > 0.05; sensitivity = 90%; specificity = 36%), PFA100 (c-index = 0.66; p > 0.05; sensitivity = 70%; specificity = 61%) or the CYP2C19*2 polymorphism (sensitivity = 30%; specificity = 71%). Survival analysis yielded that patients classified as non-responders by MEA had a substantially higher risk to develop stent thrombosis than clopidogrel responders (12.5% vs 0.3%; p < 0.001), whereas poor metabolisers (CYP2C19*1/*2 or *2/*2 carriers) were not at increased risk (2.7% vs 2.5%; p > 0.05). Multiple logistic regression analysis identified response status assessed by MEA as an independent predictor of stent thrombosis. Although the incidence of major bleedings was higher in patients with an enhanced vs. low response to clopidogrel (4% vs 0%) or in ultra-metabolisers vs. regular-metabolisers (CYP2C19*1/*17 vs. CYP2C19*1/*1; 9.5% vs 2%), neither test was predictive for bleeding events during clinical follow-up. The classification and regression tree analysis demonstrated that acute coronary syndrome at hospitalisation followed by diabetes mellitus were the best discriminators for clopidogrel responder status.

**Conclusions** Phenotyping of platelet response to clopidogrel by MEA might be a better risk predictor of stent thrombosis than genotyping of the CYP2C19 allele.

**Gender Differences in a Large Cohort of Consecutive Patients Undergoing Elective Coronary Angiography For the Evaluation of Suspected Coronary Artery Disease**

Universitätsklinik für Innere Medizin III, Medizinische Universität Innsbruck

**Background** Gender specific information from consecutive patients undergoing elective coronary angiography (CA) in daily clinical practice is sparse. We investigated gender differences in a large cohort of consecutive patients referred for elective CA for the evaluation of coronary artery disease (CAD).

**Methods** Data from 7819 consecutive elective patients referred for CA were collected. Furthermore, follow-up data from 345 randomly selected CAD patients without recent or prior myocardial infarction were obtained.

**Results** On the background of a different risk factor profile, men more frequently had a significant CAD (41.1 vs 65.6%; p < 0.001) and consequently underwent more often a percutaneous coronary intervention (PCI) (20.2 vs 32.1%; p < 0.001).
nificant CAD, PCI rate was not different between gender (49.2 vs 48.6%; women vs men resp.; p = 0.72), CAGB was more often performed in men (10.4 vs 13.4%; p = 0.01). After a mean follow-up of 3.9 ± 2.2 years, no difference in the combined endpoint (cardiac death, myocardial infarction, revascularisation) between women and men was found (18.7 vs 25.6%; p = 0.18). Kaplan-Meier analysis also revealed no gender difference using log-rank test (Figure 20).

### Conclusion
In the contemporary management of patients with suspected CAD, women present with a different risk factor profile and have less frequently a significant CAD. However, no gender difference in the rate of PCI exists in patients with significant CAD. The risk of death, myocardial infarction and further revascularisation during the next 3 years seems to be similar for both gender.

### Predictors of Periprocedural Myocardial Injury During Percutaneous Coronary Intervention

#### VIII – 8

I. Tentesinis, S. Farhan, A. Janai, E. Samaha, A. Gappert, G. Unger, J. Wöst, K. Huber

3rd Med. Dept. of Internal Medicine, Cardiology and Emergency Medicine, Wilhelmshospital, Vienna

#### Purpose
Periprocedural myocardial injury during percutaneous coronary intervention (PCI) has been associated with worse clinical short- and long-term outcome. Aim of this study was to identify patient and lesion related characteristics, which might predict occurrence of myocardial injury during PCI in patients with stable coronary artery disease (CAD) as measured by high-sensitive Troponin T (hs-cTnT).

#### Methods
Two-hundred-fifty-seven consecutive patients who underwent PCI for stable CAD were included in a prospective registry. Blood samples for hs-cTnT were withdrawn before and immediately after a successful PCI with stent implantation.

#### Results
Ninety-seven patients (37.7%) had an increase of hs-cTnT after PCI. Periprocedural hs-cTnT increase showed a correlation with arterial hypertension (p = 0.009), and diabetes mellitus (p = 0.017), while age (p = 0.07), gender (p = 0.77), total dilatation time (p = 0.39), stent length (p = 0.13), stent diameter (p = 0.61), renal dysfunction (p = 0.65), previous myocardial infarction (p = 0.35), heart failure (p = 0.54), drug-eluting stent implantation (p = 0.21), chronic total occlusion (p = 0.42), or multivessel disease (p = 0.26) had no impact on periprocedural myocardial injury.

#### Conclusion
In our series only the patient characteristics arterial hypertension and diabetes mellitus were significant predictors for periprocedural myocardial injury during PCI for stable CAD.

### Distinctive Benefit of Drug-Eluting Stents in Large Coronary Arteries of Diabetic Patients – A BASKET-PROVE Substudy

#### VIII – 9

M. Wanitschek1, A. Hvelplund2, A. Iverson2, R. Jegers2, F. Nietlispach2, J. S. Jensen2, S. Galatius1, C. Kaiser1, M. Pfisterer1, H. Alber1
1Department of Internal Medicine III, Cardiology, Medical University Innsbruck, Austria; 2Department of Cardiology, Gentofte University Hospital, Denmark; 3Department of Cardiology, University Hospital Basel, Switzerland

#### Background
Chronic renal insufficiency (CRI) is a well established predictor of worse outcomes in patients with coronary artery disease. It is less known, whether CRI influences the benefit-risk balance of drug-eluting stents (DES) versus bare-metal stents (BMS), too.

#### Methods
In the prospective multicenter BASKET-PROVE trial, 2314 patients in need of large coronary artery stenting (≥ 3.0 mm) were randomized 2:1 to DES or BMS and followed for 2 years. In an *a priori* planned secondary analysis, outcomes were evaluated according to estimated glomerular filtration rates (GFR). The primary endpoint was first major adverse cardiac event (MACE: cardiac death, myocardial infarction, target- vessel revascularization) up to 2 years. A Cox proportional-hazard model was used to evaluate the relative risk for patients with normal (GFR ≥ 60 ml/kg/min) or reduced (GFR < 60 ml/kg/min) renal function according to the stent type implanted (DES vs BMS).

#### Results
Baseline renal function was known in 1681 patients enrolled. Patients with reduced GFR (n = 119, 11.2%) had a 2-year MACE rate of 8.5% and those with normal GFR (n = 1492) of 7.4% (p = n. s.). The MACE rate of patients with reduced GFR was lower in those receiving a DES (n = 123) than in those receiving a BMS (n = 66, 4.9 vs 15.2%; p = 0.026) as was the MACE rate after DES compared to BMS implantation in patients with normal GFR (5.6 vs 11.1%; p < 0.0001). In the Cox proportional-hazard model including coronary artery disease severity and classic cardiovascular risk factors, the corresponding hazard rates (CIs) for the comparison of DES with BMS within the groups of patients with reduced and normal GFR were 5.06 (1.65–15.53) and 2.07 (1.42–3.01), respectively.

#### Conclusions
This analysis of non-selected patients in need of large coronary artery stenting documents the long-term benefit of DES compared to BMS irrespective of renal function, with a hazard ratio which was twice as high for patients with reduced than with normal renal function.

### The EXOSEAL Cohort: Outcomes of a Novel, Painfree, Vascular Closure Device

#### VIII – 9

C. Wolf
1. Medizinische Abteilung, SMZ Ost Donauspital, Wien

#### Objectives
The objective of the study was to assess the efficacy and safety of a novel and painfree vascular closure device, the EXOSEAL, in patients undergoing routine cardiac catheterization (CATH) and intervention (PCI) via a retrograde femoral artery access. Background: Successful use of current-generation vascular closure devices is highly dependent on operator methodology. To reduce dependence on operator technique, the EXOSEAL was designed to automate the closure process, specifically the deployment
Koronare Herzkrankheit (KHK)/Coronary Heart Disease (CHD)

Impact of Platelet-Turnover on the Vasodilator Activated Phosphoprotein-Phosphorylation Assay in Patients with Coronary Artery Disease

M. Freynhofer, J. Brozovic, V. Bruno, L. Yukhanyan, M. Willheim, W. Hübl, J. Wojta, K. Huber
3rd Med. Department of Internal Medicine III, Cardiology, Medical University Innsbruck
ÖKG-Annual Conference 2011 – Abstracts

Results The immature platelet levels were 3.7% (2.7–4.8%) and 3.8% (2.9–4.8%) for MEA and VASP-P, respectively. There was no (very weak) linear correlation of immature platelets with age, sex, body mass index and platelet turnover. In a multivariable regression model, age, sex, and low response to aspirin were independent predictors of immature platelet levels (p = 0.001 for MEA, p = 0.004 for VASP-P). There was no (or very weak) linear correlation of immature platelets with creatinine, eGFR, and plasma creatinine. There was no (or very weak) linear correlation of immature platelets with CRP, hsCRP, and CRP. There was no (or very weak) linear correlation of immature platelets with hsCRP, and CRP.

Conclusions The immature platelet levels were 3.7% (2.7–4.8%) and 3.8% (2.9–4.8%) for MEA and VASP-P, respectively. Multivariable logistic regression confirmed that platelet-turnover was associated with MEA and VASP-P, independently of sex, age, CAD-entity, body mass index and proportion of patients with history of cardiovascular disease.

Stability of the High On-Treatment Platelet Reactivity-Phenotype in Patients on Clopidogrel over Six Months

M. Freynhofer, V. Bruno, I. Brozovic, R. Jaraif, S. Farhan, M. Willheim, J. Wojta, K. Huber
3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna

Background Variable response to clopidogrel-therapy is an established phenomenon. Previous studies and ongoing trials randomized patients according to the high on-treatment platelet reactivity (HTPR)-phenotype based on single measurements to tailored antiplatelet regimens. The stability of the HTPR-phenotype over time is not known. We therefore investigated the stability of the clopidogrel HTPR-phenotype over 6 months.

Methods One-hundred seventeen clopidogrel treated patients undergoing coronary stenting were consecutively enrolled. Multiple electrode aggregometry (MEA) and vasodilator activated phosphoprotein–phosphorylation (VASP-P) assays were performed at baseline, 1, 3 and 6 months. Based on consensus cut-offs (47U for MEA, 50% for VASP-P assay) patients were stratified according to their HTPR-phenotype.

Results MEA HTPR-phenotype within 1 month was unstable (i.e. crossing the cut-off level) in 42.3% of patients undergoing PCI due to stable CAD. MEA HTPR-phenotype in the maintenance phase (1–6 months) was unstable in 31% of stable CAD, 37.8% of UA/NSTEMI, and 50% of STEMI patients. VASP-P based phenotype within 1 month was unstable in 31% of stable CAD, 33.3% of UA/NSTEMI and 39.3% of STEMI patients. Long-term (1–6 months) VASP-P HTPR-phenotype was unstable in 41.3% of stable CAD, 33.3% of UA/NSTEMI and 25% of STEMI patients. The assays were not significantly different regarding phenotype stability (p > 0.05 for all comparisons).

Conclusion HTPR-phenotype on clopidogrel over 6 months is stable in only half of the patients. The phenotype stability in the early treatment phase (baseline–1 month) is between 60–70% whereas in the steady-state phase (1–6 months) stability varies from only 50–75% as assessed in all patient groups with both assays. MEA and VASP-P are not different with regard to phenotype stability.

Evaluation of Appropriateness of Cardiac Computer Tomography Indications: Differences In Gender Aspects

H. Hommel, G. Feuchtner, O. Pachinger, G. Friedrich
Department of Internal Medicine III, Cardiology, Medical University Innsbruck

Background Well it is known in daily routine, that male (mp) and female patients (fp) with coronary artery disease (CAD) show different symptoms. Thus, our aim was to point out how gender differences affect to CT allocation in regard to clinical presentation and pretest probability.

Methods Mp and fp with prior cardiac computer tomography (CCT) findings were referred to us for invasive coronary angiography (CA). Data from 103 mp and 47 fp (mean age 64.0 ± 9.9) were collected retrospectively. We reviewed the individual allocation to CCT and classified indications as appropriate (A), uncertain (U) or inappropriate (I) as published. Ind not listed were rated as undefined (UD). For each pt risk factors were calculated and CAD pretest probabilities (pp) were determined.

Results Ind for mp/fp were A in 21/34%, U in 8/6%, I in 64/49% and UD in 7/11%. Regarding to the pp of CAD, low pp was 2/11%; intermediate pp was 25/38% and high pp was 73/51%. The most common A ind (19.3% of all, 76.3% of total A) was for pts with equivocal stress test, mp representing 53% of all (Figure 21). A exams prevail in pts with an intermediate pp (60.5% of A). The most common I ind was found in pts with a positive stress test (30.7% of all, 51.7% of total I) with 39% mp of all. I exams prevail in pts with a high pp (79.8% of I).
Conclusions In a preselected pt cohort referred to CA, mp present more often with a high pp for CAD because of presence of multiple risk factors. These pts as well as mp with positive prior test results underwent CCT more often than fp with similar profiles. We conclude that in general, but specially in mp, existing appropriateness criteria need a more refined implementation into clinical practice.

Erfahrungen zur Anwendung der Herzratenvariabilität unter Belastung an 115 Patienten

S. Kohl, P. Thomadis, F. Pedross, O. Pachinger
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin III, Medizinische Universität Innsbruck


Ergebnisse Mit Ausnahme von ApEn zeigten alle untersuchten HRV-Parameter unter Belastung zunehmend reduzierte Werte und einen asymptotischen Verlauf auf ein Minimum zu. Das Minimum wurde meist bei ca. 50 % Soll-Last erreicht. Ausnahmen waren α1 und SDNN, wo das Minimum erst bei ca. 100 % Soll-Last erreicht wurde (Abbildung 22). Besonders ausgeprägt war diese Dynamik für SDNN, LF, HF, α1 und besonders gering ausgeprägt für α2 und D2. Die Schwankungsbreite der HRV-Werte nahm unter Belastung kontinuierlich ab. Auch in der Nachbelastungsphase fanden sich mit Ausnahme von α1 und α2 noch reduzierte HRV-Werte und eine verringerte Schwankungsbreite (Tabelle 15). Bei ca. 5 % der Patienten musste eine manuelle Artefaktkorrektur angewandt werden, während ca. 20 % der HRV-Messungen aufgrund von Artefakten nicht verwertbar waren.

D2) lassen sich aus unseren Ergebnissen nicht gewinnen. Insgesamt ermutigen unsere Daten die Weiterentwicklung einer Diagnostik mit ausgewählten HRV-Parametern während und nach Belastung.

„Ergometrie plus“ – Voruntersuchung an 61 Patienten zur Steigerung der Sensitivität der Ergometrie durch Herzratenvariabilitätsmessung

S. Kohl, P. Thomaidis, F. Pedross, O. Pachinger
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin III, Medizinische Universität Innsbruck

Einleitung

Methodik

Ergebnisse

Diskussion
Die Ergebnisse geben Grund zur Annahme, dass eine 2-minütige Ruhe-HRV-Messung als zusätzliches Diskriminierungskriterium für eine KHK und als objektiver Messparameter des kardiovaskulären Risikos von Nutzen sein könnte. Die diagnostische
Monocyte Subsets Differently Express CD59 and Correlate with Cardiovascular Risk Factors in Stable CAD Patients

Division of Cardiology, Department of Medicine II, Medical University Vienna; 3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna

Purpose Monocytes play a key role in modulating inflammation in coronary artery disease (CAD). Different monocyte subsets can be distinguished via expression of CD14 and CD16. CD59 attenuates atherosclerosis through inhibition of the membrane attack complex. The aim of this study was to analyze the distribution of monocyte subsets and their expression of CD59 in a cohort of patients with stable CAD. Furthermore, the influence of CAD severity and known risk factors for CAD such as inflammation and diabetes should be examined.

Methods 94 patients suffering from angiographically proven stable CAD were enrolled. Monocytes were classified as CD14+/CD16low (“classical monocytes”, CM), CD14low/CD16+ (“non-classical monocytes”, NCM), CD14+/CD16+ (“intermediate monocytes”, IM) and CD14low/CD16low (“so far undefined monocytes”, SFUM), a subset that has not been described yet and expression of CD59 on each subtype was measured. We further measured their correlation with CRP levels, HbA1c and the impact of CAD severity on monocyte distribution.

Results SFUM expressed significantly higher levels of the protective CD59 (p < 0.0001) than all other subtypes. NCM showed the lowest levels of CD59 (p < 0.0001). Levels of CRP correlated inversely with levels of SFUM (p = -0.424, p < 0.001), while levels of HbA1c correlated positively with SFUM (p = 0.536, p < 0.05). Patients suffering from severe CAD, defined as 3VD, showed higher levels of NCM (p < 0.05) and lower levels of CM (p < 0.05) than all other subtypes.

Conclusion The fact that “non-classical” monocytes expressed lower levels of CD59 than the other subtypes contributes to the idea that this subset acts “pro-atherogenic”. The very high levels of CD59 on a subset that has not yet been described, the SFUM, together with inverse correlation with levels of CRP, could suggest that this subset acts protective. The positive correlation of HbA1c and NCM contributes to the observation that diabetics are especially prone to atherosclerosis.

Statins Differently Modulate Monocyte Subset Distribution in stable CAD Patients – A New Insight into their Anti-Inflammatory Effects

Division of Cardiology, Department of Medicine II, Medical University Vienna; 3rd Med. Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna

Purpose Monocytes play a key role in modulating inflammation in coronary artery disease (CAD). Different monocyte subsets can be distinguished via expression of CD14 and CD16. Current therapeutic guidelines suggest the standard use of statins in the therapy of CAD; their effect relies partly on their anti-inflammatory actions. The aim of this study was to analyze the impact of statin therapy on the distribution of monocyte subsets.

Methods 94 patients suffering from angiographically proven stable CAD, were enrolled. Monocytes were classified as CD14+/CD16low (“classical monocytes”, CM), CD14low/CD16+ (“non-classical monocytes”, NCM), CD14+/CD16+ (“intermediate monocytes”, IM) and CD14low/CD16low (“so far undefined monocytes”, SFUM), a subset that has not been described yet. We further measured their correlation with CRP levels, HbA1c and the impact of CAD severity on monocyte distribution.

Results Patients treated with atorvastatin showed less NCM than patients treated with Simvastatin (p < 0.05) and higher levels of CM (p < 0.05). Upon closer analysis simvastatin treatment revealed that...
patients treated with 40 mg of simvastatin had statistically significant higher levels of CM than patients treated with 20 mg (p < 0.05).

**Conclusion** In our study, the 2 second generation statins simvastatin and atorvastatin showed a different effect on the distribution of monocyte subsets, with atorvastatin leading to a more “anti-inflammatory” distribution. The same effects could be shown for higher dose application of simvastatin. Effects of statin therapy on monocyte distribution might add another piece to the puzzle in understanding the anti-inflammatory effects of statins.

**Ectatic Coronary Vasculopathy in Homocysteine Alpha-1 Antitrypsin Deficiency: A Case Report**

D. Petener1, J. Bergler-Klein2, F. Weidinger1, P. Wexberg1

12. Medizinische Abteilung, Krankenanstalt Rudolfstiftung; 2Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin II, Medizinische Universität Wien

**Introduction** Alpha1-Antitrypsin (AAT) is the most important inhibitor of serine proteases in the blood in humans. Its deficiency causes enhanced activity of neutrophil elastase in blood and lungs and thus an increased risk of panacinar emphysema and chronic obstructive lung disease (COPD) especially among smokers, in addition to hepatic cirrhosis and vascular aneurysms. The deficiency is treated by avoidance of damaging inhalants, by intravenous infusion of the AAT protein and by transplantation of the lungs or liver.

**Case Report** We report a 45 year old male who was evaluated for lung transplantation because of end-stage COPD with long term oxygen therapy as a result of homocysteine AAT-deficiency. The first evaluation for lung transplantation took place in 2008, when the initial coronary angiography was performed, which showed normal findings (Figure 24). The patient withdrew his consent to the transplantation at that time. The patient’s condition remained stable until spring 2010, when all essential examinations for lung transplantation were repeated because of the patient’s worsened condition. Surprisingly, repeated coronary angiography revealed that ectatic coronary vasculopathy had developed within only 2 years, predominantly in the proximal and mid left anterior descending artery. Mild ectasia was also found in the distal right coronary artery (Figure 25). No ectasia or aneurysm was detected in any other investigation such as contrast-agent CT of the aorta or duplex sonography of the carotids.

**Discussion** Arterial aneurysms and spontaneous dissections are known to occur in arterial territories. To the best of our knowledge, coronary ectatic vasculopathy has not been described in AAT deficiency. The affection of vessels might be explained by the degradation of elastic vascular fibres by enhanced activity of neutrophil elastase which can disrupt the integrity of the vessel wall and cause the formation of ectasia and/or aneurysm. Alternatively, constant hypoxemia due to the patient’s lung disease might have caused aneurysm formation: Firstly, coronary dilation is regulated independent from the endothelium by arterial pressure, myocardial metabolism and the autonomic nervous system as well as by arterial oxygen-saturation. Secondly, low blood oxygen saturation stimulates coronary vasodilatation in angiographically normal coronary arterial segments, whereas it does not affect vascular diameters in atherosclerotic segments. In our patient, chronic hypoxemia may have boosted the development of ectatic coronary angiopathy in a setting of increased proteolytic elastase-activity due to AAT deficiency. Our report emphasizes that asymptomatic development of coronary and other aneurysms should be considered during the management of AAT deficiency. The clinical management of these patients requires further investigation. On the other hand, the detection of coronary aneurysms might give a hint to underlying connective tissue disease.

**Bewusstsein von kardiovaskulären Risikofaktoren, Prävention und Barrieren zur Herzgesundheit bei österreichischen Männern**

M. Zweimüller, T. Haidinger, J. Strametz-Juranek
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin II, Medizinische Universität Wien


**Ziel** Ziel der vorliegenden Studie war es daher, das Erkennen typischer Risikofaktoren, die Selbstinschätzung des individuellen kardiovaskulären Risikos, das männliche Präventionsverhalten aber auch die Barrieren, die eine effektive Prävention verhindern, innerhalb der männlichen, österreichischen Bevölkerung zu untersuchen.

**Figure 24:** D. Petener et al. Baseline angiogram at the time of first transplant evaluation. Normal left and right coronary artery.

**Figure 25:** D. Petener et al. Follow-up angiogram 2 years later. Note ectatic segments (arrows) in the proximal and mid-left-anterior descending artery, the 2nd diagonal branch and the distal-right coronary artery.

**Figure 26:** Abbildung 26: Aorta and the 2nd diagonal branch and the distal-right coronary ectatic segments (arrows) in the proximal and mid-left anterior descending artery. Normal left and right coronary artery.

**Figure 27:** Figure 25: Ectatic coronary vasculopathy was detected.

**Figure 28:** Abbildung 28: M. Zweimüller et al.
**Pulmonale Hypertonie/Pulmonary Hypertension**

**Long-term Treatment, Tolerability and Survival with Subcutaneous Treprostinil for Severe Pulmonary Hypertension**

**Objectives**
To evaluate long-term treatment, tolerability, dosing regimens and survival with first-line subcutaneous treprostinil, a prostacyclin analogue, we report on a prospective registry of all patients with severe pulmonary hypertension.

**Background**
Recent data suggest that contemporary treatments within randomized controlled trials (RCTs) improve outcomes in pulmonary arterial hypertension, however RCTs are biased by stringent inclusion criteria, and are critically limited by pre-specified patient subsets and study durations.

**Methods**
Data were collected from patients with advanced pre-capillary pulmonary hypertension (DNA Point group I and IV, mean right arterial pressure ≥ 10 mmHg and/or cardiac index ≤ 2.2 L/min x m²), with pre-specified hemodynamic evaluations and assessment of events and survival. Dose adjustments were performed according to drug side effects and clinical symptoms.

**Results**
Between 1999 and 2010 111 patients were included in the registry and were followed for a median observational time of 2.9 years (0.8–10.6). Of those, 21 patients (18.9%) discontinued treatment within the first 6 months due to side effects, 10 patients (9%) underwent double lung transplantation, and 41 patients (36.9%) died of all-causes. Twenty-five patients (22.5%) survived non-PH related adverse events. At 1, 5 and 9 years, survival rates were 86%, 60% and 51%.

In a subgroup analysis of 85 patients (76.5%) treated longer than 6 months, significant improvements occurred in six-minute walking distance, Borg Dyspnea Score, mean pulmonary arterial pressure, cardiac output, pulmonary vascular resistance and World Health Organization functional class at a median 38.4 months (range: 16.8–75.6).

**Conclusion**
First-line treatment of severe pre-capillary pulmonary hypertension with subcutaneous treprostinil is safe and efficacious over years, improves survival and enables survival of non-PH related events.

**Plasma Levels of Soluble P-Selectin Predict Survival in Chronic Thromboembolic Pulmonary Hypertension**

**Background**
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is caused by obstruction of pulmonary arteries with organized thrombus. The role of soluble P-selectin (sP-selectin), a platelet activation marker, in the pathogenesis and outcomes of CTEPH is unknown.

**Patients and Methods**
Soluble P-selectin was determined in 147 patients (pts) at the time of diagnosis. Enzyme-linked immunosassay was used to determine sP-selectin plasma levels. Analysis of overall survival was performed using Kaplan-Meier curves that were stratified by sP-selectin levels above and below median at baseline.

**Results**
Of 147 patients, 72 (49%) were classified as operable and 75 (51%) as inoperable. SP-selectin plasma levels were elevated (median [range]; 109 [52–223]). No significance was found between operable and inoperable CTEPH patients (p = n.s.). Patients with sP-selectin values below 109 ng/ml survived longer than those with values above (p < 0.027).

**Conclusion**
Soluble P-Selectin is increased in plasma, and predicts survival in CTEPH patients. The data suggest that platelet activation is involved in venous thrombosis.
chronic thromboembolic pulmonary hypertension (CTEPH) undergoing pulmonary endarterectomy (PEA). We sought to define the impact of pulmonary arterial compliance (PAC), stroke volume (SV), and PVR on persistent/recurrent PH and long-term survival in CTEPH.

**Methods**
We monitored PAC, SV and PVR in 110 patients who underwent PEA. The data were determined at baseline, postoperative (immediate: within 3 days after PEA) and 1 year after PEA. PAC was calculated by SV/pulmonary artery pulse pressure. The impact of these parameters on survival/freedom of lung transplantation and persistent pulmonary hypertension were analyzed by Cox proportional hazard models, and T-tests.

Furthermore we analyzed survival using logistic regression models. P values were adjusted from multiple testing by Bonferroni correction.

**Results**
PAC and PVR changed significantly from baseline to immediate postoperative (+1.4 ± 1.6 mL/mmHg, −396.2 ± 334.4 dynes × cm⁻¹ × s⁻¹; p < 0.001 i.e.), showing no changes between immediate and 1-year follow-up. SV increased statistically significant from baseline to 1 year (+10.1 ± 6.9 mL; p < 0.001), while it did not change immediately postoperatively from baseline.

Neither PAC, nor SV, nor PVR at baseline showed any influence on persistent/recurrent PH or long-term survival. PVR, SV and PAC assessed immediately postoperatively had a significant influence on persistent/recurrent PH (p < 0.0001; p = 0.02; p < 0.01). Immediate postoperative PVR had a significant influence on long-term survival (p < 0.001).

Logistic regression model revealed immediate postoperative PVR as predictive of 1-year (p = 0.001), 3-year (p = 0.01) and 5-year persistent/recurrent PH and survival (p = 0.002).

**Conclusions**
Pulmonary arterial compliance, stroke volume and PVR assessed immediately after PEA are predictive of persistent/recurrent PH, however PVR was the only predictor of long-term survival in CTEPH patients undergoing PEA.

**First Experience with Intravenous Treprostinil Delivered by an Implantable Pump (Lenus Pro®) With Filling Intervals of 28 Days in a Patient with Pulmonary Arterial Hypertension (PAH) – a Case Report**

**Introduction**
Continuous subcutaneous (s.c.) Treprostinil (Remodulin®) is an established treatment for PAH. Infusion site pain is a frequent complication leading to discontinuation of treatment in about 15%. Intravenous (i.v.) administration of prostanoids using external pumps is problematic with regard to infections. Lenus Pro® implantable pump was specifically developed for i.v. administration of Treprostinil. We report the first implantation of a 40 ml Lenus Pro® pump with a constant flow rate of 1.3 ml/day.

**Methods and Results**
A 70-year old female presented in functional class IV and a history of recurrent syncope during exercise in March 2009. Right heart catheterization confirmed the diagnosis of PAH with a mean pulmonary arterial pressure (mPAP) of 62 mm Hg. Cardiac index at baseline was 1.38 l/min/m², NT-proBNP 1561 ng/l, a 6-minute-walk test (6MWD) could not be performed. Bosentan treatment was started (Figure 28). In June 2009 the mPAP was 51 mm Hg, NT-proBNP increased to 2083 ng/l, recurrent syncope remained and 6MWD still could not be performed. However, additional s.c. Treprostinil therapy (sequential combination therapy according to ESC guidelines 2009) led to a substantial improvement. In January 2010 NT-proBNP had fallen to 797 ng/l and 6MWD was 175 m, and syncope had disappeared. Despite the favorable efficacy of treprostinil the patient experienced site pain, in addition an infection of the infusion site required hospitalization and systemic antibiotic treatment in November 2009. In 2009 the first Lenus Pro® pump (40 ml) with a flow rate of 2 ml/day was implanted in Germany. As a 20-day-filling-interval seemed suboptimal for our purposes we asked the company for a revised version allowing a 28-day-filling-interval. Meanwhile we increased the Remodulin® dose up to 21 ng/kg/min. In August 2010 mPAP was 29 mm Hg, cardiac index 2.41 l/min/m²; MR testing showed an improvement of right ventricular function (RVEF increasing from 42% up to 59%). The revised pump was implanted in September 2010 in general anesthesia and filled intraoperatively; subcutaneous Treprostinil was stopped.

**Discussion**
Subcutaneous Treprostinil is a cornerstone of PAH treatment; however site pain leads to discontinuation in about 15%. Our patient improved substantially by s.c. Treprostinil, but suffered from site pain and an infection. Administration of i.v. Treprostinil with the implantable Lenus Pro® pump offers an exciting option for such patients, minimizing the risk of infections. Treprostinil therapy with a filling interval of 28 days in an outpatient setting ensures optimal patient management, compliance and an increase in quality of life.

**High Dose Subcutaneous (s. c.) Treprostinil Allows Long-Term Management of a Patient With Severe PAH Refusing Transplantation – a Case Report**

**Introduction**
Continuous long-term s.c. Treprostinil (Remodulin®) in doses up to 40 ng/kg/min has been shown to improve exercise tolerance and symptoms in patients with PAH and may provide a significant survival benefit. The safety and efficacy of high-dose intravenous Treprostinil has been reported in the literature. We describe the successful re-stabilisation of a patient with severe PAH by a high dose of s. c. Treprostinil.

**Methods and Results**
A 50-year old male was diagnosed with PAH in another hospital in February 2007. Treatment with Bosentan was initiated. In October 2007 he presented in NYHA functional class IV at our department. Right heart catheterization confirmed the diagnosis of PAH with a mean pulmonary arterial pressure (mPAP) of 65 mm Hg. Six-minute-walk test (6MWD) was 161 m. Additional s.c. Treprostinil therapy was started, the dose was titrated up to 13.75 ng/kg/min until March 2008 (Figure 29). At that time the patient was in class III with a 6MWD of 214 m. In May 2008 the patient reported dyspnea at rest and refused the 6MWD because of general weakness. Increase in Treprostinil dosage restored stabilization until October 2008. However, due to clinical deterioration to class IV we added Sildenafil, in addition the patient refused lung transplantation. Triple therapy with dose increase of Treprostinil up to 29 ng/kg/min stabilized the patient in class III for another year. However in November 2009 he deteriorated again and refused to be listed for trans-
Rhythmologie/Rhythmology

Linz

Internal 2 Kardiologie/Angiologie/Intensivmedizin, Krankenhaus der Elisabethinen

could not be performed. However, add-on s. c. Treprostinil therapy started. In June 2009 the mPAP was 51 mm Hg, NT-proBNP intraventricular end-diastolic volume of 190 ml. Bosentan treatment was associated with a right ventricular ejection fraction (RVEF) of 42% and right ventricular end-diastolic volume of 163 ml.

Conclusion This case underscores the importance of continuous follow-up of patients with PAH as proposed by the ESC guidelines. In particular, our patient showed no sufficient response to first-line Bosentan with even increasing NT-proBNP levels. Addition of Treprostinil three months later led to a substantial clinical improvement. Meanwhile the patient has been clinically stable for 15 months. The improvement of right ventricular function was documented by MRI testing. Thus, the MRI is a valuable tool for monitoring of long-term efficacy for PAH treatment.

Introduction

Idiopathic fascicular left ventricular tachycardia (ILVT) belongs to the group of normal heart VTs and is a rare arrhythmia in clinical practice. Since the first description in 1979 the characteristics and mechanisms of this peculiar arrhythmia have been investigated in detail. The aim of this retrospective study is to evaluate the electrophysiological properties of ILVT and outcome after RF ablation at a single center.

Methods The case series comprises 4 male patients (mean age 41 ± 12 yrs) who presented with symptomatic ILVT in the last 6 years. Structural heart disease was excluded using echocardiography, coronary angiography and MRI. Two patients demonstrated T wave abnormalities in the inferolateral leads. Twelve-lead ECG during palpitations showed a relatively narrow ventricular tachycardia (VT) with right bundle-branch block morphology and left superior axis deviation (n = 3) or right inferior axis deviation (n = 2) (233 ± 33 bpm). Acute termination of VT was achieved with amiodarone (n = 3) and electrical cardioversion (n = 1), none of the patients received verapamil.

Results EPS was performed after informed consent and the clinical VT was inducible in 3 of the 4 patients (75%) with programmed ventricular stimulation (n = 2) or atrial burst pacing (n = 1) under atropine and orciprenaline (CL 277 ± 35ms). Paroxysmal atrial fibrillation was found as concomitant arrhythmia in 2 patients and AVNRT in 1 patient. Three-dimensional electroanatomical mapping of the left ventricle was used in one case. Cooled RF-ablation (12 ± 7 applications, 636 ± 348 sec) was delivered either during VT and/or during SR (n = 4) while recording 2 separate serial potentials. Low amplitude diastolic potentials (DP) preceded sharp high frequency Purkinje potentials (PP) during ongoing VT. In SR low-amplitude potentials following the PP and ventricular activation were identified (retro-PP) in the infero-medial (n = 3) or anterior septum (n = 1). No complications occurred in any of the patients. After ablation ECG in SR showed an increase of QRS duration from 98 ± 3 to 112 ± 3 ms. A change of QRS axis was noted in 2 patients (left posterior or anterior fascicle, but not in cases with preexisting right or left axis deviations (n = 2). No recurrence of clinical VT occurred on a median follow up of 12 months (range 3–28 months).

Conclusions Catheter ablation is the preferred choice of therapy in patients with ILVT. Targeting specific sites with simultaneous recording of presystolic and diastolic potentials in the septal LV will result in modification of the left posterior or anterior fascicle. Three-
dimensional electroanatomical mapping and potential-guided ablation in SR may be helpful to achieve successful ablation.

**Klinische Ergebnisse mit Dronedaron (Multaq®) bei nicht-permanentem Vorhofflimmern**

M. Derndorfer, M. Martinek, H. J. Nesser, H. Pürerfellner
Intern 2 Kardiologie/Angiologie/Intensivmedizin, Krankenhaus der Elisabethinen Linz

Einleitung Dronedaron (Multaq®) ist ein Mehrkanalblocker, der in Österreich bei nicht-permanenten Vorhofflimmern (VHF) seit Anfang Februar 2010 als zusätzlicher Antiarrhythmikum zur Verfügung steht. Wir berichten über unsere Erfahrungen am eigenen Patientengut.

Methodik 40 Patienten (29 männliche/11 weibliche), die bei Einschluss im Schnitt 67 ± 10 Jahre alt waren, wurden untersucht. Von diesen war als Einschlusskriterium für 30 paroxysmale, bei 10 persistierende VHF festzustellen, wobei bei 31 Patienten Sinusrhythmus (SR) aufgezeichnet wurde. Echokardiographisch konnte bei 28 Patienten eine normale, bei 12 Patienten eine reduzierte LVEF zwischen 35 % und 50 % erfasst werden. Der durchschnittliche CHADS 2-Score wurde mit 1,05 bezeichnet. Der durchschnittliche Vorhofsgröße von 41 ± 6 mm gemessen werden. Der durchschnittliche CHADS 2-Score wurde mit 1,05 bezeichnet.

Neben EKG- und Laborkontrollen wurden zu den Visiten die NYHA-Stadien erfasst und die Patienten gebeten, ihre aktuelle Lebensqualität (QoL) hinsichtlich des VHF einzuschätzen (0 = sehr schlecht; 10 = exzellent). Fünf der Patienten hatten einen permanenten Schrittmacher/ICD und 2 Patienten einen Loop-Rekorder implantat. Die detaillierte Auswertung dieser Geräte soll zur Jahrestagung präsentiert werden.

Resultate Von 40 eingeschlossenen Patienten konnten bei 29 vollständige 6-Monats-Daten erhoben werden. Grund für das Ausscheiden war 9x unzureichende Wirksamkeit von Multaq® (erneut VHF/Palpitationen), 1x persistierende Diarrhoe und 1x ein allgemeines Verordnungsproblem. Rehospitalisierung aus kardiovaskulärer Ursache, proarrhythmische Effekte oder Todesfälle waren keine zu verzeichnen.


Bereits nach 3 Monaten Einnahme von Multaq® gab die 29 verbliebenen Patienten eine signifikante Verbesserung der Belastbarkeit gegenüber der Basisvisite an (NYHA 1,6 ± 0,6 vs. 1,1 ± 0,3, n = 29), die dann bis zur 6-Monats Kontrolle unverändert gut blieb (p = 0,0001) (Abbildung 34). Dementsprechend wurde auch die subjektive Lebensqualität bereits nach 3 Monaten mit einer Steigerung von 6,38 ± 1,916 auf 6,9 ± 1,61 Punkte besser beurteilt und diese Entscheidung bis zum letzten Follow-up beibehalten (p = 0,134; n. s.) (Abbildung 35).

**Schlussfolgerung** Unter Beobachtung von Klinik, EKG sowie Labor (Serumkreatinin, Leberwerte) zeigt sich Dronedaron nebenwirkungsfrei und sicher in der Anwendung. Zudem kam es unter Multaq® zu einer signifikanten Verbesserung der Belastbarkeit (NYHA-Stadium) und einer gering (statistisch nicht signifikant) verbesserung der Lebensqualität bereits nach 3 Monaten mit einer Steigerung von 6,38 ± 1,916 auf 6,9 ± 1,61 Punkte besser beurteilt und diese Entscheidung bis zum letzten Follow-up beibehalten (p = 0,134; n. s.) (Abbildung 35).

**Abbildung 30:** M. Derndorfer et al.

**Abbildung 31:** M. Derndorfer et al.

**Abbildung 32:** M. Derndorfer et al.

**Abbildung 33:** M. Derndorfer et al.

**Abbildung 34:** M. Derndorfer et al.

**Abbildung 35:** M. Derndorfer et al.
Die kürzlich neu herausgegebenen „ESC Guidelines for the management of atrial fibrillation“ führen den CHADS-VASc-Score ein, um das Risiko für thromboembolische Ereignisse bei Patienten mit Vorhofflimmern (VHF) bemessen zu können. Der CHADS-VASc-Score erweitert den bisherigen CHADS-Score (Herzinsuffizienz, Hypertonie, Alter > 75 Jahre, Diabetes, Schlaganfall) um die vormals „schwachen“ Risikofaktoren Gefäßerkranzung, weibliches Geschlecht und Alter (65–74 Jahre). Patienten, welche einen CHADS-VASc-Score ≥ 2 aufwiesen, sollten eine orale Antikoagulation erhalten. Durch die Einführung der neuen ESC-Leitlinien bedarf es nun einer Reevaluierung des thromboembolischen Risikos. In einer retrospektiven Annäherung quantifizieren und stratifizieren wir die Prävalenz von VHF, sowie die Veränderungen der thromboembolischen Risikobemessung zusammen mit klinischen Parametern der Patienten unserer Kardiomyopathie-Ambulanz und der allgemeinen Kardiologie-Ambulanz. In der laufenden Studie wurden 500 Patienten mit kompletten Datensätzen aufgenommen. Alter 63, ± 14,3 (Mittelwert ± Standardabweichung), 72,4 % Männer, 60,4 % mit chronischer Herzinsuffizienz, 32,4 % (n = 162) Patienten hatten Vorhofflimmern, 13,3 % (n = 71) einer VHF-Vorgeschichte (CHADS-VASc 0; 1: 23%, 2: 27%, 3: 28,6; 4: 31%; 5: 41%; 6: 59%; 7: 73%; 8: 50%). VHF trat häufiger bei Patienten mit chronischer Niereninsuffizienz auf (47,6 % vs. 26,1 %; p < 0,001, chi-square). 78 % der VHF-Patienten nahmen RAS-Hemmer, 88 % Betablocker, 83,3 % (n = 155) aller VHF-Patienten hatten im Vergleich zum CHADS-Score nun einen höheren CHADS-VASc-Score. In 66,7 % dieser Patienten führte die Koronare Herzkrankheit (KHK) zu einer Steigerung der Risikobemessung, in 77 % das Alter und in 28,8 % das weibliche Geschlecht. 69,7 % der Patienten mit VHF und CHADS = 1 hatten einen höheren CHADS-VASc-Score ≥ 2. In der Subgruppe der Patienten mit VHF, deren Risikoscore von 1 (CHADS) auf 2 (CHADS-VASc) stieg, hatten 26,7 % keine orale Antikoagulation (OAK).

Zusammenfassend ergibt sich aus der Neubemessung des thromboembolischen Risikos laut CHADS-VASc ein erhöhter Risikoscore für die Mehrheit der Patienten in unserer kardiologischen Ambulanz. Chronisches Nierenversagen war mit einer erhöhten VHF-Prävalenz assoziiert.

**Methods**

**Introduction**

The amounts of CIED devices that have been implanted since 2008 have grown exponentially, resulting in increasing numbers of patient visits in already overcrowded clinics. We also have a shortage of qualified electro physiologists. Accessing patient medical records to obtain up to date information in a timely manner to provide safe and efficient treatment can be a slow process as medical records are often located in many separate areas with access restrictions in the system. New methods need to be created that are safe and efficient to help alleviate the burden on health care services. Introducing telemonitoring with adaptable, computer-interpretable and evidence-based clinical guideline models can be a viable option for a busy clinic, utilizing the nursing staff to assess and evaluate the alerts and reports being sent from the CIED devices.

**Methods**

Using standard interfaces exposed data from the patients CIED provided by the remote monitoring service, electronic health care record (EHR) and patient health care record (PHR) are collected and then correlated. The data are converted to HL7 Clinical Document Architecture (CDA) format to interface with the iCARDEA system. In addition to the art data analysis techniques patient specific warnings and suggestions will be automatically generated enhancing the data presented. An adaptive care planner applying clinical guidelines and risk assessment will generate alarms. The care planner will be activated whenever an event is detected. An integrated patient health care record (PHR) will enable the patient to obtain knowledge, to make informed responsible decisions for their health care, allow a communication portal between nurse and patient, and provide the care givers an up to date status of the patient. The nurse is responsible for evaluating the information received from all sources including recommendations from the iCARDEA CarePlanner. A cardiologist will be contacted when medical intervention is needed. The nurse is also responsible for the telemonitoring logistics and management.

**Results**

At present care plans have been developed for atrial fibrillation and ventricular tachycardia, as well as for potential technical problems. The nurse activates the care planner whenever an event is detected. The steps for care plan execution are then provided, and a link is given for a graphic monitoring tool providing a work flow that allows the results of each step in the decision process to be visible including the data retrieved from the EHRs (medications lab results etc.). For every step in the decision process the PHR and EHR will be accessed which reduces the time staff needs to accumulate various medical information. After a recommendation is presented different options are provided, such as guidance on prescription of medications, doses, and possible side effects.

**Conclusion**

The future of CIED management in the near future lies in the implementation of high end telemonitoring platforms. The nurse is responsible for evaluating the information received from all sources including recommendations from the iCARDEA CarePlanner. A cardiologist will be contacted when medical intervention is needed. The nurse is also responsible for the telemonitoring logistics and management.

**Significant Reduction of Bleeding Complications after Pulmonary Vein Isolation Using Different Types of Anticoagulant Strategies**

**Methods**

A total of 324 P (82 females) were examined in a retrospective manner for clinical relevant hematoma after treatment of PVI for paroxysmal or short persistent atrial fibrillation. Clinical relevant hematoma were defined by requirement of blood transfusion. The first 199 P were treated with intravenous heparin and the second group with oral anticoagulation (phenprocoumon) in an ambulatory manner for clinical relevant hematoma after treatment of PVI for paroxysmal or short persistent atrial fibrillation. The first group, females developed groin-hematoma significantly more often than men (10 out of 25 females versus 7 out of 174 males, p < 0,001). In the second group, 1 female and 1 male developed a groin hematoma, respectively (p = n. s.). Surgical treatment was necessary in 3 patients (2 females, 1 male). No permanent sequelae remained in any patient. No ischemic cerebrovascular complications were observed.
brovascular events occurred in either group until therapeutic levels of oral anticoagulation (INR > 2.5) were reached.

Conclusions Continuous intravenous heparin-infusion until the day after ablation followed by LMWH at 1 mg/kg 2 times daily was associated with a significant reduction in groin-hematoma compared to intravenous heparin during ablation and change to LMWH at 0.5 mg/kg twice daily 3 hours after the ablation.

Twelve-lead ECG Patterns Fail to Identify an Epicardial Origin for Left Ventricular Tachycardia in Post-Infarction Patients

M. Martinek1, K. Inada2, W. G. Stevenson2, U. B. Tedrow2

1Department of Cardiology, Elisabethinen Hospital Linz; 2Brigham and Womens Hospital, Boston, USA

Background Several ECG features have been reported to identify epicardial origins for left ventricular tachycardias (LV-VTs) in the absence of myocardial infarction. Only limited data exist in post-infarction patients.

Objective We tested proposed algorithms for non-ischemic tachycardias for their ability to identify epicardial LV-VT origins.

Methods The QRS features of 17 successful epicardial and 29 endocardial RBBB LV-VTs were retrospectively reviewed by four independent electrophysiologists and analyzed for various 12-lead ECG features.

Results All 12-lead ECG features proposed for non-ischemic LV-VTs were unable to consistently predict an epicardial LV-VT origin in infarct-related tachycardias (Figure 36). QRS duration was 199 ± 31 ms in epicardial vs 178 ± 40 ms in endocardial LV-VTs (p = 0.063) showing significant overlap and therefore lacking a reasonable cutoff-value between epicardial and endocardial LV-VTs. Pseudo-delta duration was 47 ± 9 vs 54 ± 21 ms (p = n. s.), intrinsocid deflection time was 103 ± 32 vs 92 ± 24 ms (p = n. s.), shortest RS was 110 ± 36 vs 101 ± 34 ms (p = n. s.) and median deflection index was 0.75 ± 0.27 vs 0.85 ± 0.25 ms (p = n. s.) (Figure 37).

The finding of a Q wave in lead I and absence of a Q wave in the inferior leads failed to predict an epicardial origin in superior LV-VTs. Q waves in any inferior lead as well as an aVR/aVL ratio < 1 were not specific for an epicardial origin in inferior sites (all p = n. s.). Furthermore, most inferior LV-VTs showed a Q wave in the inferior leads which correlated with pre-existing Q-waves in sinus rhythm ECGs (p = 0.045) rendering this ECG feature not useful.

Conclusion Proposed 12-lead ECG algorithms for the differentiation of epicardial vs endocardial sites for non-ischemic LV-VTs are not valid in post-infarction patients.

Klinischer Erfolg nach Radiofrequenzisolation der Pulmonalvenen bei paroxysmalen Vorhofflimmern


Interne 2 Kardiologie/Angiologie/Intensivmedizin, Krankenhaus der Elisabethinen Linz


Durch die Reduktion bzw. Elimination rhythmusbezogener symptomaticscher Vorhofflimmerepisoden kann eine Verbeserung des subjektiven Gesundheitszustandes erreicht werden. Zudem kann bei Therapieerfolg auf eine antiarrhythmische Dauermedikation verzichtet werden.

Ziel dieser Untersuchung ist die Erhebung von Vorhofflimmerepisoden und des subjektiven Gesundheitszustandes 1,5 Jahre (19 ± 3 Monate) nach PVI.


Voller Erfolg, der als Fehlen von Vorhofflimmerepisoden (mit oder ohne antiarrhythmische Therapie) bei deutlich besseren Gesundheitszustand nach der Letztablation (1,3 ± 0,6 Ablationen pro Patient) definiert wurde, konnte bei 69 Patienten (61,6 %) verzeichnet werden, wobei 3 Patienten (4,3 %) Antiarrhythmika einnahmen.

Figure 36: M. Martinek et al.

Figure 37: M. Martinek et al.
Teilerfolg, der durch Reduktion der Vorhofflimmernagen und deutlich besseren Gesundheitszustand festgelegt wurde, konnte bei 28 Patienten (25 %) erzielt werden. Von diesen Patienten benötigten 12 Patienten (42,8 %) zusätzlich eine medikamentöse antiarrhythmische Therapie.

Nicht erfolgreich (unveränderte oder gesteigerter Anzahl von Vorhofflimmernägten), waren insgesamt 9 Patienten (8,0 %), davon standen 3 Patienten (2,7 %) unter antiarrhythmischer Therapie. Es trat eine (0,8 %; n = 120) prozedurabhängige Komplikation auf (Perikardtamponade). 4 Patienten (3,3 %; n = 120) wurden 16 ± 8 Monate nach Ablation mittels „Pace and Ablate-Konzept“ weiterbehandelt. 2 Reablationen (1,7 %; n = 120) erfolgten wegen anderer atrialer Arrhythmien (rechtsatriale fokale Tachykardie, Vorhofflimmern).

Eine orale Antikoagulation konnte bei 77 Patienten (68,6 %) aufgrund des CHADS2/CHA2DS2-VASc-Scores 3 Monate nach PVI abgesetzt werden, 46 Patienten (41,1 %) nahmen nach 19 ± 3 Monaten weder einen Thrombozytenaggregationshemmer noch eine orale Antikoagulation ein (Abbildung 38, Abbildung 39).

Schlussfolgerung Durch Radiofrequenzablation bei paroxysmalen Vorhofflimmern kann bei 86,6 % aller Patienten eine deutliche Besserung des Gesundheitszustandes und Reduktion der Vorhofflimmernägten erzielt werden. Völlige Symptomfreiheit ist bei 61,6 % der Patienten nach mehr als 1½ Jahren nach Ablation zu erreichen.

Rehospitalization of Patients with Persistent Atrial Fibrillation after DC Cardioversion – Impact of Statin Treatment

S. Öbel, L. Fiedler, M. Hauner, F. X. Roithinger, W. Mlekusch
Interne Abteilung, Thermenklinik Mödling

Background Inflammation and oxidative stress cause structural changes in the atrial myocardium. We aimed to investigate the impact of statin treatment on the maintenance of sinus rhythm in patients with persistent atrial fibrillation after DC cardioversion.

Materials and Methods We identified patients with paroxysmal AF by ICD-Code based chart-search regarding the diagnosis of admittance from January 2003 to December 2010. Patients who spontaneously or drug-induced converted to sinus rhythm had been excluded. Re-admission rates and adverse events were recorded by chart-review.

Results We included 230 patients into our final analysis. The patients were mainly male (71%) and median 66 years (IQR 59–72 years) old. In univariate comparison statins (7% vs. 26%, p < 0.001) as well as the use of ACE-inhibitors (33% vs 48%; p = 0.04) exhibited significantly reduced hospital re-admission rate due to palpitations and episodes or recurrent atrial fibrillation. This effect remained significant after adjusting for possible confounders in multivariate analysis (OR 0.47; p = 0.007).

Conclusion Inhibition of the HMG-coenzyme A reductase by statins may as potent anti-inflammatory and anti-oxidant agents protect the atrial myocytes of inflammation and oxidative stress. Therefore, statins could effectively reduce the hospital re-admission rate most likely based on maintenance of sinus rhythm after DC cardioversion in patients with persistent atrial fibrillation. Our results warrant further investigation in a prospective and randomized fashion (Figure 40).

Markers of Oxidative Stress and Inflammation Predict Early Recurrence of Atrial Fibrillation After Ablation

B. Richter, M. Gwechenberger, A. Sacas, G. Zorn, S. Albirni, M. Marx, J. Wojta, H. D. Glössinger
Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie; Universitätshilfsklinik für Kinder- und Jugendmedizin, Klinische Abteilung für Pädiatrische Kardiologie, Medizinische Universität Wien

Purpose The role of oxidative stress and inflammation after radiofrequency ablation of atrial fibrillation (AF) has not yet been well explored. We sought to assess the time course of biomarkers of oxidative stress and inflammation after AF ablation.
Methods 30 consecutive patients with paroxysmal AF underwent circumferential pulmonary vein (PV) ablation, Lasso-guided PV isolation and ablation of complex fractionated atrial electrograms. Biomarkers were measured in peripheral blood samples before ablation and 6 hours, 1, 2, 7, 30, 90 and 180 days post-ablation.

Results The pro-oxidant enzyme myeloperoxidase increased 2.9 ± 0.2-fold and was significantly up-regulated until day 2 post-ablation. Oxidized low density lipoprotein reflecting oxidative damage of lipoproteins showed a slight, but significant 1.2 ± 0.1-fold increase at day 1 and 2. The anti-oxidant enzyme copper/zinc superoxide dismutase did not change significantly. High-sensitivity C-reactive protein (hs-CRP) increased significantly until day 7 (41 ± 8-fold). The anti-oxidant enzyme superoxide dismutase showed a slight, but significant 1.2 ± 0.1-fold increase at day 1 and 2. The pro-oxidant enzyme myeloperoxidase increased 2.9 ± 0.2-fold and was significantly up-regulated until day 2 post-ablation.

Conclusions Markers of oxidative stress and inflammation showed a significant ablation-induced up-regulation detectable for up to 7 days. This up-regulation was related to the radiofrequency energy delivered during ablation and predicted early recurrence of AF, but not long-term ablation outcome (p > 0.05).

Catheterinterventional Redo Procedures After Previous Intraoperative Ablation of Atrial Fibrillation During Cardiac Surgery

R. Schönbauer, Y. Huo, A. Arya, G. Hindricks, C. Piorkowski, Rhythmologie, Herzcentrum Leipzig, Deutschland

Background Intraoperative left atrial ablation during cardiac surgery is a well established approach for treating atrial fibrillation (AF).

Objective The purpose of this study was to evaluate recurrent arrhythmias and catheterinterventional redo procedures after surgical AF ablation.

Methods From 01/2008 to 06/2010 42 patients with recurrent symptomatic supraventricular tachycardias (28 patients with macroreentrant atrial tachycardias [MRT] [67%], 14 patients with AF [33%]) after previous intraoperative left atrial ablation for treatment of AF presented for catheter ablation. Using a nonfluoroscopic system (CARTO or NavX) the left atrium (LA) was reconstructed and imageintegrated. Then the documented arrhythmia was mapped by entrainmentmapping and/or pulmonary vein isolation (PVI) checked. According to the findings ablation was performed.

Results In 32 (76%) patients gaps of the PVI required reisolation. Besides that 32 MRTs were documented and ablated: 12 perimitral, 7 days. This up-regulation was related to the radiofrequency energy delivered during ablation and predicted early recurrence of AF, but not long-term ablation outcome (p > 0.05).

Conclusions Markers of oxidative stress and inflammation showed a significant ablation-induced up-regulation detectable for up to 7 days. This up-regulation was related to the radiofrequency energy delivered during ablation and predicted early recurrence of AF, but not long-term ablation outcome (p > 0.05).

Catheterinterventional Redo Procedures After Previous Intraoperative Ablation of Atrial Fibrillation During Cardiac Surgery

R. Schönbauer, Y. Huo, A. Arya, G. Hindricks, C. Piorkowski, Rhythmologie, Herzcentrum Leipzig, Deutschland

Background Intraoperative left atrial ablation during cardiac surgery is a well established approach for treating atrial fibrillation (AF).

Objective The purpose of this study was to evaluate recurrent arrhythmias and catheterinterventional redo procedures after surgical AF ablation.

Methods From 01/2008 to 06/2010 42 patients with recurrent symptomatic supraventricular tachycardias (28 patients with macroreentrant atrial tachycardias [MRT] [67%], 14 patients with AF [33%]) after previous intraoperative left atrial ablation for treatment of AF presented for catheter ablation. Using a nonfluoroscopic system (CARTO or NavX) the left atrium (LA) was reconstructed and imageintegrated. Then the documented arrhythmia was mapped by entrainmentmapping and/or pulmonary vein isolation (PVI) checked. According to the findings ablation was performed.

Results In 32 (76%) patients gaps of the PVI required reisolation. Besides that 32 MRTs were documented and ablated: 12 perimitral,
Vernakalant: Medikamentöse Kardioversion bei Vorhofflimmern – Erste Erfahrungen am eigenen Patientengut

E. Sigmund, M. Martinik, H. J. Nesser, H. Pürerfellner
Interne 2 Kardiologie/Angiologie/Intensivmedizin, Krankenhaus der Elisabethinen Linz

Einleitung


Methodik

10 Patienten (5 männlich/5 weiblich) im Alter von 65,7 ± 13,2 Jahren wurden bislang behandelt. 8 Patienten berichteten über ein erst kürzlich aufgetretenes Vorhofflimmern (mehrere Stunden bis max. 26 Stunden). 2 Patienten erhielten Vernakalant im Rahmen einer Pulmonalvenenisolation sowie einer elektrophysiologischen Untersuchung einer linksatrialen Tachykardie.

Resultate


Diskussion


Katheterablation von persistierendem Vorhofflimmern – Langzeiterfolgsrate am KH der Elisabethinen Linz

E. Sigmund, M. Martinik, J. Moser, H. J. Nesser, H. Pürerfellner
Interne 2 Kardiologie/Angiologie/Intensivmedizin, Krankenhaus der Elisabethinen Linz

Einleitung

Die kurative Katheterablation bei medikamentös-therapierefraktären chronischen Vorhofflimmern (VHF) gewinnt zunehmend an klinischer Bedeutung und ist bereits in den aktuell gültigen Guidelines verankert. Bei Patienten mit lang anhaltendem persistierenden VHF stellen die Pulmonalvenen sehr selten das alleinige Substrat zur Initiierung und Aufrechterhaltung des VHF dar, so dass die Radiofrequenzablation (RFA) mit einer stufenweisen Erweiterung durch zusätzliche linksatriale Linien sowie Ablation komplexer fraktionierter atrialer Potentiale (CFAE) bis zur Regularisierung oder Termination des VHF weitergeführt wird.

Methodik


Resultate

Die Ergebnisse des Ablationserfolges aller Prozeduren bei persistierendem VHF im Jahr 2009 (42 Patienten) sind in Tabelle 18 zusammengefasst. Diese inkludieren 25 Erstprozeduren (59,5 %), 15 Zweitprozeduren (35,7 %) sowie 1 Drittprozedur (2,4 %; 1 unbekannt, 2,4 %), davon 13 (30,9 %) Reablationen wegen VHF-Rezidiv und 2 Reablationen wegen anderer atrialer Arrhythmien. Bei 5 Pat. (11,9 %) war ein „Misserfolg“ zu erheben, von denen 4 einer neuerlichen Ablationsbehandlung unterzogen wurden, welche bei 75 % erfolgreich verlief. Bei 2 Pat. folgte eine palliative ablative und pace-Therapie. Die subluxierte grafische Darstellung ist in Abbildung 43: E. Sigmund et al. E. Sigmund et al.

Ablationserfolg (Outcome) bei persistierendem VHF aus dem Jahr 2009

<table>
<thead>
<tr>
<th>Patientengruppen</th>
<th>Anzahl der Patienten</th>
<th>Erfolg (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voller Erfolg</td>
<td>18</td>
<td>42,9 %</td>
</tr>
<tr>
<td>Teilerfolg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>– ohne Antiarrhythmik</td>
<td></td>
<td>33,3 %</td>
</tr>
<tr>
<td>– mit Antiarrhythmik</td>
<td></td>
<td>9,5 %</td>
</tr>
<tr>
<td>Klinische Erfolgsrate gesamt</td>
<td>36</td>
<td>85,7 %</td>
</tr>
<tr>
<td>Misserfolg</td>
<td>5</td>
<td>11,9 %</td>
</tr>
<tr>
<td>Unbekannt</td>
<td>1</td>
<td>2,4 %</td>
</tr>
</tbody>
</table>
Einschätzungen des Gesundheitszustandes aller Patienten ist in Abbildung 43 veranschaulicht.

Nach Ablation wurden alle Patienten für mindestens 3 Monate nach RFA mit einem INR-Zielwert von 2,0–3,0 oral antikoaguliert, die weitere Antikoagulation (OAK) war vom CHADS₂-Score des Patienten abhängig. Somit war bei den betreffenden Pat. bei 26,2 % weder eine OAK noch eine thrombozytenaggregationshemmende Therapie notwendig, bei 26,2 % konnte auf Acetylsalicylsäure gewechselt werden, 45,2 % sind weiterhin auf einer OAK (2,4 % unbehandelt). Postprozedural ist mit genanntem Antikoagulationschema in der Beobachtungszeit kein thromboembolisches Ereignis aufgetreten.

**Diskussion**

Die Isolation der Pulmonalvenen in Kombination mit zusätzlichen atrialen Läsionen ist eine effektive therapeutische Alternative zur antirhythmischen Medikation für Patienten mit persistierendem VHF. Auch wenn nach RFA nur ein Teil der Pat. gänzlich frei von VHF ist, steigt die Lebensqualität durch eine deutliche Reduktion von Anzahl und Dauer der Episoden sowie der damit verbundene Symptomatik signifikant an.

**Robotic Navigation for Catheter Ablation of Paroxysmal and Persistent Atrial Fibrillation: A Single-Center Experience after 10 Cases**

C. Steinwender, S. Hönig, T. Lambert, R. Hofmann, F. Leisch

**Introduction**

Remote navigation systems represent a novel method for catheter ablation of atrial fibrillation (AF). The Sensei™ robotic navigation system (Hansen Medical, Mountain View, USA) enables remote catheter navigation via a robotic steerable sheath (Artisan™, Hansen Medical). The aim of this study is to report the first Austrian experience with the Sensei™ system for the treatment of patients (P) with paroxysmal and persistent AF.

**Materials and Methods**

Between November 2009 and November 2010, 110 P (59 ± 9 years, 88 males) underwent robotic circumferential pulmonary vein isolation (PVI) for paroxysmal AF (56 P, 51%) or robotic circumferential PVI plus robotic creation of a left atrial roof line for persistent AF (54 P, 49%). The EnSite NavX™ system (St. Jude Medical, Minneapolis, USA) was used for 3-dimensional mapping. For ablation, a 3,5 mm open-irrigated cooled-tip ablation catheter (Therapy Cool Path n°16, St. Jude Medical) was used. PVI was confirmed by a multipolar spiral catheter (OptimaTM, St. Jude Medical) as second left atrial catheter. Completeness of block along the roof line was confirmed by appropriate left atrial pacing manoeuvres. All procedures were performed during deep sedo-analgesia after left atrial thrombi had been excluded by transoesophageal echocardiography.

Follow-up consisted of 48-hour ECG monitoring at 3, 6, and 12 months after ablation plus additional ECGs recorded during episodes of suspicious symptoms. Freedom from atrial arrhythmias ≥ 30 seconds was counted as clinical success.

**Results**

PVI of all pulmonary veins was achieved in 103 P (94%). In 7 P (6%), one pulmonary vein could not be isolated, respectively.

Block along the roof line could be achieved in all cases. The mean procedure time was 237 ± 51 minutes (232 ± 50 minutes in paroxysmal AF versus 242 ± 48 minutes in persistent AF; p = n. s.). The mean fluoroscopic time was 27 ± 9 minutes in paroxysmal AF vs 26 ± 8 minutes in persistent AF; p = n. s.). The mean operator’s fluoroscopy exposure was 13 ± 6 minutes. As complications, 2 groin hematomata requiring transfusion and one pericardial tamponade (after the end of the procedure) requiring pericardiotomies occurred, respectively.

After a median follow-up of 9 months (range 3–14 months), the success rate after a single procedure was 65% for P with paroxysmal AF and 52% for P with persistent AF, respectively.

Success rates increased to 79% in paroxysmal AF and 74% in persistent AF, respectively, after a second procedure (in 27% of P with paroxysmal and in 40% of P with persistent AF).

**CHADS₂-VASC and HASBLED-Score bei Patienten mit Vorhofflimmern**

C. Dobias, F. Höllerl, F. Weidinger, C. Stöllberger
2. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien

**Einleitung**

In den aktuellen Guidelines der europäischen kardiologischen Gesellschaft wird zur Bestimmung des embolischen und Blutungs-Risikos bei Vorhofflimmern (AF) die Anwendung von CHADS₂-VASC- und HASBLED-Score empfohlen. In der vorliegenden Arbeit wurden die für die Ermittlung der Scores benötigten Informationen in einer Datenbank des Wiener Krankenanstaltverbundes nach Rehospitalisierungen, embolischen Ereignissen, Blutungen und Rehospitalisierungen im Follow-up zu ermitteln.

**Material und Methode**


**Ergebnisse**

Von den 100 Patienten waren 47 weiblich. Das Durchschnittsalter betrug 74 ± 12 Jahre. Der durchschnittliche CHADS₂-Score betrug 2,4 ± 1,4. Der durchschnittliche CHA₂DS₂-Vasc-Score betrug 4,2 ± 2. Einen CHADS₂-Score von 1 oder 2 wiesen 47 % der Patienten auf, damit wurden sie als „moderate risk“ mit fraglicher Indikation zur oralen Antikoagulation eingestuft. Einen CHADS₂-Score ≥ 3 wiesen 91 % der Patienten auf.

**Tabelle 19:**

<table>
<thead>
<tr>
<th>Tabelle 19: C. Stöllberger et al.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHADS₂-Score und CHA₂DS₂-Vasc-Score von 100 Patienten mit Vorhofflimmern</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHADS₂</th>
<th>CHA₂DS₂-Vasc 0</th>
<th>CHA₂DS₂-Vasc 1</th>
<th>CHA₂DS₂-Vasc 2</th>
<th>CHA₂DS₂-Vasc 3</th>
<th>CHA₂DS₂-Vasc 4</th>
<th>CHA₂DS₂-Vasc 5</th>
<th>CHA₂DS₂-Vasc 6</th>
<th>CHA₂DS₂-Vasc 7</th>
<th>CHA₂DS₂-Vasc 8</th>
<th>CHA₂DS₂-Vasc 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHADS₂ 0</td>
<td>3 (27,5 %)</td>
<td>2 (25 %)</td>
<td>1 (12,5 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHADS₂ 1</td>
<td>4 (50 %)</td>
<td>3 (37,5 %)</td>
<td>2 (20 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHADS₂ 2</td>
<td>3 (37,5 %)</td>
<td>1 (12,5 %)</td>
<td>1 (12,5 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHADS₂ 3</td>
<td>2 (10 %)</td>
<td>0 (0 %)</td>
<td>0 (0 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHADS₂ 4</td>
<td>1 (10 %)</td>
<td>0 (0 %)</td>
<td>0 (0 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHADS₂ 5</td>
<td>0 (0 %)</td>
<td>0 (0 %)</td>
<td>0 (0 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHADS₂ 6</td>
<td>0 (0 %)</td>
<td>0 (0 %)</td>
<td>0 (0 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CHADS₂-Score: 0–2 wiesen 91 % der Patienten auf

CHADS₂-Score ≥ 3 wiesen 9 % der Patienten auf
Einleitung AV-Zeit-Optimierung bei Patienten mit VDD-Schrittmacher

R. Völker, R. Jarai, J. Cup-Grundtner, J. Koch, G. Jäck-Kotascheck, M. Nürnberg, K. Huber
3. Medizinische Abteilung, Wilhelminenspital, Wien

AV-Zeit-Optimierung bei Patienten mit VDD-Schrittmacher wegen AV-Block

R. Völker, R. Jarai, J. Cup-Grundtner, J. Koch, G. Jäck-Kotascheck, M. Nürnberg, K. Huber
3. Medizinische Abteilung, Wilhelminenspital, Wien


Methode Es wurden in einer prospektiven Studie 80 Patienten (33 Frauen, 47 Männer; Altersdurchschnitt 76 ± 11 Jahre) mit einem implantierten VDD-SM bei AV-Leitungsstörung eingeschlossen. Genommen wurden das Schlagvolumen (SV) von Schlag zu Schlag mittels Impedanz-Kardiographie, der Cardiac Output (CO), die Herzfrequenz (HR) und der Blutdruck (BP), sowohl bei der nominellen als auch bei optimierter AV-Zeit. Die optimale AV-Zeit wurde dabei durch die Koglek-Formel (Verzögerung von 100 ms, gemessen vom Ende der wahrgenommenen P-Welle zur Spitze/Tiefpunkt des stimulierten Kammerkomplexes) berechnet.

Ergebnis

1. Das optimierte wahrgenommene AV-Zeit-Intervall beträgt 83 ± 20 (median 75) ms gegenüber dem nominalen Wert von 179 ± 35 (median 75) ms; p < 0,001.
2. Das SV nimmt durch die AV-Zeit-Optimierung signifikant zu (55,3 ml vs. 69,9 ml; p < 0,001).
3. Es kommt dementsprechend zu einem signifikanten Anstieg des CO (3,9 l vs. 5,0 l; p < 0,001).
4. Es kann kein Unterschied bei Blutdruck (97,6 vs. 97,5 mmHg; p = 0,9) und Herzfrequenz (72,6 vs. 71,8; p = 0,09) während der Messung von SV und CO beobachtet werden. Es besteht ein hämodynamischer Vorteil bei jedem Patienten, unabhängig von der zugrundeliegenden Herzkrankung.
5. Der Vorteil der AV-Optimierung ist von der Tragezeit des Schrittmachers unabhängig (AV-Optimierung durchschnittlich 43 Monate nach der Implantation).


Ultra-Mobile Patient-Operated Long-Term Full-Disclosure Single-Channel ECG Monitoring

T. Wolter, C. Brunnkast, F. Duru
Universitätsspital Zürich, Schweiz

Background Continuous ECG monitoring may improve detection of symptomatic and asymptomatic arrhythmias and subsequent patient treatment. However, due to technical obstacles and patient comfort issues, ambulatory continuous full-disclosure ECG monitoring has not been commercially available. The aim of this study was to determine the feasibility of a patient-managed long-term full-disclosure ECG monitoring system using a miniaturized single-channel waveform recorder and a customized mobile computing system.

Methods Thirty-three subjects underwent 72-hour conventional Holter monitoring followed by a 7-day period of continuous 1-channel ECG monitoring with a customized patient-operated monitoring system. Information related to patient symptoms and activity was collected utilizing an electronic patient log. A questionnaire was used to assess factors determining patient satisfaction and attitudes towards long-term use of the system.
**Results** Patient-managed long-term ECG monitoring was feasible in all subjects (54% male, age range 22–78 years). Overall, 5400 hours of continuous ECG tracings were recorded. Mean duration of monitoring was 19.7 ± 2.2 hours per day. Overall satisfaction with the monitoring procedure was high (82% of patients). Electrode skin irritation was the strongest factor for patient discomfort, resulting in discontinuation of ECG recording in one subject. The quality of ECG waveforms allowed determination of cardiac rhythm in 98% of time. Extending monitoring duration from 72 hours to 10 days resulted in an increased diagnostic yield of 23% (p < 0.04).

**Conclusion** Ambulatory patient-managed full-disclosure ECG recording is feasible and increases diagnostic yield compared with conventional holter monitoring. A relatively simple setup provides high-quality single-channel ECG recordings, which allows reliable diagnosis of cardiac arrhythmias while reducing interference with everyday activities. Further research is warranted to enhance long-term tolerability of continuous ECG monitoring.

---

**Risikofaktoren – Stoffwechsel – Lipide I/ Risk Factors – Metabolism – Lipids I**

**New and Old Criteria for the Diagnosis of Diabetes Mellitus in Patients with Peripheral Arterial Disease**

VIVIT-Institute, Feldkirch

Recently, an International Expert Committee concluded that haemoglobin A1c (HbA1c) may be a better means of diagnosing diabetes than glucose levels. A diagnosis of diabetes was recommended with a HbA1c ≥ 6.5%. Data on the concordance of new and old criteria for the diagnosis of diabetes are very scarce; no data at all are available for patients with peripheral arterial disease (PAD).

We enrolled 278 consecutive patients without previously known diabetes (195 men and 83 women) in whom PAD was verified sonographically. HbA1c was measured and standard 75 g oral glucose tolerance tests were performed.

From the patients with newly diagnosed diabetes according to the new diagnostic criterion of an HbA1c ≥ 6.5% (n = 26), 62% fulfilled the WHO glucose criteria for diabetes, 15% had impaired glucose tolerance (IGT), and 23% normal glucose tolerance (NGT). Conversely, the HbA1c ≥ 6.5% criterion was fulfilled in 52% of the 31 patients with diabetes mellitus type 2 newly diagnosed according to WHO criteria, in 8% of the 51 patients with IGT and in 3% of the patients with NGT. Compared to the standard of WHO criteria, the proposed HbA1c ≥ 6.5% for the diagnosis of diabetes had a sensitivity of 52% and a positive predictive value of 62% for detecting previously undiagnosed diabetes, whereas specificity and negative predictive value were 96% and 94%, respectively.

The recently recommended HbA1c criterion for the diagnosis of diabetes among PAD patients is highly specific but not sensitive. This might strongly limit its use as a screening tool for identifying individuals with diabetes.

**Auch die Bestimmung des Direct-LDL-Cholesterin unter Statinen unterschätzt vermutlich das kardiovaskuläre Risiko**

J. Pusch, P. Haider, S. Hoffmann, V. Franke, A. Podczek-Schweighofer, T. Hafner
Medizinische Abteilung mit Kardiologie, Sozialmedizinisches Zentrum Süd – Kaiser Franz Josef-Spital, Wien


**Patienten und Methoden** In einem Zeitraum von 6 Monaten wurde bei 36 konsekutiven Patienten mit hohem kardiovaskulären Risiko (LDL-Zielwert < 70 mg/dl) und Triglyzeriden < 200 mg/dl, deren Gesamtcholesterin < 150 mg/dl lag oder die bereits Statine eingenommen haben, nüchtern neben den Triglyzeriden, dem Gesamtcholesterin und dem Non-HDL-Cholesterin auch das Apo B sowie das Direct-LDL-Cholesterin bestimmt (Apo ver.2 bzw. LDL-C plus 2. Generation, jeweils von Roche).

**Ergebnis** Zwischen Direct-LDL-Cholesterin und Apo B bestand eine enge Korrelation (r = 0.88). Patienten, die in den letzten 6 Wochen ein Statin eingenommen hatten, zeigten eine trendmässig gerin
gere Ratio Direct-LDL-Cholesterin/Apo B als Patienten, die in den letzten 6 Wochen kein Statin eingenommen hatten (1.08 ± 0.12 vs. 1.17 ± 0.25 [p = 0.07]).

**Schlussfolgerung** Wie bereits von der Ratio errechnetes LDL-Cholesterin/Apo B bekannt, nimmt auch die Ratio Direct-LDL-Cholesterin/Apo B unter der Einnahme von Statinen trendmäßig ab, d. h. auch durch die Bestimmung des Direct-LDL-Cholesterins wird in dieser Situation die Atherogenität der LDL-Partikel der kardiovaskulären Risiko trendmäßig unterschätzt. Für den klinischen Alltag ist daraus abzuleiten, dass v. a. unter Statinen die Bestim
mung des Direct-LDL-Cholesterins gegenüber der Bestimmung des errechneten LDL-Cholesterins keinen wesentlichen Vorteil bietet.

**Awareness of Cardiovascular Risk Factors, Preventive Action taken and Barriers to Cardiovascular Health: A comparison between Turkish migrants living in Austria and Indigenous Austrians**

T. Haidinger, M. Zveirimüller, D. Demir, L. Stötz, J. Stratmecz-Juarez
Division of Cardiology, Department of Medicine II, Medical University Vienna

**Background** Cardiovascular disease (CVD) is the leading cause of death for men and women in industrialized countries. The aim of this study was to investigate differences in the awareness of cardiovascular risk factors, preventive action taken and barriers to cardiovascular health between the Turkish minority living in Austria and the indigenous people. All results were analyzed gender-specifically.

**Method** An anonymous questionnaire was handed out to 349 women and 276 men with no immigration background and compared with 257 female and 250 male Turkish migrants in Turkish language living in Austria. The data gained was analyzed using SPSS.

**Results** Turkish men were younger (30 ± 10.3 years) than the male cohort (54.7 ± 15.3 years) without an immigration background. Also the Turkish women were on average 6 years younger compared to the Austrian females. The majority of Turkish women (66.4%) were unemployed compared to 35% with a full time job in the Austrian cohort. By contrast, more Turkish men had a full time job compared to the Austrian women asked (85% vs 51%). The Austrian cohort was more likely to be aware of CVD as the leading cause of death (71%) than the Turkish minority (48.5%). Both had a lack of knowledge about CVD risk factors, especially the Diabetes mellitus II (DM II) was only identified by 25% of the Austrians and 22% of the Turkish minority. Two third of the Austrian cohort did not prevention in the last year compared to 25% of Turkish men and 50% of Turkish
women. More than 50% of the Turkish migrants believe that god or a higher power plays a role in the origin of the disease. Austrian women can identify more risk factors, their main barrier to CVD health is the inability to assess their personal risk correctly, while Turkish women show a lack of knowledge of how to do prevention.

Conclusion There is lack of information about CVD and its risk factors, concerning the Turkish minority to a greater extent. The main barrier for preventive action for the Turkish minority is a low educational and acculturation level, while Austrian women have difficulties in assessing their personal risk correctly. In order to minimize CVD, future preventive programs have to be conceived gender-specific and have to focus on minorities too, as the reasons that anticipate prevention show differences between indigenous Austrians and the Turkish minority.

Clinical and Angiographic Features of Coronary Heart Disease in Menopausal Women

R. Motoc, I. Tilea, C. Motoc, I. A. Tilea, L. Mihaly, R. Campean
University of Medicine and Pharmacology, Third Medical Clinic, Tîrgu Mures, Romania

Aim The aim of this retrospective study was to assess clinical characteristics of coronary artery disease (CAD) in peri- and postmenopausal women in Romania.

Material and Methods We studied women with chest pain and abnormal rest ECGs admitted between January 1, 2007 and December 31, 2010. Patients were divided in 2 groups: perimenopausal women with 49.8 ± 3.5 years of age and postmenopausal women at 59.6 ± 3.2 years of age. Clinical and angiographic data were assessed. A database was constructed, and statistical analysis was performed. Continuous variables were reported as mean ± SD. Dichotomous variables were reported as percentage with 95 percent confidence interval, comparisons were formed with a Pearson chi-square test. For comparison of continuous data, a 2-tailed Student test was performed when appropriate. A value of p < 0.05 was considered significant.

Results In perimenopausal women stable angina was most common in 40%, while in postmenopausal women acute coronary syndromes accounted for up to 50% of first clinical presentations. Cardiac syndrome X was found in 16% of pre- and 12% of postmenopausal women. Coronary angiograms revealed normal coronary arteries in 16% of pre- and 12% of postmenopausal women. Muscle bridges double and triple vessel disease was observed in 12 of pre- and 10% of postmenopausal women. The LAD (left anterior descending artery) was the most commonly affected vessel, both in single and 2-vessel disease (where it was mostly associated with RCA disease). There were statistically significant differences regarding obesity 61% vs. 79% (p = 0.04), diabetes mellitus 12% vs 27% (p = 0.03). Cholesterol levels, including HDL levels were higher in postmenopausal patients (92% vs 86%, and 97% vs 82%; p = 0.04), and a statistically significant difference was found for elevated triglyceride levels (77% in premenopausal and 52% in postmenopausal women; p = 0.001).

Conclusions In premenopausal women, stable angina was the most common first clinical manifestation of CAD, while after menopause unstable angina and acute myocardial infarction, with 2- and 3-vessel disease were common primary CAD manifestations. Women after menopause have a significantly increased incidence of cardiovascular risk factors such as: obesity, diabetes mellitus and elevated lipid levels. Primary preventive measures are warranted in Romania.

Alpine Skiing and Endothelial Progenitor Cells: Results of a 12-week Skiing Intervention in Healthy Elderly Skiers

D. Niederseer, M. Mayr, J. Cdadamuro, W. Patche, F. Dela, E. Muller, J. Niebauer
Sportmedizin, Universitatsklinikum Salzburg

Introduction Numerous studies have shown that modulation of cardiovascular risk factors is associated with significant changes in endothelial biology. Endothelial dysfunction predisposes for cardiovascular events and can be counteracted by exercise training. This is the first randomized study to assess the effects of alpine skiing on endothelial markers and endothelial progenitor cells (EPC) in elderly recreational skiers.

Material and Methods We randomized 25 apparently healthy elderly subjects into a group of 12 weeks of guided alpine skiing (intervention group, IG, n = 14; 6 males/8 females; age: 66.6 ± 2.1 years) or a control group (CG, n = 11; 3 males/8 females; age: 67.5 ± 5.0 years). EPC as defined as CD34+/CD45+/KDR+ mononuclear cells were assessed before and after alpine skiing intervention using flow cytometry. Furthermore we measured cardiovascular biomarkers (E-Selectin, ICAM, VCAM, Endothelin-1).

Results Study participants completed 28.4 ± 2.5 skiing days (skiing time: 65.9 ± 7.9 minutes lift and resting time: 121.1 ± 15.9 minutes, break time: 24.0 ± 20.9 minutes per day) at an average heart rate of 72.7 ± 8.5% of maximum heart rate and maintained an average of 5137 ± 828 meters of altitude per skiing day. Logarithmically transformed EPC counts increased in IG (1.36 ± 0.56 to 1.74 ± 0.56; p = 0.020) but remained unchanged in CG (2.03 ± 0.54 to 1.89 ± 0.52; p = 0.563; IG vs CG: 0.023). Subjects that skied longer had higher EPC levels (r = 0.065; p = 0.022). However, no correlation could be found between altitude exposure and changes in EPC levels (r = -0.49; p = 0.130). Biomarkers (E-Selectin, ICAM, VCAM, Endothelin-1) for endothelial function and low-grade inflammation were not elevated and similar in IG and CG, and did not change throughout the study.

Conclusion Alpine skiing in the elderly increased endothelial progenitor cells indicating a change in endothelial biology. The beneficial changes where more pronounced in skiers that skied more often.

Effects of a 12-week Skiing Intervention on Glucose Homeostasis and Cardiovascular Biomarkers in Elderly Alpine Skiers

D. Niederseer, F. Dela, Ch. Finch, J. Cdadamuro, W. Patche, F. Muller, J. Niebauer
Sportmedizin, Universitatsklinikum Salzburg

Objective Alpine skiing involves elements of static and dynamic exercise training, and may therefore improve insulin sensitivity and cardiovascular biomarkers.

Material and Methods Healthy elderly men and women who where beginners/intermediate level alpine skiers, were studied before (PRE) and immediately after (POST) 12 weeks of alpine ski training. After additional 8 weeks a third test (retention study, RET) was performed. The subjects were randomized into an intervention (IG, n = 22, age = 66.6 ± 0.4 yrs) or a control group (CG, n = 20, age = 67.0 ± 1.0 yrs). Plasma glucose decreased (p < 0.05) in IG, but increased (p < 0.05) again at RET, while a continued decrease was seen in IG (RET vs POST; p < 0.05). Plasma insulin decreased (p < 0.05) with training in IG, while no effect was seen in CG. HOMA index for insulin resistance decreased (p < 0.05) from 0.80 ± 0.08 to 0.71 ± 0.09 in IG. The value at RET (0.57 ± 0.08) tended (p = 0.067) to be different from POST. In CG the corresponding values were 0.84 ± 0.09, 0.81 ± 0.12 and 0.70 ± 0.09, respectively. Biomarkers for endothelial function and low-grade inflammation were not elevated and similar in IG and CG, and did not change throughout the study.

Conclusions Alpine skiing improves glucose homeostasis and insulin sensitivity in healthy, elderly individuals.
Resistance Training in Patients with Type 2 Diabetes: Effects on Glycemic Control, Endothelial Function, Muscle mass and Strength X – 2

Sportmedizin, Universitätssklinikum Salzburg

Objective To compare the effects of 2 resistance training protocols in combination with aerobic endurance training (AET) in type 2 diabetes mellitus (T2DM) on body composition, glycemic control, endothelial function, muscle mass and strength.

Research Design and Methods We performed an 8-week randomized controlled training intervention in 32 T2DM patients (age 64.8 ± 7.8 years). Patients were randomly assigned to either AET (cycle ergometer, 70% of heart rate reserve) combined with hypertrophy resistance training (HRT, n = 16, 2 sets, 10–12 repetitions, 70% of the one-repetition maximum) or with endurance resistance training (ERT, n = 16, 2 sets, 15–20 repetitions, 40% of the one-repetition maximum). Body composition, blood analyses, physical work capacity, and upper body strength were measured pre- and post-intervention.

Results At baseline, no statistically significant differences were found between groups with the exception of intra-abdominal mass in ERT (p < 0.005) and greater upper arm strength during back pull in HRT (p < 0.002). After 8 weeks of intervention, fasting plasma glucose (p = 0.04) and fructosamine (p = 0.002) improved significantly in the HRT group and there was a trend toward an improvement in ERT (p = 0.06 and p = 0.08 respectively). Muscle mass showed a significant increase in both groups without significant differences between groups (HRT: p = 0.003; ERT: p = 0.005, ΔHRT vs ΔERT: p = 0.86). Upper body strength improved in both groups (chest-press: HRT: p < 0.001; ERT: p < 0.001; back-pull: HRT: p < 0.001; ERT: p < 0.001), whereas a greater increase was achieved by HRT during chest press (ΔHRT vs ΔERT: p = 0.01). Improvement in physical work capacity, waist circumference, and subcutaneous fatty tissue was comparable in both groups (all p < 0.05).

Conclusion Glycemic control and muscle mass improved in both groups by a similar magnitude, whereas gain in upper body strength was superior in HRT. Overall, both resistance training protocols can be judged equally potent and be included into the exercise regime of patients according to their personal preference. This will further individualize exercise programs and may result in a greater sustainability of training effects.
Methods From July to December 2005 we conducted a cross-sectional online survey with 170 items among all physicians working in 2 university clinics in Austria (Innsbruck and Salzburg).

Results Of 1877 physicians contacted, 590 (31.4%) filled out an online questionnaire and 396 (21.1%) were included into final analysis. The sample (37.3 ± 8.1 years, 219 [55.3%] males, 177 [44.7%] females) was stratified into 5 groups according to their perceived fitness status: very good (n = 26), good (n = 106), average (n = 181), not good (n = 71) and bad (n = 12). Strong correlations could be found for health parameters, stress coping, sexual satisfaction, research activities, work performance and job position of the participating physicians (Table 20).

Conclusions In hospitals in Austria good physical fitness of physicians was significantly associated with the ability to cope with workplace stress. Unfortunately, only a minoritio of physicians in Austria is physically fit enough to withstand the threat of workplace stress.

Randomized Evaluation of the Effects of a Structured Education Program on Blood Pressure (BP) in Essential Hypertensive Patients (Pts) (herz. leben) X – 6

S. Perl, V. Riegelnik, C. Kos, P. Mirk, I. Rakovac, G. Klima, T. Pieber, R. Zwekker
Universitätsklinik für Innere Medizin, Medizinische Universität Graz

Objective Despite improved awareness and excellent therapeutic options hypertension remains one of the most powerful cardio- and cerebrovascular risk factors. A major impact of pts related aspects like life-style and adherence to medical recommendations is acknowledged broadly. In this respect a structured educational program for diabetics has got remarkable merits (DAFNE-trial). For hypertensives this strategy might provide significant benefits as well. A previously evaluated structured curriculum imparted in cooperation with doctors and hypertension nurses was used. Groups of 6–10 pts were instructed on issues of BP self measurement, healthy salt reduced diet, active life style and pharmacologic antihypertensive therapy. In order to determine the isolated effect of participation in the educational program neglecting the possible impact of more intense care this prospective multicenter randomized controlled study was designed (NCT00453037).

Design and Methods Between 2007 and 2010 256 pts in 13 centers (9 offices of GPs and 4 outpatient departments) were enrolled into the study. After initial evaluation (T0) and written informed consent all pts were invited to 2 follow-up visits after 6 (T6) and 12 (T12) months. Pts at each center were randomly assigned to 2 groups (G-I, n = 137) underwent the educational program at T0, G-II (n = 119) was designated for participation after T6. Primary endpoint was a suspected difference in office and home BP at T6. At this point (n = 119) was designated for participation after T6. Primary endpoint was a suspected difference in office and home BP at T6. At this point of time differences in BP observed at T6 disappeared completely. Patient flow was as follows: At T6/T12 120/88 pts of G-I and 97/88 pts of G-II adhered to the scheduled visits.

Conclusion The results of this multicenter RCT provide significant evidence for benefit by participation in a structured educational program. Positive effects seem to be mediated by achieving higher levels of information and patient empowerment. Therefore, educational strategies should be considered strongly as standard of care for hypertensive pts.

High Prevalence of Impaired Glucose Metabolism in Overweight Patients With Peripheral Arterial Disease XIX – 3

VIVIT-Institute, Feldkirch

Epidemiologic studies show a high prevalence of type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), and of impaired fasting glucose (IFG) in patients with coronary artery disease. However, the prevalence of abnormal glucose metabolism in patients with sonographically proven peripheral arterial disease (PAD) is unclear and is addressed in the present study. We enrolled 294 overweight and obese patients (223 men, 71 women) who underwent routine duplex sonography for the evaluation of suspected or established PAD and in whom PAD was verified sonographically. Oral glucose tolerance tests were performed in non-diabetic subjects. From our patients, 119 (40.5%) had a normal glucose tolerance, 31 (10.5%) IGT, and 144 (49.0%) T2DM (previously known in 121 and newly diagnosed in 23 patients). Impaired fasting glucose was diagnosed in 39 patients with normal glucose tolerance and in 12 patients with IGT. Thus, glucose metabolism was normal in only 80 (27.2%) of our PAD patients.

In conclusion, the prevalence of abnormal glucose metabolism is extremely high in overweight PAD patients. Routine screening for abnormal glucose metabolism (including oral glucose tolerance tests) in PAD patients therefore is warranted.

Prevalence of Diabetes and of Impaired Glucose Tolerance in Patients with Atherosclerosis: The Importance of the Involved Arterial Beds XIX – 2

VIVIT-Institute, Feldkirch

We aimed at comparing the prevalence of impaired glucose metabolism between patients with peripheral arterial disease (PAD), patients with coronary artery disease (CAD), and controls. We enrolled 937 consecutive Caucasian patients undergoing coronary angiography for the evaluation of stable CAD and who did not have a history of PAD. Patients with significant coronary stenoses ≥ 50% were defined as having significant CAD (n = 500), and those without such lesions served as controls (n = 424). Additionally, we enrolled 447 patients undergoing duplex sonography for the evaluation of suspected or established PAD and in whom PAD was verified sonographically. Oral glucose tolerance tests were performed in non-diabetic subjects.

The prevalence of diabetes was significantly higher in patients with significant CAD than in controls (27.2 vs 17.7%; p = 0.001) and was highest (41.8%) in PAD patients, in whom it was significantly higher than in both controls (p < 0.001) and in subjects with significant CAD (p < 0.001). Similarly, the prevalence rates of impaired glucose tolerance significantly increased from the control group over the group of patients with CAD to the group of patients with CAD (31.4, 41.4 and 54.1%, respectively; p < 0.001); it was significantly higher in CAD patients than in controls (p = 0.002) and significantly higher in PAD patients than in both controls and CAD subjects (p < 0.001 for both analyses).

In conclusion, diabetes and impaired glucose tolerance are highly prevalent in patients with CAD and even more so in patients with PAD. Routine screening for abnormal glucose metabolism including oral glucose tolerance tests is therefore warranted for these patients.
Type 2 Diabetes and the Progression of Visualized Atherosclerosis to Clinical Cardiovascular Events

C. H. Saely, P. Rein, A. Vordank, K. Huber, H. Drexel
VWF-Institute, Feldkirch

We aimed at prospectively evaluating to what extent pre-existing coronary artery disease (CAD) accounts for the increased long-term vascular event risk of patients with type 2 diabetes (T2DM). We hypothesized that baseline CAD among patients with T2DM may account substantially for their increased cardiovascular risk.

Over 8 years we recorded vascular events in 750 consecutive patients whose baseline CAD state was verified angiographically.

The prevalence rates of CAD (87.8% vs 80.4%; p = 0.029) and of significant coronary stenoses ≥ 50% (69.5% vs 58.4%; p = 0.010) as well as the extent of CAD, defined as the number of significant coronary stenoses (1.7 ± 1.6 vs 1.4 ± 1.5; p = 0.014) were higher in patients with T2DM (n = 164) than in non-diabetic subjects. During follow-up, T2DM strongly predicted vascular events (n = 257) independently from the presence and extent of baseline CAD (hazard ratio [HR] 1.36 [1.03–1.81]; p = 0.032; conversely, the presence and extent of baseline CAD predicted vascular events independently from T2DM (HR 3.20 [1.93–5.64]; p < 0.001 and 1.37 [1.23–1.53]; p < 0.001, respectively). The overall risk increase conferred by T2DM was driven by the extremely high 53.3% event rate of patients with both T2DM and significant CAD at baseline; individuals with T2DM who did not have significant CAD at baseline showed a significantly lower event rate (22.0%; p < 0.001).

We conclude that T2DM and angiographically visualized coronary atherosclerosis are mutually independent predictors of vascular events. The overall risk increase conferred by T2DM is driven by accelerated progression of pre-existing atherosclerosis to clinical cardiovascular events.

Impact of Diabetes Mellitus on Exercise Related Antiangiogenic Endostatin/Collagen XVIII Release: Does Gender Matter?

1Department of Cardiology; 2Department of Endocrinology; 3Department of Medical-Chemical Laboratory Diagnostics, Medical University Vienna

Background Type 2 diabetes mellitus (T2DM) is one of the most important risk factors for cardiovascular diseases in men and women resulting in endothelial dysfunction and subsequent atherosclerosis. However, the cardiovascular risk is higher in diabetic women compared to diabetic men. Endostatin (Endo), a fragment of collagen VXIII, induces inhibition of proliferation and migration of endothelial cells and stimulation of endothelial nitric oxide synthase (e-NOS), and has been shown to contribute to the beneficial vasoprotective effects of physical exercise in young, healthy men. Therefore the aim of the present study was to investigate the impact of gender and diabetes on exercise related Endo/collagen XVIII release.

Study Population and Methods A total of 64 patients, divided into diabetics (11 female; 14 male; mean age 58.5 ± 10.1) and young healthy non-smokers (20 female; 19 male; mean age 23.1 ± 3.9), were investigated during a graded physical stress test. Venous blood samples for deterioration of Endo was measured (ng/ml) by ELISA at baseline (Sample 1) and at peak work-load (Sample 2) (Figure 44).

Furthermore heart rate, BMI and blood pressure were measured.

Results Endo serum levels were similar in the young healthy group in both genders at baseline (female: 89.3 ± 15.32 vs male: 93.4 ± 15.0 ng/ml) and increased to 112.1 ± 26.1 in females and to 114.8 ± 20.7 ng/ml in males at maximum workload. Male diabetics showed markedly elevated baseline Endo levels compared to healthy male controls (108.5 ± 17.4 vs 93.4 ± 15.0 ng/ml) but a blunted Endo increase at peak workload (119.9 ± 15.8 vs 114.8 ± 20.7 ng/ml). However, diabetic females showed statistically significant higher baseline Endo levels compared to young females (150.8 ± 41.0 vs 89.3 ± 15.3 ng/ml) as well as to the male diabetics (108.5 ± 17.4 ng/ml) but a blunted increase at peak work load compared to the young female control group (150.8 ± 41.0 vs 165.6 ± 48.3 vs 89.3 ± 15.3 vs 112.1 ± 26.1 ng/ml).

Conclusion/Discussion We could show for the first time that (1) in young healthy controls graded exercise is associated with a significant increase in Endoserum levels comparable in both genders (2) male diabetics have statistically higher baseline Endo levels compared to young healthy males however exercise-related Endo increase is blunted compared to the control group (3) female diabetics show markedly increased baseline Endo serum levels compared to young healthy females as well as diabetic males, but an albeit blunted exercise related Endo increase, reflecting a markedly decreased platelet-derived Endo production.

Thus, altered Endo release may be the missing link to impaired endothelial function, inflammation and advanced progression of atherosclerosis in diabetics. However, in diabetic females platelet-derived Endo release seems to be physiologically markedly up-regulated reflecting a physiological adaptive effect sustaining normal endothelial function in the female vasculature.

Influence of Age, Smoking and Diabetes on Exercise Related Antiangiogenic Endostatin/Collagen XVIII Release in Men

1Department of Cardiology; 2Department of Endocrinology; 3Department of Medical-Chemical Laboratory Diagnostics, Medical University Vienna

Background Smoking and diabetes mellitus II (T2DM) are important cardiovascular risk factors inducing endothelial dysfunction and atherosclerosis. However, men are more affected by cardiovascular diseases before the age of 50 compared to females. Endostatin (Endo), a fragment of collagen VXIII, induces inhibition of proliferation and migration of endothelial cells and stimulation of endothelial nitric oxide synthase (e-NOS), and has been shown to contribute to the beneficial vasoprotective effects of physical exercise in young, healthy men. Therefore the aim of the present study was to investigate the impact of age, smoking and diabetes on exercise related Endo/collagen XVIII release in men.

Study Population and Methods A total of 101 patients, divided into elderly male smokers (≥ 45 years), elderly non-smokers (≥ 45 years), young healthy non-smokers (< 45 years) and diabetics (≥ 45 years) were investigated during a graded physical stress test. Venous blood samples for deterioration of Endo (ng/ml) by ELISA were measured at baseline (Sample 1) and at peak work load (Sample 2) (Figure 45). Furthermore heart rate, BMI and blood pressure were measured.

Results Young, healthy male non-smokers showed the lowest Endo baseline levels (90.8 ± 17.0 ng/ml) with a significant exercise-
Insulin Resistance is Associated with the Metabolic Syndrome But Not With Peripheral Arterial Disease

VIVIT-Institute, Feldkirch

Insulin resistance (IR) is the key feature of the metabolic syndrome (MetS); its association with peripheral arterial disease (PAD) is unclear. We hypothesised that insulin resistance is associated with both the MetS and sonographically proven PAD.

IR was determined using the HOMA index in 197 patients with sonographically proven PAD as well as in 214 controls who did not have a history of PAD and in whom coronary artery disease was ruled out angiographically; the MetS was defined according to NCEP-ATPIII criteria.

HOMA-IR scores were higher in MetS patients than in subjects without the MetS (5.9 ± 6.2 vs 2.9 ± 3.9; p < 0.001). However, HOMA IR did not differ significantly between patients with PAD and controls (4.2 ± 5.4 vs 3.3 ± 4.3; p = 0.124). When both, the presence of the MetS and of PAD was considered, HOMA-IR was significantly higher in patients with the MetS both among those with PAD (6.1 ± 5.7 vs 3.6 ± 5.2; p < 0.001) and among controls (5.8 ± 6.8 vs 2.3 ± 1.8; p < 0.001), whereas it did not differ significantly between patients with PAD and controls among patients with the MetS (5.8 ± 6.8 vs 6.1 ± 5.7; p = 0.587) nor among those without the MetS (2.3 ± 1.8 vs 3.6 ± 5.2; p = 0.165). Similar results were obtained with the IDF or harmonized consensus definitions of the MetS.

We conclude that IR is significantly associated with the MetS but not with sonographically proven PAD.
Assessment of Disease Severity by Speckle Tracking Echocardiography in Patients with Low Flow-Low Gradient Aortic Stenosis: Results from the Multicenter TOPAS Study

P. E. Bartko1, S. Graf1, R. Rosenhek1, I. G. Burwash2, J. Bergler-Klein1, M. A. Clavel3, J. KARDIO 2011; 18 (5–6)

Results
878 patients had non-CAD and 1387 had any form of CAD (n = 505 non-significant CAD, n = 438 1-VD, n = 232 2-VD, n = 212 3-VD). The latter had a significantly higher VAS on univariate analysis (13.5 ± 5.0 vs 10.9 ± 9.2, p < 0.001). On multivariate analyses, the VAS remained a strong independent predictor of CAD prevalence (per point: OR 1.21 [1.16–1.25], p < 0.0001). Additionally, VAS was also independently associated with CAD severity in general. ROC analysis revealed an AUC of 0.705 [0.683–0.726] (p < 0.0001). The sensitivity and positive predictive value for CAD prevalence of a VAS of > 10 were 83.1% and 70.0% (specificity and negative predictive value: 43.7% and 62.1%).

Conclusion
A modification of this vascular age score – initially developed to predict the incidence of cardiovascular events – is also independently associated with CAD prevalence and severity. Therefore it may be a useful and easily applicable tool in the decision making process for or against further testing of patients with suspected CAD.

Vitien/Cardiac Defects

First Austrian Experiences with the MitraClip System in Elderly Patients with Significant Mitral Regurgitation, Distinct Impairment of LV-Function and Co-Morbidities


Abstract

First Austrian Experiences with the MitraClip System

Purpose
Patients with severely reduced left ventricular function and aortic stenosis of unknown significance remain a diagnostic and therapeutic challenge. NT-proBNP has been shown to be a strong prognostic marker in these patients. We investigated whether peak systolic global longitudinal 2d-strain (GLS) obtained by speckle tracking could serve as a new echocardiographic modality for evaluation of disease severity in patients with low flow, low gradient aortic stenosis (LFAS).

Methods
We consecutively enrolled 46 patients with LFAS, which was defined by aortic valve area (AVA) ≤ 1.2 cm² and indexed AVA ≤ 0.6 cm²/m², LVEF ≤ 40% and mean pressure gradient ≤ 40 mmHg. As a measure of stenosis severity, projected valve area (AVApr)j from dobutamine stress echocardiography was calculated as described previously. LVEF was assessed using biplane Simpson method. Offline GLS analysis was derived from the apical 4, 2, and long axis views by a blinded observer using commercial software. NT-proBNP was measured at the time of echocardiographic examination in a subset of 36 patients.

Results
39 (85%) male and 7 (15%) female patients, age 73 ± 11 years were examined. LVEF was 28 ± 6%, indexed AVA 0.4 ± 0.1 cm²/m², AVApr 0.92 ± 0.13 cm², GLS -7 ± 2%, and NT-proBNP 7578 ± 3722 pg/ml. Correlation between GLS and NT-proBNP was r = 0.536; p = 0.001, and between EF and NT-proBNP r = -0.491; p = 0.003. AVApr was inversely related to GLS (r = -0.386; p = 0.008).

Conclusions
GLS is impaired in patients with LFAS and associated to stenosis severity. Moreover, GLS is related to NT-proBNP and therefore may provide a new echocardiographic technique for evaluation of disease severity and risk stratification in patients with LFAS.

Complications
One patient developed cardiac tamponade treated successfully by conservative means. In-hospital and 30 days mortality was 0%. ICU mean duration was 2 days and total hospitalisation was median 11 ± 8 days (9.3–33 days). The logistic Euroscore of the overall group was 22.1 ± 13.7% and increased in the patient group with LVEF ≤ 50% to 25.6 ± 13.7%. In the very high surgical risk group (LVEF ≤ 35%) including multiple co-morbidities the 12 month mortality was 28.7%. The mean device implantation time was 114.7 ± 63 minutes. Mitral regurgitation intensity could be reduced from grade 3.5 ± 0.3 to grade 1.75 ± 1.5.

Complications
In the high risk surgical group (LVEF ≤ 35%) one year mortality correlated significantly with high pre- (p = 0.034) and postinterventional NTproBNP levels (p = 0.034).

Conclusion
Mitril valve repair using the MitraClip system was shown to be feasible with high success rate in patients with significant mitral regurgitation. Particularly patients with distinct impaired LV-function in combination with co-morbidities may improve but have to be selected very carefully.

Single Center Experience in TAVI with the CoreValve System in Symptomatic Patients with Advanced Age and Significant Aortic Valve Stenosis


Intemte 2 Kardiologie/angiologie/intensivmedizin, Krankenhaus der Elisabethinen Linz

Introduction
Aortic valve stenosis (AS) is the most common degenerative valve disease in the elderly and an increasing problem for public health. Symptomatic patients should be treated by valve replacement but Transcatheter Aortic Valve Intervention (TAVI) is an alternative option for patients with symptomatic aortic valve stenosis deemed high risk or unsuitable for surgical valve replacement.

Methods and Results
From October 2007 to March 2011, a total of 75 patients (mean 83 ± 5 yrs, 41.3% male) with a logistic Euroscore of 25.3 ± 14.3% with severe, symptomatic aortic stenosis (mean valve area 0.59 ± 0.14 cm²) underwent TAVI with the third generation 18-Fr. Medtronic CoreValve prosthesis. Preinterventional the mean instantaneous gradient was 97.4 ± 24.8 mmHg and decreased
postprocedural significantly to 22.9 ± 6.9 mmHg (p = 0.008). Mean LVEF was 45.8 ± 7.4% in the overall population. Procedural technical success was achieved in 98.6%. Paravalvular regurgitation was mild in the majority of cases (90.5%). Initially 9.5% of patients had a postprocedural regurgitation > grade 2 which decreased to 5.1% after 1 year. Permanent pacemaker implantation after TAVI procedure was necessary in 24% due to relevant conduction disturbances. Complications included pericardial tamponade in 10.6%, stroke in 6.6% and myocardial infarction in 1.3%.

30 days mortality in the overall study population was 10.7% and was mainly driven by complications related to the first patient’s group who we started already in 2007, despite assistance of an experienced proctor.

After changing devices and proceeding (ballon and wires), in cooperation with the company, remarkable improvement in patient outcome could be achieved. This resulted in less 30 day- (8.5%) and 12 month mortality rate (15.6%).

Conclusion TAVI procedure with the CoreValve device in very advanced age and high risk for a surgical approach, was associated with high technical success rate and acceptable complication rates in appropriately selected patients. In none of our patients switch to open heart surgery was necessary, however, careful patient selection is mandatory to maintain good results.

Prädiktion der intraoperativen Implantationsebene mittels 128-Zeilen-Dual-Source-„FLASH“-CT-Angiographie: Sinnvoll zur Planung von Transkatheter Aortic Valve Implantationen (TAVI)?

Von G. Friedrich, T. Bartel, S. Müller, L. Müller, F. Plank, G. Feuchter, O. Pachinger, N. Bonaroos
Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin III; Universitätsklinik für Herzchirurgie, Medizinische Universität Innsbruck

Einleitung und Fragestellung Transkatheter Aortenklappen-implantationen (TAVI) erfordern eine präoperative nicht-invasive Evaluierung des Gefäßsystems. Die 128-Dual Source High-Pitch-CT-Angiographie erlaubt neben aorto-iliakalen CT-Angiographie in prospektiver EKG-Synchronisation (high-pitch, 3.4) die endgültig intraoperativ verwendete angiographische Ebene (C-Bogeneinstellung) für eine mögliche TAVI gescreent. Folgende Messwerte wurden ermittelt: 1) Die optimale LAO/RAO und CC (kranio-kaudale) Ebene für eine mögliche TAVI gescreent. Folgende Messwerte wurden er- hoben: 1) Die optimale LAO/RAO und CC (kranio-kaudale) Ebene für eine mögliche TAVI gescreent. Ihre genaue Positionierung von der Annulusebene: < 8 mm wurde als „kritisch-niedrig“ definiert (= “Risiko”-Overstenting), 8–11 mm als „niedrig- ausreichend“, und > 11 mm als „hoch“. 3) Effektive Strahlendosis der 128-Zeilen-CTA betrug etwa 0.8 cm²/m².

Results Patients were followed for 5.9 ± 2.8 years. SVD was present in 35 (13.5 %) patients and was diagnosed 32.5 ± 33.8 months after surgery. 26 patients (74.3%) had stenosis-type SVD, whereas 9 (25.7%) suffered from incompetence type SVD. The frequency of SVD was similar among patients with PPM (25 patients, 11.9%) compared to patients without mismatch (10 patients, 14.3%, p = 0.60). However, 80% of stenosis-type SVD occurred in patients with PPM (n = 20, p = 0.04). In 9 patients (3.5%) SVD occurred early within 6 months after surgery (6 stenosis-type, 3 incompetence-type). All early stenosis-type SVD patients had PPM, as well as 2 of the 3 patients with incompetence-type SVD.

Conclusions SVD within 6 years after bioprosthetic aortic valve replacement is more common than previously shown. In our series 13.5% of patients were affected. Stenosis-type SVD is more frequent than incompetence-type SVD and strongly related to PPM, particularly in patients who present with early stenosis-type SVD. Therefore, SVD might be preventable to some extent by the use of large bioprostheses as possible.

Veränderung des N-terminalen pro-B-Typ-natriureti- schen Peptids nach kathetergestütztem Aortenklappen- peneratsatz (TAVI) in Relation zu klinischen und ekochardiographischen Veränderungen

J. Mair, S. Bartl, M. Mueller, S. Mueller, T. Bartel
Universitätsklinik für Innere Medizin III, Medizinische Universität Innsbruck

Hintergrund Für viele Patienten mit symptomatischer hochgradi- ger Aortenstenose ist das operative Risiko für einen konventionellen chirurgischen Herzklappenersatz zu hoch. Für dieses Kollektiv bieten der kathetergestützte Aortenklappenersatz (TAVI) eine neue therapeutische Option. Wir untersuchten Veränderung des N-terminalen pro-B-Typ-natriuretischen Peptids (NT-proBNP) nach kathe- tergestützter Aortenklappenersatz in Relation zu klinischen und ekochardiographischen Veränderungen.

Methoden 18 Patienten (6 männlich, 12 weiblich) mit symptomati- scher hochgradiger Aortenstenose wurden über einen Zeitraum von 6 Monaten nach TAVI verlaufskontrolliert. Das mittlere Alter der Patienten betrug 81 ± 6.8 Jahre. Der Eingriff erfolgte bei 9 Pati-
enten von transfemoral, und in der anderen Hälfte von transapikal. Beurteilt wurden echokardiographische Parameter, wie maximaler und mittlerer Druckgradient über der Aortenklappe sowie die linksventrikuläre Ejektionsfraktion (LVEF), und Basislaborwerte unter besonderer Berücksichtigung des NT-proBNP. Zusätzlich wurde der klinische Verlauf dokumentiert. Die Messzeitpunkte lagen vor und ca. 6 Monate nach TAVI.

**Resultate** Der maximale Druckgradient über der Aortenklappe nahm von 73,5 mmHg ± 18,2 auf 12,3 mmHg ± 10,5 (p = 0,008), und der mittlere Gradient von 50,2 mmHg ± 13,3 auf 7,45 mmHg ± 6,6 (p = 0,005) ab. Die LVEF veränderte sich von 49,6% ± 13,6 auf 54,3% ± 9,5 (p = 0,004) auf 6 Monaten nicht signifikant (p = 0,363). Beim NT-proBNP war ein nicht signifikanter Rückgang (p = 0,20) von initial Median 2406 ng/L (987–30124 ng/L) auf 1621 ng/L (452–8064 ng/L) zu verzeichnen. Eine Besserung des klinischen Allgemeinzustandes (AZ) konnte bei 12 Patienten erreicht werden, ein unveränderter AZ bestand bei 4, bei 2 Patienten verschlechterte sich der AZ. Es bestand keine signifikante Korrelation zwischen der Abnahme des Druckgradienten und der Abnahme des NT-proBNP.

**Schlussfolgerung** Die Mehrheit der Patienten zeigte nach TAVI eine Besserung des AZ. Durch TAVI konnte erwartungsgemäß der Druckgradient über der Aortenklappe signifikant gesenkt werden, die LVEF wurde hingegen nur nicht-signifikant verbessert. Leber- und Nierenfunktionsparameter zeigten keine signifikante Änderung, beim NT-proBNP bestand ein statistisch nicht-signifikanter Trend der Abnahme nach TAVI.

**Impact of Tricuspid Regurgitation on Survival in Patients with Chronic Heart Failure. A Long-Term Observational Study** XX – 6

S. Neuhold, M. Hülsmann, E. Pernicka, C. Adlbrecht, T. Binder, G. Maurer, R. Pacher, J. Mascherbauer
Universitätsklinik für Herz-Thorax-Gefäßchirurgie und Innere Medizin, Universitätsklinik für Herz-Thorax-Gefäßchirurgie und Innere Medizin, Medizinische Universität Wien

**Purpose** Tricuspid regurgitation (TR) is common in patients with chronic heart failure (CHF). However, data about the prognostic value of significant TR in CHF patients are sparse.

**Methods** 575 consecutive patients with CHF were prospectively included. Patients represent an unscreened contemporary cohort of CHF patients treated according to current guidelines in a tertiary heart failure clinic. At study entry detailed clinical and echocardiographic data were collected. The prognostic impact of significant TR was assessed and compared with established risk factors.

**Results** Patients were followed for 69.18 ± 50.24 months. TR was common in the study population. 10.6% of patients had severe, 24.0% moderate, and 65.4% of patients had no or mild TR. Kaplan Meier analysis showed a considerably increased mortality rate of patients with moderate and severe TR (p < 0.0001). However, by multivariable analysis NTpro-BNP (p = 0.0054), systolic blood pressure (p = 0.0012), heart rate (p = 0.0152), age (p < 0.0001), serum creatinine, (p < 0.0001), serum sodium (p = 0.0449) and left ventricular function (p = 0.0130), but not TR independently predicted mortality. These independent predictors of mortality were used to define disease severity to analyze the predictive value of TR at different stages of CHF. In patients with mild and moderate CHF, characterized by NT-proBNP concentrations < 500 mg/dl, serum creatinine values < 1.5 mg/dl, sustained systolic blood-pressure > 100 mmHg, heart rate < 90/min, severe TR was highly predictive of mortality (p < 0.0001) for all, except NTproBNP (p = 0.00175). In patients with advanced disease, however, significant TR did not add additional information.

**Conclusion** The prognostic impact of TR strongly depends on the severity of heart failure. Whereas TR excellently predicts excess mortality in mild to moderate CHF, it has no additive value in advanced CHF when compared with established risk factors. Since it is one of the most common regurgitant lesions, severe TR is associated with adverse outcome it is this group of patients that might benefit from tailored pharmacological or surgical interventions.

**Outcome and Risk-Stratification in Asymptomatic Combined Stenotic and Regurgitant Aortic Valve Disease** XX – 7

R. Zilberszack, H. Gabriell, G. Maurer, R. Rosenberg
Division of Cardiology, Department of Medicine II, Medical University Vienna

**Background** Outcome and criteria for surgery have been defined for isolated aortic stenosis and for isolated aortic regurgitation. We sought to describe the outcome of patients with combined stenotic and regurgitant aortic valve disease.

**Methods** 71 consecutive asymptomatic patients (21 female, age 52 ± 17 yrs) with at least moderate aortic stenosis in combination with at least moderate aortic regurgitation were included and followed at regular intervals. Patients with other significant valvular lesions were excluded. 35 patients had bicuspid aortic valves, of the remaining 36 patients, all but 5 had moderately to severely calcified valves. There was no rheumatic etiology. Outcome was assessed and event-free survival with events defined as indication for aortic valve replacement based on current practice guidelines or cardiac death was determined.

**Results** During a median potential follow-up of 33 ± 5 months, 50 patients developed criteria warranting aortic valve replacement. No cardiac deaths were observed before indications for surgery were reached. Event-rate was high with an event-free survival for the entire patient-population of 76 ± 4%, 56 ± 5%, 43 ± 5% and 28 ± 5% at 1, 2, 3 and 4 years, respectively. Indications for surgery were symptoms, 33; positive exercise test, 3; rapid hemodynamic progression, 5; aortic aneurysm, 3; aortic dissection, 1; before major noncardiac surgery, 2; endocarditis, 2; and left ventricular dysfunction, 1. There was no perioperative mortality. In patients with combined stenotic and regurgitant aortic valvular disease, event-free survival was significantly worse for patients with severe aortic stenosis as compared to moderate aortic stenosis (p < 0.0001) but was not different between the groups with severe or moderate aortic regurgitation (p = 0.805). Peak aortic jet velocity (AV-Vel), which accounts for both stenosis and regurgitant severity, was a significant quantitative predictor of outcome with event-free survival rates of 61 ± 8%, 34 ± 9% and 13 ± 7% for patients with an AV-Vel ≥ 5 m/s compared to 86 ± 5%, 70 ± 7% and 42 ± 7% for patients with an AV-Vel between 4 and 5 m/s and 94 ± 4%, 86 ± 6% and 65 ± 8% for patients with an AV-Vel between 3 and 4 m/s, after 1, 2, 3 and 4 years, respectively (p < 0.001).

**Conclusion** Patients with combined stenotic and regurgitant aortic valve disease have a high event-rate and require close follow-up. Peak aortic jet velocity is a prognostic marker representing the hemodynamic load of combined aortic valve disease, permitting risk-stratification in these patients.

**Delayed Symptom-Reporting in Aortic Stenosis: Importance of Risk Stratification and Impact of a Valve Clinic Program on Timing of Surgery** BAI

R. Zilberszack, H. Gabriell, G. Maurer, R. Rosenberg
Division of Cardiology, Department of Medicine II, Medical University Vienna

**Background** We sought to assess the impact of a valve clinic based regular follow-up program on timing of surgery for patients with severe aortic stenosis (AS).

**Methods** The severity of symptom onset and the delay in symptom reporting was assessed in 388 consecutive patients (198 female, age 71 ± 10 yrs) having an indication for aortic valve replacement due to AS based on current practice guidelines. Of these, 100 patients had been regularly followed in our valve clinic (including serial clinical and echocardiographic exams); these patients were instructed to promptly report the onset of symptoms and had developed indications for surgery during follow-up. 288 pts presented with an indication for surgery at first presentation in our valve clinic.

**Results** AS severity (peak aortic-jet velocity 5.1 ± 0.6 m/s, aortic valve area 0.6 ± 0.2 cm²) and prevalence of cardiovascular risk fac-
tors (hypertension, hypercholesterinemia, diabetes or coronary artery disease) were not significantly different between the 2 groups. The delay of symptom reporting was significantly longer in the group of patients being symptomatic at the first visit (351 ± 471 days) than for patients being regularly followed (88 ± 141 days, p < 0.001). Despite being instructed to promptly report symptoms after their onset, only 21 of the 100 patients being regularly followed reported a symptom-onset before their next scheduled exam (delay of symptom onset reporting: 21 ± 26 days), whereas 79 of these 100 patients reported symptoms at the scheduled follow-up visit only (delay of symptom onset reporting: 106 ± 154 days, p < 0.001). Severe symptom onset (NYHA or CCS ≥ 2.5) was observed in 61% of patients being symptomatic at their first visit and in 33% of patients followed in the valve clinic (p < 0.001). A very severe symptom onset (NYHA or CCS ≥ 3) was found in 25% of patients who presented with an indication for surgery and in 9% of patients enrolled in the follow-up program (p < 0.001).

Conclusion Delayed symptom reporting is common in patients with aortic stenosis. In patients being regularly followed in a valve clinic program, symptoms are detected at an earlier and less severe stage resulting in an optimized timing of aortic valve surgery. These findings also emphasise on the importance of risk stratification to identify patients benefiting from early elective surgery.
Authors’ Index  
(First Authors)

A

Abend P. ............................................. 178
Adlbrecht C. ........................................ 141, 178
Avanzini M. ........................................ 161

B

Bangerl K. ........................................... 180
Bartko P. E. .......................................... 216
Beer L. .................................................. 149
Benkeoe-Karner J. ................................ 172
Berger T. .............................................. 162
Bergler-Klein J. .................................... 173
Boehnel C. .......................................... 174, 209
Bonaros N. .......................................... 168 (2x)
Breier R. .............................................. 174
Buchmayr G. ........................................ 164
Bühner A. ........................................... 150

C

Colantonio C. ........................................... 175
Czerny M. ............................................ 169 (3x)

D

Danmayr F. ............................................. 199
Dernberg M. ......................................... 200
Dernil M. ............................................. 184
Distelmaier K. ....................................... 141
Doleschal B. ......................................... 151
Dörler J. ............................................. 142 (2x)
Drexel H. ............................................. 177
Dumfarth J. ............................................ 169
Dzilic B. ............................................... 151
Dzoidzio T. .......................................... 152

E

Ebner C. ............................................. 216 (2x)
Ess M. .................................................. 181

F

Forstner H. ........................................... 201
Freudenthaler B. .................................... 164
Frey B. ............................................. 184
Freyhofscher M. .................................... 184, 191 (2x)
Friedrich G. ........................................ 217
Furnau G. ........................................... 142, 164

G

Gang C. .............................................. 185
Gasser R. ............................................ 152 (2x)
Gasser S. ............................................ 153
Goliasch G. ......................................... 143, 181
Granitz C. ........................................... 165
Gyöngyösi M. ....................................... 153, 185

H

Hafner T. ............................................. 209
Haidinger T. ......................................... 209
Harb B. M. .......................................... 170

J

Jarai R. ............................................. 143
Jungbauer L. ......................................... 175

K

Kauferscher C. .................................... 143
Keil P. ................................................ 175
Kilo J. ............................................ 171 (2x)
Klug G. ............................................ 165 (2x)
Kohl S. ............................................. 192, 193
Kraus J. ............................................. 144
Kren L. ............................................. 217
Krychtiuk K. ....................................... 194 (2x)

L

Lambert T. .......................................... 186
Leherbauer L. ....................................... 166
Lichtenauer M. ...................................... 155 (2x), 156

M

Mair J. ............................................. 144, 145, 186, 217
Martinek M. ......................................... 202
Mayr A. ............................................. 166
Mlekasch W. ....................................... 186
Moser J. ............................................. 202
Motoc R. ............................................ 210
Muendlein A. ....................................... 156
Mussner-Seeber C. ................................ 172

N

Neuhold S. ......................................... 181, 218
Niederer D. ......................................... 210 (2x), 212 (3x)

O

Öbel S. ............................................. 203

P

Panzner P. .......................................... 176
Pätzold S. .......................................... 187
Pavo I. ............................................. 156
Pejek H. ........................................... 187
Perl S. ............................................. 213
Petener D. .......................................... 195
Pfaffenerberger S. ................................ 166
Plass C. ............................................ 177
Polzli G. ........................................... 182
Povathrinkl A. .................................... 157
Preis N. ........................................... 187
Primeissig U. .................................... 157

R

Rein P. ............................................. 213 (2x)
Renner M. R. ....................................... 178
Richter B. .......................................... 203
Roth C. ............................................. 188 (2x)
Roth D. ............................................. 145

S

Sadushi-Kolic R. ................................... 196 (2x)
Saely C. H. ........................................ 214
Saleh K. ............................................ 204
Schäfl-Doweik L. .................................. 178
Schatz S. ........................................... 172
Scherzer S. ........................................ 188
Schönbauer R. ..................................... 204
Schwarz M. ....................................... 158 (2x)
Sigmund B. ........................................ 205 (2x)
Siller-Matula J. ..................................... 189
Sipótz H. ........................................... 176
Skoro-Sajer N. .................................... 196
Smolte B. .......................................... 182 (2x)
Spönder M. ......................................... 214 (2x)
Steinacher R. ....................................... 183 (2x)
Steinwender C. ................................... 206
Steringer-Mascherbauer R. ................................ 199
Stifter K. ........................................... 171
Stojkovic S. ....................................... 160
Stöllberger C. ..................................... 145, 167, 173, 206
Sturmberger T. .................................... 183
Suppan M. ........................................... 146
Süssenbacher A. .................................... 189

T

Taheri N. ............................................. 171
Tentzeris I. ......................................... 146, 190
Tuller R. van ...................................... 146, 148

V

Vogel B. ............................................. 148
Völker R. ........................................... 208 (2x)
Vonbank A. ......................................... 215 (2x)

W

Wallner H. .......................................... 149
Wanitschek M. ..................................... 190 (2x), 215
Weidenaer D. ...................................... 167
Weihis V. .......................................... 173
Weihis W. .......................................... 167
Werba G. .......................................... 160
Wolber T. .......................................... 208
Wolf C. ............................................. 190

Z

Zilberszac R. ....................................... 218 (2x)
Zweimüller M. .................................... 195

220  J KARDIOL 2011; 18 (5–6)

Bitte beachten Sie auch diese Seiten:

Impressum  Disclaimers & Copyright  Datenschutzerklärung